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1General introductionTesticular cancers represent the most frequent solid malignant tumor in men 20-40 years of 
age and the incidence of testicular cancer has been arising world-wide (1). Based on histo-
logy these tumors can be divided in seminomatous and non-seminomatous testicular cancer. 
Non-seminomas tend to metastasize more widely and are less sensitive to radiotherapy than 
seminomatous testicular cancer. This has consequences for prognosis and treatment strate-
gies. Non-seminomas display various stages of differentiation, ranging from the undifferen-
tiated embryonal carcinoma (EC) to more differentiated extra-embryonic components like 
yolk sac carcinomas (YS) and choriocarcinomas (Chc) to the highly differentiated teratoma 
(T) component (2).
Platinum-based chemotherapy is the cornerstone of treatment of many cancers types 
and used as first-line therapy for testicular, bladder, lung, ovarian cancers. In case of blad-
der, lung and ovarian cancer the initial response to platinum-based chemotherapy is high, 
however is in the majority of these patients of limited duration. Most patients eventually will 
relapse with platinum-resistant disease. In contrast, testicular cancer is considered to be a 
paradigm of a platinum-sensitive solid tumor. Since the introduction of cisplatin in the mid 
1970s there is an enormous improvement in outcome and survival of testicular cancer pa-
tients even in case of extensive metastatic disease (3). Further improvement of the cisplatin-
based regimens has been executed in the years following the initial success (4,5). Bleomycin 
has proven to be an essential component of the cisplatin-based chemotherapy regimens (6), 
leading to the current standard systemic treatment for testicular cancer BEP combination 
chemotherapy (bleomycin, etoposide and cisplatin).
Patients with disseminated testicular cancer are classified according to the International 
Germ Cell Consensus Classification into three prognosis groups with good, intermediate and 
poor prognosis, with a 5-year survival rate after treatment with cisplatin combination che-
motherapy of  91%, 79% and 48%, respectively (7). Despite the overall treatment success, 
about 20~50% of the testicular cancer patients with extensive metastatic spread belonging to 
the intermediate or poor risk group will not achieve a durable remission after initial treatment 
and will eventually die from their disease (5).
Cisplatin becomes activated intracellularly by the aquation of one or both of the two 
chloride ligands before it covalently binds to DNA (8), while bleomycin has DNA-cleaving 
activity when it is in complex with an oxygenated iron (9). Upon treatment with either cis-
platin or bleomycin, lethal DNA adducts are formed (8,9), which cause arrest of the DNA 
replication fork, and distortions in DNA, including unwinding and bending, and which are 
recognized by several cellular proteins (8,10). This process activates various signal-transduc-
tion pathways involved in DNA-damage recognition followed by cell-cycle arrest and repair 
or apoptosis (8,10,11). Resistance to cisplatin or bleomycin can be the result of reduced drug 
uptake, increased drug export, intracellular detoxification, enhanced efficiency of DNA re-
pair systems (8,10-13) and defects in the apoptotic pathway (14).
Apoptosis, also known as programmed cell death, is an active cellular process, cha-
racterized by biochemical and morphological changes (Figure 1). Apoptosis is involved in 
development and homeostasis of normal tissues (15), among which normal testis. During 
spermatogenesis, apoptosis occurs in the testis as an important physiological mechanism to 
adjust germ cell numbers to that of the supporting Sertoli cells and to ensure quality control 
(16,17). A central component of the apoptotic machinery is a proteolytic system that invol-
ves caspases, a family of proteases which activity eventually leads to the cleavage of a set of 
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1 downstream proteins, resulting in the overall disassembly of the cell (Figure 1). Apoptosis can be induced by two major apoptosis signaling pathways namely the “extrinsic” death 
receptor pathway and the “intrinsic” mitochondrial pathway (15) (Figure 1). The tumor sup-
pressor protein p53 plays a central role in the response to DNA-damage, induced by chemo-
therapeutic drugs, and can activate both the extrinsic and intrinsic death signaling pathways 
(14) (Figure 1).
Figure 1. Apoptosis or programmed cell death is an active cellular process, characterized by biochemical and mor-
phological changes. The tumor suppressor protein p53 plays a central role in the response to DNA-damage, induced 
by chemotherapeutic drugs such as cisplatin, and can activate both the extrinsic apoptosis pathway (including Fas/
FasL) and intrinsic (mitochondrial) apoptosis pathway; e.g. Bax and Bak. Activation of p53 leads to upregulation 
of pro-apototic genes (green lines) and anti-apoptotic genes (red lines). These activate various signal-transduction 
pathways involved in DNA-damage recognition following cell-cycle arrest and repair (via p21) or apoptosis. Upon 
severe DNA-damage pro-apoptotic proteins will activate a proteolytic system that involves caspases, a family of 
proteases which eventually leads to the cleavage of a downstream set of proteins, resulting in the overall disassembly 
of the cell. Further explanation is provided in the text. Figure modifi ed from Di Pietro et al., 2005 and Spierings et 
al., 2003; Refs (22,23).
P53 is a tumor suppressor protein with a dual role in stress response by transactivating 
genes that induce apoptosis, such as Fas (death receptor pathway), as well as genes that 
induce cell-cycle arrest, such as CDKN1A (encoding p21cip1/waf1). In addition, p53 regulates 
its negative feed-back regulator, MDM2, which interferes with p53 transactivation activity 
and targets it for degradation (18) (Figure 1). P53 is the most frequently mutated gene in hu-
man cancers (19,20), but surprisingly not in testicular cancer. Only in a small proportion of 
testicular cancer patients, mutations in TP53 were found (21). In these patients, mutant p53 
led to cisplatin resistance of the cancer by affecting the downstream apoptotic pathway (21). 
Therefore, the presence of wild-type p53 might explain the sensitivity to cisplatin (22,23), 
especially since it is expressed at high levels in the majority of TCs (24-27). Though, others 
have studied chemo-sensitivity of testicular cancer cell lines and failed to support a role for 
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1resulted in enhanced levels of p53 and MDM2, activation of the Fas apoptotic pathway, and induction of apoptosis, while the expression levels of p21 were hardly affected (25,31). The-
se results demonstrated the involvement of the Fas apoptotic pathway in cisplatin-induced 
apoptosis in testicular cancer cells (25,31). However, it is not known why cisplatin-induced 
p53 activation did not result in activation of p21. This suggests that changes in the balance of 
key-players in the cisplatin-induced p53-mediated apoptotic pathway might determine fate 
of testicular cancer cells treated with cisplatin. Deciphering the complex regulation of these 
molecular determinants of cisplatin-sensitivity and -resistance in testicular cancer treatment, 
may provide a way to improve chemotherapy sensitivity in resistant TCs and other solid 
tumors.
Scope of the thesis
Though p53 is one of the most studied proteins, the precise effect of wild-type p53, and 
downstream targets, on the response to DNA-damage in testicular cancer is still not clear. 
Therefore, this thesis mainly focuses on the functionality of wild-type p53 and downstream 
targets Fas, MDM2 and p21 and their role in determining the response to cisplatin-induced 
apoptosis in testicular cancer.
Recent studies have demonstrated that enhanced p21 expression protects TC/EC cells 
against Fas-induced apoptosis (25), though the role of p21 in protecting against cisplatin-
induced apoptosis in not clear. In Chapter 2 we, therefore, determined the role of p21 in 
cisplatin-induced apoptosis, using cisplatin-sensitive and -resistant TC cell lines. Expression 
levels of p21 and CDKN1A and the sub-cellular localization of p21 at baseline and after tre-
atment with cisplatin were investigated. To demonstrate the importance of cytoplasmic p21 
in the protection against apoptosis-induction, p21 was suppressed in the TC cells. Moreover, 
cytoplasmic p21 was ectopically over-expressed in the cisplatin-sensitive Tera cells. Next, 
targets of cytoplasmic p21 were identified by co-immunoprecipitation and their involvement 
in cisplatin sensitivity was investigated. Mechanism involved in p21 cytoplasmic localiza-
tion and strategies to relocate cytoplasmic p21 to the nucleus were explored. Furthermore, 
clinical relevance of cytoplasmic p21 expression in EC components from chemo-sensitive 
and -refractory TC patients was studied in detail. Finally, we dissected the pathway involved 
in the regulation of p21 expression levels, i.e. the role of Oct4 in regulating p21 expression 
via the miR-106b seed family in EC.
Several reports have been studying chemo-sensitivity of human TC cell lines in relation 
to wild-type p53 expression, however with contradicting results. In Chapter 3 we deter-
mined in detail the role of the p53-dependent and p53-independent apoptotic pathway in 
cisplatin sensitivity and resistance in a model resembling the clinically observed variation in 
chemo-sensitivity between testicular cancers. We compared p53-dependent cellular and mo-
lecular changes with respect to p21, MDM2 and Fas at baseline and after cisplatin treatment 
in two cisplatin-sensitive cell lines (833KE and Tera), a subline of Tera with acquired resis-
tance to cisplatin (Tera-CP) and two intrinsic cisplatin-resistant cell lines (Scha and 2102EP). 
Furthermore, the effect on cisplatin-induced apoptosis was studied after p53 suppression.
P53 interacting proteins, such as MDM2, are important regulators of wild-type p53 
functional activity (32,33). MDM2 interferes with p53 transactivation and targets p53 for 
degradation (18). High levels of wild-type p53 are frequently observed in TC and correlate 
with high MDM2 expression levels (29,34,35). A tight regulation of p53 by MDM2 may 
explain the lack of TP53 mutations in TC. Various reports have focused on the p53 pathway 
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1 to explain the chemo-sensitivity of TCs. A recent study demonstrated that expression of p53 and MDM2 did not predict for cisplatin sensitivity, though the presence and functionality of 
the p53-MDM2 complex following cisplatin treatment was not assessed (29). In Chapter 4, 
we therefore extensively explored the role of p53 and MDM2 in cisplatin-induced apoptosis 
using cisplatin-sensitive and -resistant TC cell lines. Next to expression levels, the sub-cellu-
lar localization of p53 and MDM2 and p53-MDM2 complex formation after treatment with 
cisplatin was determined. The biological importance of MDM2-p53 complexes in relation to 
hyper-activation of the p53 pathway and apoptosis-induction was further investigated using 
the MDM2 small molecule antagonist Nutlin-3 as single agent and in combination with cis-
platin. Finally, we determined if the Fas death receptor pathway is a key factor in Nutlin-3 
induced apoptosis.
In Chapter 5, an overview of the literature and new insights obtained in this thesis on the 
potential pathways responsible for the extreme sensitivity of testicular cancers to cisplatin-
based chemotherapy are presented. This review takes into account p53-activated genes, such 
as CDKN1A (p21), FAS and MDM2 (the negative feed-back regulator of p53) and the role of 
these genes in sensitivity to cisplatin-induced apoptosis. Therapeutic options to target these 
key-players are discussed in more detail as well.
Recently, we showed that the somatic homozygous variant G/G for the single nucleotide 
polymorphism (SNP) A1450G in bleomycin hydrolase (BLMH) was associated with redu-
ced survival and a higher prevalence of early relapses in TC patients treated with bleomy-
cin, etoposide and cisplatin chemotherapy (36). BLMH metabolically inactivates bleomycin 
(37) and this SNP in BLMH is thought to be involved in controlling the enzymatic activity 
(38,39). Of interest, elevated expression of BLMH was observed in bleomycin-resistant hu-
man tumor cell lines (12,13), suggesting that activity and/or levels of BLMH influence toxi-
city and antitumor efficacy of bleomycin. Therefore we investigated in Chapter 6 the sen-
sitivity of TC cell lines to bleomycin and cisplatin, and related the sensitivity to the BLMH 
genotype and expression levels of BLMH. Moreover, we suppressed BLMH in these cells 
with siRNA, to investigate the relation between BMLH level and the cytotoxic response to 
bleomycin or cisplatin.
In Chapter 7, results and findings from this thesis are summarized. Potential future per-
spectives and therapeutic approaches are discussed.
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Chapter 2
Cytoplasmic p21 expression levels determine cisplatin-
resistance in human testicular cancer
Roelof Koster, Alessandra di Pietro, Hetty Timmer-Bosscha,
Johan H. Gibcus, Anke van den Berg, Albert J. Suurmeijer,
Rainer Bischoff, Jourik A. Gietema and Steven de Jong
J Clin Invest. 2010;120 (10):3594-3605
Abstract
Platinum-based chemotherapies such as cisplatin are used as first-line treatment for many 
cancers. Although there is often a high initial responsiveness, the majority of patients even-
tually relapse with platinum-resistant disease. For example, a subset of testicular cancer pa-
tients still die even though testicular cancer is considered a paradigm of cisplatin-sensitive 
solid tumors, but the mechanisms of chemo-resistance remain elusive. Here, we have shown 
that one key determinant of cisplatin-resistance in testicular embryonal carcinoma (EC) is 
high cytoplasmic expression of the cyclin-dependent kinase (CDK) inhibitor p21. The EC 
component of the majority of refractory testicular cancer patients exhibited high cytoplasmic 
p21 expression, which protected EC cell lines against cisplatin-induced apoptosis via CDK2 
inhibition. Localization of p21 in the cytoplasm was critical for cisplatin-resistance since 
relocalization of p21 to the nucleus by Akt inhibition sensitized EC cell lines to cisplatin. We 
also demonstrated in EC cell lines and human tumor tissue that cytoplasmic high p21 expres-
sion and cisplatin-resistance of EC were inversely associated with the expression of Oct4 and 
miR-106b seed family members. Thus, targeting cytoplasmic p21, including by modulation 
of the Oct4/miR-106b/p21 pathway, may offer new strategies for the treatment of chemo-
resistant testicular and other types of cancer.
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Introduction
In testicular cancer, even in case of extensive metastatic disease an enormous decrease in 
mortality has been observed with the introduction and use of highly effective cisplatin-con-
taining chemotherapy schemes (1-2). Therefore, testicular cancer (TC) is considered the pa-
radigm for curative disease. Despite the overall treatment success, about 20-50% of the TC 
patients with extensive metastatic spread belonging to the intermediate or poor risk group 
will not achieve a durable complete remission after initial treatment and will eventually die 
from this disease (3). The molecular basis for resistance, however, remains obscure.
A major role in the response to chemotherapeutic drugs and the execution of apoptosis 
has been ascribed to wild type p53 (4). In only a small proportion of TCs, mutations in p53 
effect the downstream apoptotic pathway and lead to resistance (5), in particular as wild type 
p53 is expressed at high levels in the majority of TCs (6-9). p53 is a tumor suppressor protein 
with a dual role in stress response by transactivation of genes that induce apoptosis, such 
as FAS, as well as genes that induce cell-cycle arrest, such as CDKN1A (encoding p21cip1/
waf1). Interestingly, the cyclin dependent kinase inhibitor p21cip1/waf1 (p21) has been shown to 
inhibit apoptosis (10-13). Remarkably, several studies have demonstrated that p21 protein 
and CDKN1A mRNA expression are abundantly expressed in more differentiated TCs, like 
mature teratoma (14-15). Worthy of note, these teratomas are resistant to cisplatin-based che-
motherapy (8,15-17). In contrast, p21 is almost not detectable in seminomas and embryonal 
carcinomas (EC) that are predominantly sensitive to cisplatin (9,14,18).
In human TC/EC cell lines, similar to patients, cisplatin proved to be an extremely cy-
totoxic drug, inducing massive apoptosis (19-22). Cisplatin treatment of EC cells resulted in 
enhanced levels of p53 and MDM2, activation of the Fas apoptotic pathway, and induction 
of apoptosis, while the expression levels of p21 were almost not affected (7,20). In contrast, 
gamma-irradiation induced p53 and MDM2 levels and a massive induction of cytoplasmic 
p21 without inducing apoptosis or cell cycle arrest in EC cells (7). These results suggested 
an important role for cytoplasmic p21 in preventing DNA damage-induced apoptosis in EC 
cells.
Materials and Methods
Cell Lines & Reagents. A well defined panel of cisplatin-sensitive and cisplatin-resistant human EC cell lines, all 
expressing wild type p53 were used (7,20,22-24). The 2102EP cell line was obtained from Dr. L. Looijenga (Depart-
ment of Pathology, Erasmus Medical Center Rotterdam, the Netherlands). Tera, Tera-CP, 2102EP, Scha and 833KE 
and the human breast carcinoma cell line MCF-7 (used as a control) were cultured in RPMI 1640 medium (Gibco, 
Invitrogen) supplemented with 10% FCS (Sanbio) at 37oC in a humidified atmosphere with 5% CO2. Cisplatin was 
purchased from Bristol-Myers Co., LY294002 from Cell Signalling and Triciribine from Biomol.
Drug Sensitivity Assay & Apoptosis. Drug sensitivity testing was performed as described previously (20,24). 
Acridine orange fluorescent staining of nuclei was used to distinguish apoptotic from vital cells as described previ-
ously (7,20,25).
Western Blotting & Preparation of fractionated proteins. Lysates were examined by WB as described pre-
viously (7,20). Nuclear and cytosolic protein fractions were prepared as described previously (7). The following 
antibodies were used: mouse anti p21 (F5, Santa Cruz), mouse anti p53 (DO-1, Santa Cruz), mouse anti b-Actin 
(MP Biomedicals), mouse anti pRB (IF8, Santa Cruz), rabbit anti-Parp (Roche Diagnostics), mouse anti ASK1 (F9, 
Santa Cruz), goat anti CDK2 (M2, Santa Cruz), rabbit anti p-p21 (Thr145, Santa Cruz), rabbit anti p-Akt/Akt (Cell 
Signalling), goat anti Oct4 (C20, Santa Cruz) and rabbit anti caspase 3 (cell Signalling). The antibody binding was 
eventually determined using horseradish peroxidase (HRP)-conjugated secondary antibodies (DAKO) and visu-
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alised with the POD chemoluminescence kit (Roche Diagnostics). WB membranes were imaged with Molecular 
Imager Gel Doc XR System (Biorad). Equal protein loading was checked for with the Bradford total protein assay, 
Ponceau S staining of the blots and ß-actin immunobloting.
Quantitative real-time PCR for p21 (CDKN1A). Total RNA was isolated using the RNeasy Midi Kit according 
to the manufacturer's instructions (Qiagen). cDNA was synthesized from total RNA as described by the manufac-
turer’s protocol (Life Technologies) using oligo dT primers and M-MLV transcriptase. Quantitative real-time PCR 
was performed using SYBR Green qPCR SuperMix (Invitrogen). P21 mRNA levels were normalized to the level 
of GAPDH in the same sample. Results of at least 3 experiments in duplicate are expressed as mean ± SD. Used 
primers: GAPDH For: CAC CAC CAR GGA GAA CGC TGG, GAPDH Rev: CCA AAG TTG TCA TGG ATG 
ACC, P21 For: CCT GTC ACT GTC TTG TAC CCT, P21 Rev: GCG TTT GGA GTG GTA GAA ATCT.
Immunofluorescence. Cells were fixed with 4% paraformaldehyde and blocked with 0.1% Triton X-100, 1% 
BSA and 1% NGS in PBS. Followed by immunostaining with the corresponding antibodies and counterstained with 
Alexa-Fluor goat secondary antibodies (Molecular Probes, Invitrogen). Finally, cells were stained with Hoechst 
33258 (Molecular Probes, Invitrogen) and mounted with Vectashield (Vector Laboratories). Quantimet 600S system 
(Leica Microsystems) was used for analysis. The data were exported as bmp files and processed using Corel Photo-
paint X4 (Corel Corperation).
Caspase 3 activity. Caspase-3 was assayed according to the manufacturer's instructions using DEVD-MCA 
(Zebra Bioscience BV). Fluorescence was monitored in an FL600 Fluorimeter Bio-tek plate reader (Beun de Ronde).
Tera-p21-D-NLS stably transduced cell line. pMSCV-p21-D-NLS, pMSCV-IGFP and pCL-Ampho were 
kindly provided by Dr. J.J. Schuringa & Dr. H Schepers (Hematology Research, University Medical Center Gronin-
gen, the Netherlands). For viral production, 293T cells were transfected with pCL-Ampho and MSCV-IGFP, either 
with or without p21-D-NLS. GFP positive Tera cells were sorted on a fluorescent-activated cell sorter (MoFlow, 
Cytomation).
RNA interference & miRNA antisense & Transfections. Specific siRNA and negative control (scrambled) were 
purchased from Eurogentec. Synthetic anti-miRNA were purchased from IDT and pre-miR-17-5p from Ambion. EC 
cells were transfected in 6 well plates with 5 ml of 20 mM siRNA duplex or miRNA antisense using Oligofectamine 
reagent according to the manufacturer’s instructions (Invitrogen). After 24h, cells were treated with cisplatin. 24h 
after the treatment cells were harvested for protein isolation. Alternatively, in order to perform an apoptosis assay, 
at 24h after transfection, cell were harvested and plated in 96-well plate. The day after, cells were treated with 
cisplatin. For the luciferase reporter assay Tera cells were transfected with psiCHECK2-p21-3’UTR using Fugene, 
lysates were made and assay was performed as described previously (26). p21-I: 5’-CUU CGA CUU UGU CAC 
CGA GdTdT (sense), 5’-CUU ACG CUG AGU ACU UCG AdTdT (anti-sense); P21-II: 5’-GAC CAU GUG GAC 
CUG UCA CTdT (sense), 5’-GUG ACA GGU CCA CAU GGU CdTdT (antisense); CDK2: 5’-GCC AGA AAC 
AAG UUG ACG GGA dTdT (sense), 5’-UCC CGU CAA CUU GUU UCU GGC dTdT (anti-sense); CDK2 II: 5’-
GGU GGU GGC GCU UAA GAA AdTdT (sense), 5’-UUU CUU AAG CGC CAC CAC CdTdT (anti-sense); Akt1: 
5’-GGA GGG UUG GCU GCA CAA AdTdT (sense), 5’-UUU GUG CAG CCA ACC CUC CdTdT (anti-sense); 
Akt2:   5’-CUU CUC CGU AGC AGA AUG CdTdT (sense),  5’-GCA UUC UGC UAC GGA GAA GdTdT (anti-
sense); Akt3: 5’-CUG GAG GCC AAG AUA CUU CdTdT (sense),  5’-GAA GUA UCU UGG CCU CCA GdTdT 
(anti-sense); Oct4 I: 5’-CAU GUG UAA GCU GCG GCC CdTdT (sense), 5’-GGG CCG CAG CUU ACA CAU 
GdTdT (anti-sense), Oct4 II: 5’-AGC AGC UUG GGC UCG AGA AdTdT (sense), 5’-UUC UCG AGC CCA AGC 
UGC UdTdT (anti-sense).
Immunoprecipitation. Cells (107) were harvested, washed with ice-cold PBS, and lysed in 500 ml lysis buffer 
(20 mM Tris HCl pH 7.6, 150 mM NaCl, 0.2% NP-40, protease inhibitor COMPLETE®, 1 mM PMSF, 1mM NaF 
and 1 mM DTT). Lysates were clarified and protein concentration was equalized with Bradford, and incubated for 
16h with a mixture of agarose conjugated anti-p21 (F5 & C19, Santa Cruz). Immunocomplexes were washed 5 times 
and eluted with 0.5 M Glycine/HCl pH 2.4, mixed 1:1 with standard 2x Western Blot sample buffer and examined 
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by Western blot analysis as described above.
Facs analysis p-p21 (Thr145). For FACS analysis of the levels of phosphorylated p21 EC cells were seeded 
in 6 wells plates and 24h after cisplatin or gamma-irradiation treatment the cells were collected, washed with PBS 
and fixed with Methanol/Aceton for 20 min at room temperature. Fixed cells were washed 2 times with 1% BSA 
in PBS followed by immunostaining with p-p21 antibody in 1% BSA in PBS and counterstained with Alexa-Fluor 
secondary antibody. Fluorescence intensity was detected with the FACS-Calibur (Becton Dickinson).
Patients, immunohistochemistry & miRNA in situ hybridization. General patient characteristics and histopatho-
logy are summarized in Supplemental Table 1. The TC patients with chemo-sensitive disease have been reported be-
fore (27). From the patients with TC diagnosed and treated at our institution between 1985 and 2007 with refractory 
disease (defined as patients not achieving a response on initial treatment or renewed elevation of tumor marker levels 
within 4 weeks after completion of chemotherapy), patients with sufficient EC component in their tumor samples 
(n=7) were selected. TC specimens were used to represent all histological subtypes of the primary tumor (Embryo-
nal Carcinoma = EC: Yolk Sac Tumour = YS; Choriocarcinoma = ChC; Mature Teratoma/Immature Teratoma =T; 
Seminoma = S) and each of the three different prognosis groups according to the IGCCCG classification (28). The 
studies were approved by the medical ethical committee of University Medical Center Groningen, the Netherlands, 
and all patients gave informed consent prior to study entry. For each patient, representative paraffin embedded tumor 
material was collected and serial 3-mm sections were cut.
For immunohistochemistry sections were deparaffinized in xylene and rehydrated in alcohol; antigen retrieval 
was performed followed by blocking of endogenous peroxidase (30 min, 3% H2O2). Subsequently, slides were 
incubated for 1h with the primary antibodies: Oct4 (C20, Santa Cruz), p21 (EA10, Oncogene), p-p21 (Thr145, 
Santa Cruz) and Ki-67 (MIB-1, Dako) and counterstained with HRP-conjugated secondary antibodies (DAKO). 
DAB was used as chromagen to visualize peroxidase activity. Counterstaining was performed with hematoxylin. 
Immunoglobulin class-matched control sera were used as negative controls. Normal colon and normal skin served 
as a positive control for p21.
miRNA ISH was performed as reported previously (29). For both ISH and IHC slides were scanned using 
ScanScope CS System (Aperio) and pictures were taken with ImageScope software package (Aperio).
RNA isolation & TaqMan miRNA quantitative PCR. Total RNA was isolated and miRNA-106b family expres-
sion was measured as previously described (26). The miRNA expression was normalized to RNU48 expression 
resulting in a ΔCt from which the 2−ΔCt value was derived and depicted.
Statistical Analysis. Results of at least 3 experiments are expressed as mean ± SD. Student’s unpaired t test was used 
to compare values of test and control samples. Differences were considered significant when at least p < 0.05. Fisher 
exact χ2 test was used for categorical patient variables. Differences were considered significant when at least, with 
2 sided p < 0.05.
Results 
High cytoplasmic p21 expression is associated with cisplatin-resistance in EC cells. A panel 
of cisplatin-sensitive and -resistant EC cell lines was used in this study to compare cisplatin 
responses (Figure 1A & Supplemental Figure 1A) with the levels of (induced) p21 (Figure 
1B-C). Resistance to cisplatin was predominantly associated with high p21 expression le-
vels, since the intrinsically resistant EC cell lines Scha and 2102EP showed higher basal 
and cisplatin-induced p21 and CDKN1A levels compared to the cisplatin-sensitive EC cell 
lines Tera and 833KE (Figure 1A-C). Low levels of p21 were not associated with cisplatin 
response in Tera-CP, a subline with acquired cisplatin-resistance due to p21 unrelated me-
chanisms (23).
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Figure 1. High cytoplasmic p21 expression is associated with cisplatin-resistance in EC cell lines. (A) Survival of 
EC cells after 96h of continuous cisplatin treatment as indicated. (B) Difference in p21 and p53 levels of the EC 
cell lines treated and untreated with cisplatin for 24h as indicated. A representative example of three independent 
experiments is shown. (C) Difference in CDKN1A expression levels of the EC cell lines treated and untreated. Note 
that the intrinsic cisplatin-resistant EC cell lines (2102EP and Scha) have higher basal and cisplatin-induced p21/
CDKN1A levels compared to cisplatin-sensitive EC cell lines (Tera 833KE). (D) p21 is localized in the cytoplasm in 
EC cells when untreated and after 24h of cisplatin treatment. Scale bar, 30 mm. (E) 24h after cisplatin (CP) treatment 
or gamma-irradiation (IR), nuclear and cytoplasmic proteins were isolated and analyzed by WB for expression of 
p21 using retinoblastoma protein (pRB) as nuclear control whereas b-actin is shown as a loading control. WB of 
total lysates show that, despite an almost similar p53 increase, gamma-irradiation in contrast to cisplatin treatment, 
strongly induced accumulation of p21 both in cisplatin-resistant Scha and cisplatin-sensitive Tera cells. Representa-
tive examples of three independent experiments are shown.
The subcellular localization of p21 was investigated with immuno-fluorescence micro-
scopy (IF) and Western blot analysis (WB) using fractionated protein samples. We stained 
the EC cell lines Tera, Tera-CP, 833KE, Scha and 2102EP for basal levels of p21 and p21 
levels after treatment with cisplatin (or gamma-irradiation). All untreated EC cell lines sho-
wed a predominant cytoplasmic localization of p21, albeit with large differences in p21 
intensity (Figure 1D-E). Cytoplasmic localization was not affected by cisplatin treatment 
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p21 induction in EC cells (7). Despite almost a similar p53 increase, gamma-irradiation, in 
contrast to cisplatin treatment, strongly induced accumulation of p21 in the cytoplasm in 
both cisplatin-resistant Scha and cisplatin-sensitive Tera cells (7)(Figure 1E & Supplemental 
Figure 1C). We next hypothesized that high levels of cytoplasmic p21 have a causal role in 
cisplatin-resistance in EC cell lines.
Cytoplasmic p21 protects EC cells against cisplatin- induced apoptosis. To investigate 
the importance of high levels of cytoplasmic p21 both cisplatin-sensitive and cisplatin-re-
sistant EC cell lines were depleted of p21, using siRNA. Downregulation of p21 led to an 
increase in apoptosis upon cisplatin treatment in the intrinsically resistant cell lines Scha and 
2102EP as compared to cells transfected with scrambled siRNA (Figure 2A). The loss of p21 
in Scha and 2102EP resulted in enhanced PARP cleavage and higher caspase 3 activation 
compared to control cells following cisplatin treatment (Figure 2B-C). In the cisplatin-sen-
sitive 833KE and Tera cells and the acquired cisplatin-resistance Tera-CP cells, all expres-
sing low endogenous cytoplasmic p21 levels, no significant effect of p21 downregulation on 
apoptosis levels was observed (Supplemental Figure 2A-C).
Next, we stably transduced the cisplatin-sensitive cell line Tera with a retroviral construct 
containing both p21-D-NLS and Green Fluorescent Protein (GFP), or GFP only (Tera-mock) 
to study more extensively whether enhanced levels of cytoplasmic localized p21 is involved 
in suppressing apoptosis. The p21-D-NLS protein lacks its bipartite nuclear localization sig-
nal and is therefore maintained in the cytoplasm (Supplemental Figure 2D). Treatment with 
cisplatin resulted in less apoptosis and reduced caspase 3 activity in Tera-p21-D-NLS com-
pared to Tera-mock (Supplemental Figure 2E-F). We downregulated p21-D-NLS in Tera-
p21-D-NLS cells using p21 siRNA, and we showed that these cells became as sensitive as 
Tera-mock cells to cisplatin. No effect of p21 siRNA on cisplatin-induced apoptosis was 
observed in Tera-mock cells (Figure 3A-B & Supplemental Figure 2G-H).
Figure 2. Increased cisplatin sensitivity after 
p21 downregulation in intrinsically resistant 
EC cell lines. (A) Downregulation of p21 
sensitizes intrinsically resistant EC cells 
for cisplatin-induced apoptosis. Cells were 
treated with scrambled siRNA (siRNA scr) 
or with p21 siRNA (siRNA p21) for 24h. 
After cisplatin treatment for 24h apoptosis 
induction was analyzed by fluorescence mi-
croscopy on acridine orange stained cells for 
2102EP and Scha. (B) Successful downre-
gulation of p21, using siRNA against p21, 
and enhanced cleavage of PARP in cisplatin 
treated 2102EP and Scha, a representative 
example of three independent experiments is 
shown. (C) Increased caspase 3 activity, af-
ter treatment with siRNA against p21, in cis-
platin treated 2102EP and Scha. *p < 0.05; 
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Figure 3. Over-expression of cytoplasmic 
p21 protects against cisplatin induced 
apoptosis via complex formation of p21 
with CDK2 and ASK1. (A) p21 siRNA 
mediated downregulation of p21-D-NLS 
in Tera-p21-D-NLS sensitizes for cisplatin 
induced apoptosis. (B) Western blot analy-
sis showing downregulation of p21-D-NLS 
and enhanced cisplatin-induced cleavage 
of PARP in Tera-p21-D-NLS after treat-
ment with p21 siRNA (C) EC cells were 
harvested 24h after gamma-irradiation (IR) 
or cisplatin (CP) treatment. Cell lysates 
were subjected to p21 immunoprecipita-
tion (IP). Immunoblotting was performed 
using anti-p21, anti-CDK2, and anti-ASK1 
antibodies. In Scha and Tera-p21-D-NLS 
higher amounts of p21 are precipitated and 
more CDK2 and ASK1 are co-precipitated 
compared to Tera, whereas in irradiated 
Tera and Scha almost similar levels of p21, CDK2 and ASK1 are co-precipitated. The data presented are representa-
tive of three independent experiments. (D) CDK2 acts pro-apoptotic after 24h cisplatin treatment in Tera. Decreased 
apoptotic response and increased PARP cleavage after successful downregulation of CDK2. *p < 0.05; **p < 0.01 
compared to matching siRNA scrambled (scr) control.
Cytoplasmic p21 forms a complex with pro-apoptotic CDK2 in cisplatin-resistant EC 
cells. It has been described that caspase 3 mediated cleavage of p21 activates the proapopto-
tic role of cyclin dependent kinase 2 (CDK2) (30-32). Therefore, we analyzed the presence 
of CDK2 in p21 immunoprecipitates. As shown in Figure 3C, in Tera, Tera-p21-D-NLS and 
Scha CDK2 co-precipitated with p21, indicating that CDK2 is in complex with cytoplasmic 
p21 in untreated cells and in cells treated with cisplatin or gamma-irradiation (Figure 3C). In 
addition, we stained for the presence of ASK1 since cytoplasmic p21 can bind to apoptosis 
signaling kinase 1 (ASK1) thereby inhibiting ASK1-mediated apoptosis via the intrinsic mi-
tochondrial apoptotic pathway (10-13). In fact, more CDK2 and ASK1 was co-precipitated 
with p21 in untreated and cisplatin-treated Scha and Tera-p21-D-NLS, which have higher 
p21 levels compared to Tera. In irradiated Tera and Scha, expressing equal p21 levels, high 
levels of p21 were precipitated leading to co-precipitation of almost similar levels of CDK2 
and ASK1 (Figure 3C). We further established the important proapoptotic role of CDK2 by 
downregulating CDK2 with siRNA in cisplatin-sensitive cell lines, which led to a decrease in 
cisplatin-induced apoptosis and PARP cleavage compared to scrambled siRNA in Tera and 
833KE (Figure 3D & Supplemental Figure 3A). Next, we investigated the pro-apoptotic role 
of CDK2 in the high p21 expressing 2102EP and Scha. Therefore, we sensitized these cells to 
cisplatin by suppression of p21 and, additionally, transfected these cells with CDK2 siRNA. 
The observed increase in apoptosis in p21 suppressed 2102EP and Scha cells upon cisplatin
treatment could be dramatically reduced by co-transfection with CDK2 siRNA (Supplemen-
tal Figure 3B).
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Figure 4. Dephosporylation of p-p21, nuclear localization of p21 and sensitization for cisplatin after combined 
treatment with LY294002 or Triciribine. (A-C) 24h after cisplatin (CP) treatment in combination with either 10 mM 
LY294002 (LY) or 10 mM Triciribine (TR) decreased phosphorylated levels of p21(Thr145), whereas p21 is more 
pronounced localized in the nucleus of 2102EP and Scha (Scale bar, 30 mm) (A) and dephosporylation of p-Akt 
occurred after treatment with LY294002 or Triciribine in Scha and 2102EP (B). This treatment led to increased 
apoptosis induction in 2102EP and Scha (C). **p < 0.01; ***p < 0.001 compared to matching DMSO control. (D) 
siRNA against Akt1-3 sensitizes intrinsically resistant EC cell lines for cisplatin. Akt1-3 downregulation increased 
apoptosis induction and enhanced PARP cleavage after cisplatin treatment in 2102EP and Scha. **p < 0.01; ***p < 
0.001 compared to matching siRNA scrambled (scr) control.
Interfering in p-Akt mediated cytoplasmic localization of p21 sensitizes cisplatin-re-
sistant EC cells. The cytoplasmic localization of p21 can be caused by phosphorylation of 
Thr-145 located in the NLS of p21 (11,33). Upon phosphorylation of the NLS domain by p-
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the nucleus and the cytoplasm (11,33-34). In untreated and cisplatin-treated EC cells, p-p21 
was detectable with WB (Supplemental Figure 4A). IF indicated that p-p21 was also loca-
lized in the cytoplasm (Figure 4A). In order to find out if phosphorylation of Thr-145 could 
occur via p-Akt, we stained the EC cells for p-Akt and its natural inhibitor PTEN. In Tera, 
Scha and 2102EP p-Akt is present (Figure 4B & Supplemental Figure 4B), whereas PTEN is 
not expressed in these cells (data not shown)(35).
Treatment with the PI3K inhibitor LY294002 or with the specific Akt inhibitor Trici-
ribine (currently in phase I trial) resulted in dephosphorylation of Akt in Tera, Scha and 
2102EP and concomitant dephosphorylation of p21 (Thr-145), which is consistent with a 
more pronounced nuclear localization of p21 (Figure 4A,B & Supplemental Figure 4B-E). In 
the cisplatin-sensitive cell line Tera either LY294002 or Triciribine did not affect cisplatin 
sensitivity (Supplemental Figure 5A), though shuttling of the weakly detectable cytoplasmic 
p21 to the nucleus was observed (Supplemental Figure 4C,D). Interestingly, a strong sensi-
tization to cisplatin was observed in Scha and 2102EP with the combined treatment for 24h 
with cisplatin and either LY294002 or Triciribine (Figure 4C & Supplemental Figure 5A). 
Shuttling of p21 to the nucleus following LY294002 treatment resulted in a loss of CDK2 in 
complex with p21 in Scha cells (Supplemental Figure 5B). Release of CDK2 was instrumen-
tal in the enhanced induction of apoptosis, since the sensitization to cisplatin combined with 
LY294002 in 2102EP and Scha cells was almost completely blocked following suppression 
of CDK2 (Supplemental Figure 5C).  Downregulation of Akt using siRNA targeting Akt1-3 
reduced the overall levels of p-p21 and resulted in a more pronounced nuclear localization of 
p21 (Supplemental Figure 5D). In addition, Akt1-3 suppression sensitized 2102EP and Scha 
for cisplatin-induced apoptosis (Figure 4D).
Enhanced cytoplasmic p21 positivity and low levels of apoptosis were found in Tera and 
Scha 24hrs after gamma-irradiation (Figure 1E & Supplemental Figure 4D). The combined 
treatment of gamma-irradiation with either LY294002 or Triciribine for 24h resulted in less 
p-p21, predominantly nuclear localization of p21, and augmented apoptosis in both Tera and 
Scha (Supplemental Figure 4B,D & 5E). In Tera-p21-D-NLS, lacking the phosphorylation 
site Thr145, treatment with the PI3K/Akt inhibitors, however, had no effect on the cytoplas-
mic localization of p21-D-NLS (Supplemental Figure 4C) and treatment with the inhibitors 
did not lead to sensitization to cisplatin (data not shown). These results show that the sensi-
tizing effect of PI3K/Akt inhibitors on cisplatin-induced apoptosis is mediated via dynamic 
changes in p21 localization.
Cytoplasmic expression of p21 and p-p21 in the EC component of chemo-refractory TC 
patients. Next, we investigated the p21 and p-p21 (Thr145) expression patterns in EC con-
taining TC tissue from 23 patients with metastatic disease, who were cured and considered 
sensitive to cisplatin containing chemotherapy and from 7 patients with metastatic disease 
not cured and considered refractory to cisplatin containing chemotherapy. Histological ana-
lysis after H&E staining was used to distinguish the various TC components. In addition, 
Oct4 (also known as POU5F1 and Oct3/4) immunohistochemistry (IHC) was used as marker 
for embryonal pluripotency (16). Mature teratoma showed an intense p21 and p-p21 staining, 
whereas no staining of Oct4 was noticed (Supplemental Figure 6A). EC components from 
TC patients, sensitive to cisplatin containing chemotherapy, were negative for p21 in 23 
(100%) and negative for p-p21 in 21 (91%) of the patients (Figure 5A & Supplemental Figure 
6A). In contrast, the EC component of refractory TC patients stained positive for p21/p-p21 
in 6 out of 7 (86%) patients, including 2 patients with EC as only component (Figure 5B). 
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Positive staining for p21/p-p21 in the EC component was significantly more often observed 
in refractory TC patients compared with TC patients sensitive to cisplatin containing che-
motherapy (P < 0.0003, Fisher’s exact test). Moreover, IF showed that the localization of 
p21/p-p21 in the EC component of refractory patients was mainly cytoplasmic, whereas the 
localization of p21/p-p21 in teratomas is more nuclear (Figure 5C). In addition, presence of 
Ki-67 staining indicated proliferation instead of cell cycle arrest in abundantly p21/p-p21-
positive EC (Supplemental Figure 6B). Taken together, our results show that cytoplasmic 
p21 and p-p21 positivity of EC components in TC patients is associated with the response 
(poor outcome) to cisplatin-containing chemotherapy.
Figure 5. Cytoplasmic p21 expression in 
embryonal carcinoma of non-responding 
TC patients. (A) Embryonal carcinoma 
(EC) or seminoma (S) components of 
chemo-sensitive patients stain negative 
for p21 (IHC) and intensively positive for 
Oct4 (IHC) and miR-17-5p (ISH). Repre-
sentative examples of staining are shown. 
Scale bar, 300 mm. (B) The embryonal 
carcinoma component (EC) of patients 
refractory to cisplatin-containing chemo-
therapy, in contrast to responders, stains 
in the majority of cases positive for p21 
and less positive for Oct4 and miR-17-5p. 
All teratoma component (T) stains posi-
tive for p21/p-p21 and negative for Oct4 
and miR-17-5p. Representative examples 
of staining are shown. Scale bar, 300 mm. 
Pictures of the panels with higher magni-
fication were made with Leica DM3000 
(Leica Microsystems). Scale bar, 30 mm. 
(C) Immunofluorescent staining showing 
that p21 is nuclear localized in mature 
teratoma (T) and negative in chemo-
sensitive EC patients, whereas p21 is 
cytoplasmic localized in the EC compo-
nent of refractory patients. Representative 
example of stainings is shown. Scale bar, 
30 mm. Insets represent a selected area of 
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Figure 6. Positivity for p21 and p-p21 protein is inversely associated with the expression of the miR-106b seed 
family in EC. (A) Quantitative RT-PCR on miR-106b seed family expression in EC cell lines. Note that the intrinsic 
cisplatin-resistant EC cell lines (2102EP and Scha) have lower levels of the miR-106b seed family and lower Oct4 
expression compared to cisplatin-sensitive EC cell lines (Tera and 833KE). All reactions were run in triplicate. 
The miRNA expression was normalized to RNU48 expression resulting in a ΔCt from which the 2−ΔCt value was 
derived and depicted. (B) Enhanced p21 levels in Tera 24h after treatment with synthetic anti-miR-106b seed family 
members. Synthetic anti-miR-220 was used as negative control, since miR-220 expression was not detectable in 
TC (38). (C) Differences in p21 enhancement in EC cells 24h after synthetic anti miR-17-5p treatment. (D) Levels 
of cytoplasmic localized p21 were enhanced after treatment with synthetic anti-miR-17-5p (a-miR-17), compared 
to control (a-miR-220). Treatment with 10 mM LY294002 (LY) decreased phosphorylated levels of p21(Thr145) 
and p21 became more localized in the nucleus of synthetic anti-miR-17-5p transfected Tera cells (Scale bar, 30 
mm) (E) Synthetic anti-miR-17-5p strongly up-regulates p21 and reduces cisplatin induced apoptosis and reduces 
PARP cleavage in Tera. Cells were treated with 0, 4 and 8 mM cisplatin. ***p < 0.001 compared to matching anti-
miR-220 control. (F) Reduced apoptosis induction and reduced PARP cleavage depends on upregulation of p21 by 
synthetic anti-miR-17-5p, as shown by co-transfection with siRNA against p21. Cells were treated with 0, 4 and 
8 mM cisplatin. ***p < 0.001 compared to matching anti-miR-17-5p + scrambled siRNA. (G) Lower expression 
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Reduced levels of Oct4 and miR-106b family members causes high cytoplasmic p21 ex-
pression in cisplatin-resistant EC cells. Involvement of miRNAs belonging to the miR-106b 
seed family in regulating p21/CDKN1A and cell cycle control has previously been demon-
strated (36-37), Therefore, we examined the expression levels of the miR-106b seed family 
in the EC cell lines. The intrinsically resistant Scha and 2102EP cell lines, with high p21 
levels, showed lower levels of the miR-106b seed family compared to the cisplatin-sensitive 
Tera and 833KE cell lines (Figure 6A & Supplemental Figure 6C). Subsequently, we used 
synthetic anti-miRNA to specifically inhibit the miR-106b seed family and to demonstrate 
its relation with localization and expression level of p21 in EC cell lines. In Tera cells, trans-
fection with synthetic anti-miRNA against miR-17-5p, miR-20a, miR-93, miR-106a, or ei-
ther miR-106b resulted in a massive increase in cytoplasmic p21 levels compared to control 
(Figure 6B,D). Although treatment with synthetic anti-miR-17-5p resulted in enhanced p21 
levels in Tera, Tera-CP, Scha and 2102EP, the strongest enhancement of p21 was found in 
Tera and Tera-CP (Figure 6C), which may at least in part be explained by the higher miR-17-
5p levels in these cell lines  (Figure 6A) (38). The strongly enhanced cytoplasmic p21 levels 
in Tera following synthetic anti-miR-17-5p treatment completely blocked cisplatin-induced 
apoptosis (Figure 6D,E). Suppression of cytoplasmic p21 with siRNA or shutteling of p21 
to the nucleus with LY294002 resensitized synthetic anti-miR-17-5p treated Tera cells to 
cisplatin (Figure 6F & Supplemental Figure 6D). Overexpression of pre-miR-17-5p resulted 
in lower p21 levels and an increase in cisplatin-induced apoptosis in Scha and 2102EP cells 
(Figure 6G), demonstrating the important causal relation between the presence of miR-17-
5p, the reduced p21 expression and high cisplatin sensitivity.
Figure 7. Oct4 regulates the expression 
level of the miR-106b seed family in EC. 
(A) Quantitative RT-PCR on miR-106b 
seed family expression in EC cell lines, 
showing less expression of the miR-106b 
seed family in Oct4 suppressed cells, after 
48h of treatment with siRNA against Oct4, 
compared to control. ***p < 0.001 compa-
red to control. (B) Reporter assay showing 
increased p21-3’UTR dependent luciferase 
translation in cells 48h after cotransfection 
of psiCHECK2-p21-3’UTR with either 
anti-miR-17-5p or Oct4 siRNA. Bars indi-
cate Firefly luciferase activity normalized 
to Renilla luciferase activity. *p < 0.05; 
**p < 0.01. (C,D) Oct4 suppression leads 
to upregulation of p21 and concomitantly 
resistance to cisplatin in Tera (C), 2102EP 
and Scha cells (D), while downregulation 
of p21 with siRNA resensitized Oct4 suppressed Tera cells for cisplatin (C). (E) Oct4 suppression leads to upregu-
lation of p21 in Tera and 2102EP cells. Pre-miR-17-5p transfection abolished p21 expression in Tera and 2102EP 
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We performed in situ hybridization (ISH) for miR-106a and miR-17-5p on paraffin-
embedded formalin-fixed tumor tissue from patients with multi-component (primary) TC, to 
define in-vivo the relation between p21/p-p21 expression and the presence of miR-106b seed 
family members in the EC component. A strong positive staining for miR-17-5p, miR-106a 
and Oct4 but not for p21/p-p21 was found in the EC components of chemo-sensitive patients. 
In contrast, mature teratomas showed no staining of miR-17-5p, miR-106a and Oct4, while 
stained intensively positive for p21/p-p21 (Figure 5A & Supplemental Figure 6A). On the 
contrary, in chemo-refractory TC patients almost no miR-17-5p staining was observed in 
EC components, while p21/p-p21 was clearly detectable. Moreover, the staining intensity of 
Oct4 in the EC component is less pronounced in refractory patients compared to chemothera-
py-sensitive patients (Figure 5B). Additionally, the expression levels of both Oct4 and miR-
106b seed family members are lower in the intrinsically resistant cell lines Scha and 2102EP
compared to the cisplatin-sensitive cell line Tera (Figure 6A). These results suggest a relation 
between the reduced expression of Oct4 and the miR-106b seed family member in refractory 
ECs. In murine embryonic stem cells, Oct4 has been implied in controlling expression of 
several miRNA families, including miR-17~92 and miR-106a~363 cluster of the miR-106b 
seed family (39). We downregulated Oct4 in Tera cells with siRNA, in order to establish the 
direct relation between Oct4, miR-106b and p21 expression in ECs. Suppression of Oct4 
lowered the expression level of miR-106a, miR-17-5p and miR-20a compared to control 
Tera cells (Figure 7A & Supplemental Figure 6E), and resulted in enhanced p21-3’UTR 
dependent luciferase translation (Figure 7B) and robust induction of p21 (Figure 7C & Sup-
plemental Figure 6F). A similar enhancement of p21-3'UTR dependent luciferase translation 
was observed following transfection of Tera cells with synthetic anti-miR-17-5p (Figure 7B). 
Furthermore, Oct4 suppression in Tera, Scha and 2102EP resulted in an upregulation of p21 
and a concomitant resistance to cisplatin, which could be reverted by p21 downregulation 
(Figure 7C-D). Sustained miR-17-5p expression using pre-miR-17-5p precluded the induc-
tion of p21 protein even in the context of Oct4 knockdown in Tera and 2102EP cells (Figure 
7E). Some p21 expression, however, was still observed in 2102EP cells, albeit at a lower 
level compared to control 2102EP cells, indicating that not all effects of Oct4 on p21 expres-
sion are mediated by the miR-106b seed family. Overall these results reveal an important role 
of Oct4 in regulating p21 expression via the miR-106b seed family in EC. 
Discussion
The functionality of many proteins is thought to be related to their intracellular localization. 
Nuclear localized p21 is known to control the cell cycle and DNA replication, whereas cy-
toplasmic p21 has been implicated in the inhibition of apoptosis. Here, we have demonstra-
ted that high levels of cytoplasmic localized p21 protect embryonal carcinoma (EC) cells 
against cisplatin-induced apoptosis. Furthermore, we dissected the pathway involved in the 
regulation of p21 expression levels, i.e. OCT4 and the miR-106b family, and identified the 
key protein causing the cytoplasmic localization of p21. Our results indicate that p-Akt me-
diated p21 phosphorylation is essential for p21 localization in the cytoplasm. Inhibition of 
p-Akt retained p21 in the nucleus resulting in less p21 complex formation with CDK2 and 
sensitized EC cells to cisplatin-induced apoptosis. In cisplatin-sensitive EC cell lines and 
EC components of chemo-sensitive TC patients, p21 is not commonly expressed, which is 
related to the expression levels of miR-106b seed family members and Oct4. On the contrary, 
in cisplatin-resistant EC cell lines and EC components of refractory TC patients, indicating 
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clinical cisplatin-resistance, cytoplasmic p21 expression was clearly detectable and related to 
reduced Oct4 and miR-106b expression. Therefore, we conclude that high levels of cytoplas-
mic localized p21 are important determinants of resistance to cisplatin-based chemotherapy 
in EC (Figure 8).
Figure 8. Proposed simplified model showing the mechanisms through which cytoplasmic p21 can inhibit cisplatin-
induced apoptosis in EC cells. Cisplatin-induced DNA damage activates p53, which in turn transcribes CDKN1A 
(p21), and activates the Fas apoptosis pathway and the mitochondrial apoptosis pathway. Activated Akt is important 
for dynamic shuttling of p21 from the nucleus towards the cytoplasm, where p21 can block apoptosis. miR-106b 
seed family members (miR-106b fam.) are involved in regulating p21 expression levels. Oct4 regulates the expres-
sion levels of the miR-106b seed family members. Cisplatin sensitive cells are characterized with high levels of 
Oct4 and miR-106b family members and as a consequence low amounts of cytoplasmic p21, resulting in cisplatin-
induced apoptosis. Cisplatin resistant cells have lower levels of Oct4 and miR-106b family members and high 
amounts of cytoplasmic p21, resulting in CDK2 inhibition and concomitantly moderate levels of cisplatin-induced 
apoptosis. Interestingly, deactivation of Akt with LY294002, Triciribine or siRNA against Akt sensitized cisplatin 
resistant cells. Deactivation of Akt leads to nuclear localization of p21, which in turn is no longer capable of bloc-
king cisplatin-induced apoptosis. Overexpression of pre-miR-17-5p in cisplatin resistant cells resulted in lower p21 
levels and an increase in cisplatin-induced apoptosis. Dotted lines indicate interaction, whereas solid lines indicate 
(p53-induced) transcription.
 
We recently demonstrated that cisplatin induces apoptosis mainly in a Fas-dependent 
manner in EC cells (20), while enhanced p21 expression protects EC cells against Fas-me-
diated apoptosis (7). This protection might be mediated via the inhibition of caspase 3 (40), 
CDK2 and ASK1 by cytoplasmic p21. We have no indication that p21 binds to caspase 
3 and inhibits activation in irradiated EC cells (7) or cisplatin treated EC cells (data not 
shown). In the present paper, we show that endogenous cytoplasmic p21 forms a complex 
with CDK2 and ASK1 in EC cells. In EC cells, expressing low p21 levels, CDK2 downre-
gulation strongly reduced the cisplatin induced apoptotic response. Moreover, relocalization 
of p21 to the nucleus using LY294002, which completely abolished p21-CDK2 complexes, 
as well as suppression of p21 made initially cisplatin-resistant cells sensitive to cisplatin in a 
CDK2 dependent manner, indicating the importance of cytoplasmic CDK2 as a pro-apoptotic 
factor in cisplatin treated EC cells. The pro-apoptotic signaling of CDK2 is not clear yet. It 
has been reported that cytoplasmic CDK2 activity is induced in a caspase-dependent way 
following activation of the Fas pathway (41) and leads to depolarization of the mitochondrial 
membrane potential (42) by cytoplasmic CDK2 mediated translocation of Bax to the mito-
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damage can be an important mechanism to enhance, among others, Fas ligand expression 
(44). Taken together, these results indicated that the high cytoplasmic p21 levels, in complex 
with cytoplasmic CDK2, protect against cisplatin-induced apoptosis in EC cells.
In the present study, in-vivo relevance of p21 expression was demonstrated in the EC 
component of TC patients with refractory disease, being positive for p21, whereas no p21 
was detected in the EC component of patients with chemo-sensitive tumors. Lack of p21 
staining in the EC component but strongly positive p21 staining in mature teratoma compo-
nents has been frequently observed (9,14-15,18). Teratomas, however, predominately show 
a nuclear localization of p21. Moreover, teratomas in contrast to EC express Rb (17,45) sug-
gesting a putative role for p21 in cell cycle control in these non-growing or rarely growing 
tumors, also known as growing teratoma syndrome (17). Furthermore, teratomas are, pos-
sibly via p21-mediated cell cycle arrest, not responsive to treatment with cisplatin (8,15-17). 
Interestingly, p21 staining in the EC component of refractory patients was mainly localized 
in the cytoplasm of EC cells. In addition, Ki-67 staining revealed no cell cycle arrest, but 
proliferation in EC with abundant expression of p21, indicating a similar role in-vivo for high 
levels of cytoplasmic p21 in the protection against cisplatin-induced apoptosis as we have 
demonstrated for cisplatin-resistant EC cell lines. Cytoplasmic p21 expression has been re-
lated to drug resistance in several other types of cancer (11). Previous studies in non-TC cell 
types have shown that phosphorylation of Thr-145 in the p21-NLS by p-Akt is important for 
dynamic shuttling of p-p21 between the nucleus and the cytoplasm (11,33). PTEN can pre-
vent phosphorylation of Akt in EC cells (35). Virtually all ECs (cell lines and TC patients), 
however, lack PTEN expression (35), which is shown to be important for the development 
of invasive TCs (35,46). Here, we show that re-localization of p21 to the nucleus by dep-
hosphorylation of p21, using the PI3K inhibitor LY294002, the Akt inhibitor Triciribine or 
siRNA against Akt, sensitized cells for cisplatin-induced apoptosis. Phosphorylation of Akt 
might be inhibited by targeting tyrosine kinase membrane receptors like KIT and ERBB2, 
that have been implied in TC (8,47-52). An even more direct approach to target Akt phosp-
horylation, besides Triciribine, is the use of PI3K/Akt inhibitors that are currently in clinical 
development (53). However, the efficacy of the various subclasses of PI3K- or Akt-inhibitors 
to relocalize p21 and subsequently enhance cisplatin sensitivity in refractory TC patients 
needs to be further elucidated.
The role of miRNAs in tumorigenesis is attracting increasing attention and miRNAs 
have actually been implicated in TC/EC carcinogenesis (54-55). The miR-106b seed family 
is potentially oncogenic (56) and has been implied in embryonal stem cells in their main-
tenance and control of differentiation (57). ECs share many similarities with embryonic 
stem cells (16,38) including their miRNA expression profile (38). Interestingly, our results 
indicate differences in expression levels of p21-3’UTR regulating miR-106b seed family 
members between intrinsically cisplatin-resistant EC and cisplatin-sensitive EC cell lines. 
Additionally, we report that high levels of the miR-106b seed family members are causing 
low levels of (cytoplasmic) p21 in EC cells and consequently sensitivity to cisplatin. In con-
trast, low levels of the miR-106b seed family members were associated with high levels of 
(cytoplasmic) p21 in EC cells and EC of refractory TC patients. In murine embryonic stem 
cells, miR-17~92 and miR-106a~363 clusters of the miR-106b seed family are under control 
of embryonic stem cell factor Oct4 (39). ECs, like embryonic stem cells, also express a cas-
sette of pluripotency genes (16,38,58), where Oct4 is supposed to be the key pluripotency 
regulator (58). Here, we show that expression of members of the miR-106b seed family 
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colocalizes with Oct4 expression in TC. Our results indicate that Oct4 regulates expression 
of miR-17-5p, miR-106a and miR-20a, belonging to the miR-106b seed family, via the p21-
3’UTR. Furthermore, in EC cells, expressing high basal levels of Oct4, over-expression of 
miR-17-5p completely precluded p21 induction when Oct4 was suppressed. Similar results 
were obtained with EC cells, expressing lower basal levels of Oct4, however, some p21 
expression was still detectable in these cells after combined transfection of Oct4 siRNA and 
pre-miR-17-5p. This suggests that besides the miR-106b seed family the regulation of p21 
expression through Oct4 may be more complex, involving other factors as well. In summary, 
we provide evidence that Oct4 regulates expression of p21-3’UTR targeting miR-106b seed 
family members and thus indirectly p21 levels and cisplatin sensitivity in EC cells.
In conclusion, we demonstrate an important mechanism in EC that causes elevated cy-
toplasmic p21 levels and consequently results in cisplatin-resistance. Moreover, we provide 
a target to overcome resistance, which may form the basis for the development of novel 
therapeutic approaches to alleviate cisplatin-resistance in TCs or other cisplatin-
resistant types of solid tumors.
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Supplemental Figure 1. (A) IC50 values for cisplatin were calculated from the graph in Figure 1A. (B-C) Localiza-
tion of p21 was determined with immuno-fluorescence; 24h after cisplatin treatment p21 is,cytoplasmic localized in 
833KE, using the breast carcinoma cell line MCF-7 as a control for nuclear staining after chemotherapy treatment 
(59-60) Scale bar, 30 mm. (B). 24h after gamma-irradiation (IR) p21 is localized in the cytoplasm of Tera and Scha 
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Supplemental Figure 2. (A-C) No significant effect of p21 siRNA on cisplatin induced apoptosis in Tera, Tera-CP 
and 833KE compared to scr siRNA. Values are the mean ± SD of three independent experiments. Inset shows suc-
cessful p21 suppression. (D) p21-D-NLS is localized in the cytoplasm of Tera-p21-D-NLS cells when untreated or 
treated with cisplatin (CP). Scale bar, 30 mm. (E,F) Tera-p21-D-NLS is less sensitive for cisplatin compared to Tera 
Mock as shown by a lower percentage of apoptotic cells (E) and reduced caspase 3 activation (F) following cispla-
tin treatment for 24 h. Values are the mean ± SD of three experiments. (G) No significant effect of p21 siRNA on 
cisplatin induced apoptosis in Tera Mock to scr siRNA. (H) Enhanced caspase 3 activity in Tera-p21-D-NLS after 
treatment with p21 siRNA. Values are the mean ± SD of three experiments.
Supplemental Figure 3. (A) Decreased PARP cleavage after successful downregulation of CDK2 24h after cisplatin 
treatment of 833KE. (B) Dramatically reduced apoptosis response after co-transfection with CDK2 and p21 siRNA 
in 2102EP and Scha cells.
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Supplemental Figure 4. (A) Difference in p-p21 levels of the EC cell lines treated and untreated with cisplatin. Note 
that intrinsic cisplatin-resistant EC cell lines (2102EP and Scha) have higher basal and cisplatin-induced p21/p-p21 
levels compared to cisplatin-sensitive EC cell lines. (B) Following treatment with cisplatin or gamma-irradiation of 
EC cells p-Akt is induced, whereas dephosporylation of p-Akt occurred after treatment with Ly294002 or Triciribine 
in Scha and Tera. (C) After treatment with 10 mM LY294002 for 24h, p21 is localized in the nucleus of Tera and 
Scha, whereas this treatment in Tera-p21-D-NLS had no effect on p21-D-NLS localization. Scale bar, 30 mm. (D) 
24h after treatment with gamma-irradiation in combination with either 10 mM LY294002 (LY) or 10 mM Triciribine 
(TR), phosphorylated levels of p21(Thr145) decreased and p21 is more pronounced localized in the nucleus of Tera 
and Scha. Scale bar, 30 mm. (E) Dephosporylation of p-Akt and downregulation of Akt reduces the levels of p-p21.
Supplemental Table 1. Patient characteristics
Chemo-sensitive disease Refractory disease
No. of patients 31 7
Median age at start of chemotherapy (range) 29 (17-35) 31 (19-44)
Histologie*
 Ec (pure component) 23 (5) 7 (2)
 YS (pure component) 6 (1) 1 (0)
 ChC (pure component) 6 (0) 2 (0)
 T (pure component) 17 (0) 4 (0(
 S (pure component) 7 (3) 0 (0)
Prognosis group**
 Good 22 1
 Intermediate 5 2
 Poor 4 4
Disease outcome
 Death of disease 0 7
 Alive with disease 0 0
 No evidence of disease 31 0
*single or multiple components; each component listed.
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Supplemental Figure 5. (A) Enhanced caspase 3 activity after the combined treatment of Scha and 2102EP with 
Ly294002 or Triciribine and cisplatin, while there is no increase in activity in Tera in combination with cisplatin. 
The combined treatment for 24h of LY294002/Triciribine and gamma-irradiation enhanced caspase 3 activity in 
both Tera and Scha. (B) Treatment with LY294002 (LY) resulted in the loss of complex formation between p21 and 
CDK2 in Scha cells. (C) Suppression of CDK2 considerably reduced the increase in apoptosis induction of 2102EP 
and Scha cells upon combined treatment with cisplatin and LY294002 (LY). (D) Downregulation of Akt reduced 
the levels of p-p21 and resulted in a more pronounced nuclear localization of p21 in 2102EP. Scale bar, 30 mm. (E) 
The combined treatment of 24h LY294002/Triciribine and irradiation sensitized both Tera and Scha for gamma-
irradiation induced apoptosis. Values are the mean ± SD of three independent experiments.
Supplemental Figure 6. (A) Mature teratoma 
component (T) stains positive for p21/p-p21 
but negative Oct4, whereas the embryonal 
carcinoma component (EC) stains negative 
for p21/p-p21 and intensively positive for 
Oct4 using IHC. A representative sample 
is shown. Scale bar, 300 mm. (B) Presence 
of Ki-67 staining indicating proliferation 
instead of cell cycle arrest in abundant p21 
positive EC. (C) Quantitative RT-PCR on 
miR-106b seed family expression in EC cell 
lines. Note that the intrinsic cisplatin-resistant EC cell lines (2102EP and Scha) have lower levels of the miR-106b 
family compared to cisplatin-sensitive EC cell lines (Tera and 833KE). All reactions were run in triplicate. The 
miRNA expression was normalized to RNU48 expression resulting in a ΔCt from which the 2−ΔCt value was derived 
and depicted. (D) Treatment with LY294002 (LY) resensitized synthetic anti-miR-17-5p transfected Tera cells to 
cisplatin. (E) Quantitative RT-PCR on miR-106b seed family expression in EC cell lines, showing less expression of 
the miR-106b family in Oct4 suppressed cells, after 48h of treatment with siRNA against Oct4, compared to control.
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Abstract
In murine testicular carcinoma (TC) cells wild-type p53 contributes to the sensitivity to 
DNA-damaging drugs in a dose-dependent way. In human TC, however, the role of wild-ty-
pe p53 functionality in chemotherapeutic response remains elusive. We analysed functiona-
lity of wild-type p53 in the unique cisplatin sensitivity of human TC using a short interfering 
(si)RNA approach. A panel of cisplatin sensitive TC cell lines (833KE and Tera), a subline 
with acquired cisplatin resistance (Tera-CP) and a panel of intrinsic resistant TC cell lines 
(Scha and 2102EP), all expressing wild-type p53 were used. Cisplatin sensitivity was related 
to apoptosis induction in the TC cell lines. P53 and p53-transcriptional targets MDM2 and 
p21Waf1/Cip1 (p21) were expressed in all TC cell lines. Basal levels of MDM2 and p21 mRNA 
and protein were highest in Scha and 2102EP and depending on p53 transactivation. Follo-
wing cisplatin exposure, expression levels of p53 increased within 6 h and further enhanced 
at 24 h with a subsequent increase in MDM2 mRNA and protein levels and Fas cell membra-
ne levels in all TC cell lines. Previously, we demonstrated that high induction of p21 protein 
levels protected TC cell lines against Fas-mediated apoptosis following irradiation. In con-
trast, cisplatin treatment resulted in a small induction of p21 mRNA and protein in these TC 
cells. Down-regulation of p53 with siRNA lowered cisplatin-induced apoptosis in Tera and 
Tera-CP, which was associated with a diminished Fas membrane expression. In contrast, p53 
suppression augmented cisplatin-induced apoptosis in Scha and 2102EP and concomitantly 
strongly suppressed MDM2 and p21 mRNA and protein expression. Our results indicate that 
p53 is involved in transactivation of pro- and anti-apoptotic genes in TC cells. The opposite 
role of p53 in cisplatin-induced apoptosis demonstrates the importance of the cellular context 
on the p53 transactivation pathway among TC cell lines.
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Introduction
Testicular cancer (TC) represents the most frequent solid malignant tumour in men 20-40 
years of age (1) and the most frequent cause of death from solid tumours in this age group. 
The incidence of testicular cancer has been arising world-wide (2). Despite the rising inci-
dence of testicular cancer and the presence of metastatic disease up to 50% at the time of 
diagnosis (3), a decrease in mortality has been observed thanks to highly effective chemothe-
rapy schemes (2,4). In general, TCs are successfully treated, however, about 20% of patients 
diagnosed with metastatic disease will not achieve a durable complete remission after initial 
treatment, either due to incomplete response or relapse, and will eventually die from this 
disease. Understanding the molecular determinants of chemotherapy sensitivity and resis-
tance in testicular cancer treatment may provide a way to improve chemotherapy sensitivity 
in other solid tumours.
Two DNA damaging agents, cisplatin and etoposide, are mainly responsible for the suc-
cessful outcome in TC treatment (5).  So far, the analyses of potentially relevant parameters 
in cisplatin response (detoxification mechanisms, DNA platination and repair, p53 status, 
Bcl-2 family status) have not elucidated the determinants of sensitivity in human TC cell 
lines (6-10). Most human TC cell lines, however, show a characteristic hypersensitivity to 
apoptosis-induction by chemotherapeutic drugs (10-13).
A major role for p53 in the response to chemotherapeutic drugs and the execution of 
apoptosis has been described (14-18). P53 is a tumour suppressor gene with a dual role in 
stress response, regulating a number of genes that co-ordinately force cells into either cell 
cycle arrest (via trans-activation of p21Waf1/Cip1) allowing time for DNA repair or into apop-
tosis. In turn, the function of p53 is regulated by several mechanisms, acting not only at the 
transcriptional and translational level, but also influencing the stability of p53 as well as its 
post-translational modifications and subcellular localisation (19). P53 is the most frequently 
mutated gene in human cancers (20), but surprisingly, in human TCs almost no p53 muta-
tions occur, while the p53 protein is expressed at high levels in the majority of TCs (21). In 
human ovarian germ cell tumours, displaying high sensitive to cisplatin-containing chemo-
therapy, no p53 mutations were detected (22). Despite the still increasing knowledge about 
the p53 protein as transactivator and cellular gatekeeper for cell growth and division, the 
effect of wild-type p53 and mutated p53 on drug sensitivity of human TC tumours is still not 
clear. Several reports have studied chemosensitivity of human TC cell lines in relation to p53 
expression, with contradicting results (10,13,23-27).
In order to extensively determine the role of the p53-dependent and p53-independent 
apoptotic pathway in cisplatin sensitivity and resistance in a setting closely related to the 
clinic, a well-defined panel of human TC cell lines was used (6,28-30). We recently repor-
ted that p53 was upregulated following cisplatin treatment as well as irradiation. However, 
cisplatin exposure induced apoptosis in TC cells in contrast to irradiation (30). Furthermore, 
p21Waf1/Cip1 (p21) was almost not upregulated in TC cell lines following cisplatin treatment 
(30). Therefore, we compared p53-dependent cellular and molecular changes with respect 
to p21 and apoptosis induction by cisplatin in two cisplatin sensitive cell lines (833KE and 
Tera), a subline of Tera with acquired resistance to cisplatin (Tera-CP) and two intrinsic 
cisplatin resistant cell lines (Scha and 2102EP).
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Materials and methods
DNA and Chemicals. RPMI 1640 medium was obtained from Gibco (Paisley, Scotland) and foetal calf serum 
from Sanbio (Uden, the Netherlands). Cisplatin was purchased from Bristol-Myers Co. (Weesp, the Netherlands). 
3-(4,5-dimethylthiazol-2-yl) 2,5-diphenyltetrazolium bromide (MTT) was obtained from Sigma (St.Louis, Mo).
Cell Lines. For the cell lines used in this study, origin and pre-treatment were described by Sark et al (28). 
2102EP was a gift from L. Looijenga, (Erasmus University, Rotterdam, the Netherlands). The testicular cancer cell 
lines Tera, Tera-CP, 833KE, 2102 EP and Scha and the human ovarian carcinoma cell line A2780, used as a control 
for different protein, were cultured in RPMI 1640 medium supplemented with 10% foetal calf serum at 37oC in a 
humidified atmosphere with 5% CO2. All cell lines grew attached, 833KE was harvested by treatment with prote-
ase XXIV 0.005% for 3 min, 2102EP was harvested by treatment with trypsin and Tera, Tera-CP and Scha were 
harvested by scraping.
RNA interference. p53 I small interfering RNA (siRNA) molecules, sequences 5’-GCA UGA ACC GGA GGC 
CCA UdTdT-3’ (sense) and 5’-AUG GGC CUC CGG UUC AUG CdTdT-3’ (anti-sense), p53 II siRNA, sequences 
5’-CUU CGA CUU UGU CAC CGA GdTdT-3’ (sense) and 5’-CUU ACG CUG AGU ACU UCG AdTdT-3’ (anti-
sense) and negative control (scrambled) were purchased from Eurogentec (Maastricht, the Netherlands). TC cells 
(0.4 x 106/ well) were transfected in 6 well plates with 5 ml of 20 mM siRNA duplexes using Oligofectamine reagent 
according to the manufacturer’s instructions (Invitrogen BV, Breda, the Netherlands). After 24 h, cells were treated 
with cisplatin. At 6 h or 24 h after the treatment cells were harvested for protein isolation. Alternatively, in order 
to perform an apoptosis assay, at 24 h after transfection, cell were harvested and plated in 96-well plates. The day 
after, cells were treated with cisplatin. At 24 h after the treatment, the percentage of apoptotic cells was determined 
by acridine orange apoptosis assay.
Drug Sensitivity Assay. Drug sensitivity testing was performed with the microculture tetrazolium assay as 
described previously (28). The linear relationship of cell number to MTT formazan crystal formation and the expo-
nential growth of cells in the wells were checked. Cytotoxicity for all cell lines was determined after 4 days. Each 
drug concentration was tested in quadruplicate.
Western Blotting. After 6 hrs or 24 h cisplatin incubation cell were harvested and lysates were examined by 
Western Blot analysis as described previously (30). Immunodetection of p53, p21, MDM2, poly-(ADP-ribose)-po-
lymerase (PARP) was performed with the following antibodies:anti-p53-DO-1 (clone sc-126; Santa Cruz Biotech-
nology, CA, USA),  anti-phospho-p53 (ser15 and ser46; Cell Signaling, MA, USA) mouse anti-MDM2 (SMP14, 
Oncogene Research Products; San Diego, USA), mouse anti-p21 (EA10, Oncogene Research Products), rabbit anti-
Parp (Roche Applied Science, Almere, the Netherlands) and mouse anti-ß-actin (C4, MP Biomedical, Eindhoven, 
the Netherlands). The antibody binding was eventually determined using horseradish peroxidase (HRP)-conjugated 
secondary antibodies (all from DAKO, Glostrup, Denmark) Chemiluminescence was detected with the BM Chemi-
luminescence detection kit (Roche Applied Science). Membranes were exposed to Kodak X-OMAT films. Equal 
protein loading was checked for with Ponceau S and ß-actin staining.
Apoptosis. For apoptosis measurements cells were plated in 24-well culture plates. Cells were continuously 
incubated with cisplatin at various concentrations. Acridine orange fluorescent staining of nuclei in unfixed cells was 
used to distinguish apoptotic from vital cells (6). Staining was performed 6, 24, 48 and 72 h after start of incubation. 
Results are expressed as the percentage of apoptotic cells in a culture by counting at least 300 cells per well.
Caspase 3 activity. After 6 hrs or 24 h cisplatin incubation, cells were harvested as usual and centrifuged at 
1400 rpm for 8 min. After one wash step with cold PBS 1x, cells were resuspended in 50 ml of chilled Cell Lysis 
Buffer [10 mM HEPES, 2 mM EDTA, 0.1% CHAPS / NP40, 5 mM DTT, 1 mM PMSF (10 µg/ml pepstatin A) (20 
µg/ml leupeptin) (10 µg/ml aprotinin)] and incubated on ice for 10 min. Subsequently cell lysates were centrifuged 
in a microcentrifuge at 10,000 g for 3 min at 4C to precipitate cellular debris. The supernatants were then transfer-
red to new microcentrifuge tubes. From each sample, 5 ml were used to perform Bradford protein quantification. 
Samples were then diluted to the final protein concentration of 1 mg/ml for caspase assay, with lysis buffer. 25 ml 
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of 2X Reaction Buffer [31.25% sucrose, 0.3125% CHAPS (3-[3-cholamido-propyl)-dimethammonio]-1propane-
sulphonate), HEPES: 312.5 mM (pH 7.5 Mw: 238.31g/l)] (containing DTT and caspase 3/7 substrate DEVD-AFC) 
were added to each 25 ml sample in a 96-wells plate (Cliniplate flat bottom black) and incubated for 1 h at 37C. 
Fluorescent detection of protease activity was performed by means of a fluorometer equipped with a 400-nm excita-
tion filter and 505-nm emission filter. Fold-increase in protease activity was determined by comparing these results 
with the level of the control.
Detection of Fas membrane expression. Cisplatin-treated or untreated cells were stained with a phycoerythrin 
(PE)-conjugated Ab against Fas (DX2 from Becton Dickinson, Erembodegem-Aalst, Belgium) for 1 hour at room 
temperature. Subsequently, cells were washed and analysed by flow cytometry (FACS-Calibur; Becton Dickinson). 
The mean fluorescence intensity was determined by comparison of the fluorescence intensity with the fluorescence 
intensity of isotype control cells.
Quantitative real-time PCR for p21 and MDM2. Total RNA was isolated using the RNeasy Midi Kit accor-
ding to the manufacturer’s instructions (Qiagen, Venlo, the Netherlands). cDNA was synthesized from total RNA 
as described by the manufacturer’s protocol (Life Technologies, Invitrogen) using oligo dT primers and M-MLV 
transcriptase. Quantitative real-time PCR was performed using SYBR Green qPCR SuperMix (Invitrogen). p21 and 
MDM2 mRNA levels were normalized to the level of GAPDH in the same sample. Results of at least 3 experiments 
in duplicate are expressed as mean ± SD. Used primers: GAPDH For: CAC CAC CAC GGA GAA CGC TGG, 
GAPDH Rev: CCA AAG TTG TCA TGG ATG ACC, P21 For: CCT GTC ACT GTC TTG TAC CCT, P21 Rev: 
GCG TTT GGA GTG GTA GAA ATCT, MDM2 For: TCC CAA TTA GCT TGG CCT AC, MDM2 Rev: TAA 
CAC GGT GAA ACC CTG TC.
Results
Expression of p53 and the p53 transactivated proteins MDM2 and p21. All TC cell lines 
express wild-type p53 (31). Basal p53 levels are highest in 833KE, followed by Scha, Tera 
and Tera-CP. Expression levels of MDM2, an important target of p53 transactivation, were 
higher in 833KE and Scha compared to Tera and Tera-CP. P21, another target of p53 trans-
criptional activation was expressed in Scha, and minimally detectable in 833KE, Tera and 
Tera-CP (Figure 1). The human A2780 ovarian cancer cell line was used as a positive control 
for wild-type p53 expressing cells (30). These results suggest there is a relation between con-
stitutively high wild-type p53 and MDM2 expression levels in 833KE and Scha compared to 
Tera or Tera-CP, however this relation was not observed for p21.
Figure 1. Large differences in p53, p21 and MDM2 ex-
pression levels between TC cell lines. Expression levels 
in TC cells were determined using western blot of proteins 
in whole-cell lysates. Human A2780 ovarian cancer cells 
were used as control for wild-type p53 expressing cells. Im-
munoblotting was performed as described in “Material and 
Methods”. Each lane was loaded with 20 mg protein. Actin 
was used as a loading control. A representative example of 
at least three independent experiments is shown.
Effect of cisplatin treatment on the expression of p53, p21and MDM2 in TC cells. To 
determine whether cisplatin treatment induces expression of p53, cells were incubated for 6 
h and 24 h with cisplatin concentrations ranging from the ID50 of highly sensitive cell lines 
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measured the drug-induced protein expression of genes, which are transcriptionally activated 
by wild-type p53, i.e. p21 and MDM2. Within 6 h a concentration-dependent increase in p53 
expression levels was observed in the TC cell lines (results not shown), however, no changes 
in expression of p21 and MDM2 were observed (results not shown). A prolonged incubation 
with cisplatin for 24 h resulted in a concentration-dependent increase in cellular p53 levels 
in the TC cell lines (Figure 2). The p53 induction levels in the TC cell lines after treatment 
with cisplatin for 24 h were higher than p53 levels after a 6 h treatment (results not shown). 
With lower cisplatin concentration for 24 h, the increase in p53 was more pronounced in 
833KE than in Scha cells, while at higher cisplatin concentrations a similar induction of p53 
was found. As to the isogenic cisplatin resistant Tera/Tera-CP model, a stronger induction of 
p53 was detectable in Tera and Tera-CP after cisplatin treatment for 24 h, with a more pro-
nounced induction in Tera at lower cisplatin concentrations. Note that the constitutive level 
of p53 was at least 5-fold higher in 833KE and Scha, indicating that the absolute cellular p53 
expression levels after cisplatin induction are comparable between the TC cell lines.
MDM2 levels increased in all TC cell lines after a 24 h treatment with increasing cisplatin 
concentrations (Figure 2). At the highest cisplatin concentration used, MDM2 levels slightly 
declined in the TC cell lines, except for Scha. Despite the high induction of p53 and MDM2, 
a minor induction or even no induction of p21 was detectable in the TC cell lines (Figure 
2).  These results are in agreement with our previous study showing that irradiation but not 
cisplatin strongly induces p21 mRNA and protein expression demonstrating that p21 can be 
induced depending on the type of DNA damage in TC cell lines (30-31).
Figure 2. Induction of p53, p21 and MDM2 
protein levels in TC cells after cisplatin tre-
atment for 24 h. Cells were treated with in-
creasing concentrations of cisplatin for 24 h. 
Immunoblotting was performed as described 
in “Material and Methods”. Each lane was 
loaded with 20 mg protein. Actin was used as 
a loading control. A representative example 
of three independent experiments is shown. 
To detect p21 in lysates of Tera, Tera-CP, 
and 833KE membranes had to be exposed to 
X-ray films longer compared to Scha.
Cisplatin induced apoptosis in TC cells. Despite the induction of p53, no PARP cleavage 
nor apoptotic cells, defined as cells with condensed and fragmented nuclei, were observed 
after 6 h (data not shown). However, treatment of cisplatin for 24 h resulted in a massive 
induction of apoptosis. Apoptosis was also reflected in caspase 3 activation, and cleavage of 
PARP in all TC cell lines in a cisplatin concentration-dependent manner (Figure 3A-C). For 
Scha and Tera-CP higher cisplatin concentration were needed compared to 833KE and Tera. 
The results of the different assays were in accordance with each other showing that Tera and 
833KE are the most sensitive cell lines, while Tera-CP and Scha were relatively resistant to 
cisplatin (Figure 3A-C).
Influence of p53 down-regulation on response to cisplatin treatment. The minimal in-
duction of p21 suggested that p53 is not functional in TC cells following cisplatin treatment. 
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To study the role of p53 in more detail, we suppressed p53 expression with p53 siRNA. 
When p53 suppressed TC cells were treated with cisplatin, different effects on apoptosis 
were observed (Figure 4). Down-regulation of p53 makes the cisplatin-sensitive Tera parti-
ally resistant to cisplatin-induced apoptosis compared to both untransfected and scr siRNA 
transfected Tera. Similar observations were made for Tera-CP, except that these cells had to 
be treated with cisplatin for 48 h and the effect of p53 siRNA was slightly less pronounced in 
Tera-CP. No effect of p53 suppression was observed in 833KE (results not shown). In con-
trast, the down-regulation of p53 sensitized Scha to cisplatin-induced apoptosis compared to 
control cells and scr siRNA transfected cells. This sensitizing effect was detectable after 3 h 
and 6 h of cisplatin treatment (data not shown) and more pronounced after 24 h (Figure 4A). 
We added 2102EP, an additional intrinsic cisplatin-resistant human TC cell line known to 
be wild-type p53 and to express relatively high levels of p21 (31), to our panel to extent our 
findings of the protective role of p53 in cisplatin-resistant TC cells.. Following downregula-
tion of p53, a similar sensitization to cisplatin was observed in 2102EP as in Scha (Figure 4).
Figure 3. Cisplatin treatment for 24 h resul-
ted in apoptosis in TC cells. Apoptosis was 
determined with several different assays 
using cell morphology, caspase 3 activity 
and PARP cleavage as read-outs. Cisplatin 
concentration-dependent apoptosis (0, 4 and 
8 µM) is related to the cell survival (see table 
1). (A) The percentage of apoptotic cells was 
determined with fluorescence microscopy on 
acridine orange stained cells, (B) caspase 3 
activity was determined in whole cell lysates 
using a fluorescence assay, and (C) PARP 
cleavage was determined with immunoblot-
ting on whole-cell lysates after exposure of 
the cells to cisplatin. Counting of apoptotic 
cells, caspase 3 activity assay and immunoblotting were performed as described in “Materials and Methods”. Values 
are the mean ± SD of three experiments. *p < 0.05; **p < 0.01; ***p <0.005; compared to matching siRNA scram-
bled (scr) transfected cells.
At the protein level, down-regulation of p53, MDM2 and p21 was observed in p53 siRNA 
treated cells both in the absence of cisplatin and after addition of cisplatin for 24 h compared 
to control cells and scr siRNA transfected cells. Although treatment of p53 siRNA transfec-
ted cells with a high cisplatin dose induced p53 as well as MDM2 and p21 protein expression, 
these levels still remains lower when compared to the corresponding levels in untransfected 
or scr siRNA transfected cells treated with cisplatin (Figure 4B).
To strengthen the p53 dependent effect of the siRNA approach, we used two different 
p53 siRNAs. The caspase activity assay results were in agreement with those obtained with 
the apoptosis assay. A clear induction of caspase 3 activity was observed in all four cell lines 
treated with 4 µM cisplatin. Differences in cisplatin-induced caspase 3 activity reflect the dif-
ferences in cisplatin concentration dependent apoptosis-induction between the four cell lines. 
A 2 to 2.5-fold lower caspase activity was observed in p53 suppressed Tera and Tera-CP cells 
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after cisplatin treatment compared to scr siRNA transfected cells (Figure 5A). In contrast, in 
cisplatin-treated p53 suppressed Scha and 2101EP cells a 2 to 2.5-fold higher caspase activity 
was observed compared to scr siRNA transfected cells (Figure 5A). In Tera-CP, p53 siRNA 
strongly reduced the p53 expression level and less PARP cleavage was observed following 
cisplatin treatment. In 2102EP, a similar reduction in p53 was observed but now more PARP 
cleavage was observed following cisplatin treatment (Figure 5B). Similar effects were ob-
served with either of the two p53 siRNAs in the caspase 3 activity assays and with western 
blotting (Figure 5A and B).
Figure 4. Suppression of p53 has op-
posite effects on cisplatin-induced 
apoptosis in different TC cell lines. TC 
cells were either untransfected (con), 
or transfected with p53 siRNA (p53) 
or scr siRNA (scr) and after 24 h tre-
ated with cisplatin (0, 4, or 8 mM) for 
an additional 24 h. (A) Apoptotic cells 
were visualised with fluorescence mi-
croscopy on acridine orange stained 
cells with acridine orange using a flu-
orescence microscopy counted with on 
stained cells. Values are the mean ± SD 
of three experiments. *p < 0.05; **p < 
0.01; ***p < 0.005; compared to mat-
ching siRNA scrambled (scr) transfec-
ted cells. (B) Transfection with p53 siR-
NA suppressed  p53, p21 and MDM2 
expression in Tera and Scha cells also 
after cisplatin treatment (4 mM)  for 24 
h. PARP cleavage, however, was redu-
ced in p53 suppressed Tera cells but 
enhanced in p53 suppressed Scha cells 
following cisplatin treatment. Protein 
expression was determined in whole-
cell lysates using immunoblotting as 
described in “Material and Methods”. 
Each lane was loaded with 20 mg protein. Actin was used as a loading control. To detect p21 in lysates of Tera mem-
branes had to be exposed to X-ray films longer compared to Scha. A representative example of three independent 
experiments is shown.
Influence of p53 down-regulation on p21 and MDM2 mRNA and Fas membrane expres-
sion. Since p53 acts as a transcription factor of p21 and MDM2, we analysed the effect of 
p53 suppression on mRNA levels of both proteins using quantitative PCR. Downregulation 
of p53 had almost no effect on basal p21 and MDM2 mRNA levels in Tera and Tera-CP, 
whereas an apparent effect on p21 and MDM2 mRNA levels was found in Scha and 2102EP. 
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which was almost completely blocked in p53 suppressed cells (Figure 6A and B). Previously, 
we have shown that cisplatin-induced apoptosis is depending on activation of the Fas/FasL 
system in the cisplatin-sensitive Tera and 833KE cells, while activation of the Fas/FasL 
system is inhibited in the cisplatin-resistant Tera-CP and Scha cells (29). Fas is induced in a 
p53-dependent manner and, in addition, p53 is involved in the translocation of Fas to the cell 
surface (29,30,32-36).  Therefore, we monitored the effect of p53 siRNA on Fas membrane 
expression. In agreement with our previous results, cisplatin strongly induced Fas membrane 
expression in Tera and to a lesser extent in Tera-CP, Scha and 2102EP. The upregulation was 
p53-dependent, since downregulation of p53 with p53 siRNA resulted in a strong inhibition 
of cisplatin-induced Fas membrane expression in all cell lines (Figure 6C). Notably, the ef-
fect of p53 suppression on Fas membrane expression in the absence of cisplatin was less evi-
dent. These results indicate that p53 is involved in basal transcription and cisplatin-induced 
transcriptional activation of p21and MDM2 and Fas membrane expression in a cell context 
dependent manner.
Figure 5. Suppression of p53 has 
opposite effects on cisplatin-indu-
ced caspase 3 activity in different 
TC cell lines. Cells were either 
transfected scr siRNA (scr), and 
with p53 siRNA set I (p53 I) or p53 
siRNA set II (p53 II). Following 
siRNA treatment for 24 h, cells 
were treated with cisplatin (4 mM) 
for an additional 24 h. (A) Caspase 
3 activity was determined in whole 
cell lysates using a fluorescence as-
say as described in “Material and 
Methods”. Values are the mean ± 
SD of three experiments. Values 
are the mean ± SD of three experi-
ments. *p < 0.05; **p < 0.01; ***p 
< 0.005; compared to matching 
siRNA scrambled (scr) transfected 
cells. (B) Both p53 siRNA sets sup-
pressed p53 expression in Tera-CP 
and 2102EP cells, also after cis-
platin treatment (4 mM) of the p53 
suppressed cells for 24 h. PARP 
cleavage, however, was reduced 
in p53 suppressed Tera-CP cells 
and enhanced in p53 suppressed 
2102EP cells following cisplatin treatment. Protein expression was determined in whole-cell lysates using immuno-
blotting as described in “Material and Methods”. Each lane was loaded with 20 mg protein. Actin was used as a 
loading control.  A representative example of three independent experiments is shown.
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Figure 6. Cisplatin-induced p21 and 
MDM2 mRNA and Fas surface expres-
sion in TC cells is strongly reduced in 
p53 suppressed TC cells. Cells were 
either transfected with p53 siRNA 
(p53 I) or scr siRNA (scr). Following 
siRNA treatment for 24 h, cells were 
treated with cisplatin (4 mM) for an 
additional 24 h. (A) Quantitative real-
time PCR was used to determine p21 and MDM2 mRNA levels that were 
normalized to the level of GAPDH in the same sample. (B) Fas membrane 
expression was determined with flow cytometry and indicated as mean flu-
orescence intensity (MFI). Values are the mean ± SD of three experiments. 
Values are the mean ± SD of three experiments. *p < 0.05; **p < 0.01; ***p 
< 0.005; compared to matching siRNA scrambled (scr) transfected cells.
Discussion
In the present study, we demonstrate that p53 is functional in most TC cell lines, but its invol-
vement in the response to cisplatin, i.e. pro-apoptotic or anti-apoptotic involvement, is cell 
context dependent. It is shown here that in a panel of cisplatin-sensitive and -resistant human 
TC cell lines cisplatin-induced apoptosis induction is related to the difference in cisplatin 
sensitivity between TC cell lines. Functionality of p53 was demonstrated by p53 siRNA, 
which suppressed basal p53 as well as p21 and MDM2 protein and mRNA expression levels 
in TC cell lines. Our results further showed that cisplatin treatment resulted in enhanced 
wild-type p53, p21 and MDM2 mRNA and protein expression and Fas cell surface expres-
sion, which was prevented by p53 suppression in most TC cell lines. Remarkably, inhibition 
of cisplatin-induced p53 expression with p53 siRNA causes a decrease in apoptosis levels in 
the cisplatin-sensitive Tera cell line and its cisplatin-resistant subline Tera-CP and an enhan-
ced induction in apoptosis in two intrinsic cisplatin-resistant cell lines, 2012EP and Scha, but 
had no effect on cisplatin sensitivity of 833KE.
In this study, we have demonstrated that higher basal levels of wild-type p53 in TC cells 
were accompanied by higher MDM2 and p21 protein and mRNA levels. Moreover, we sho-
wed that down-regulation of p53 using an siRNA approach resulted in a lower expression of 
MDM2 and p21 mRNA, suggesting the presence of a transcriptionally active p53 in human 
TC cell lines. Similar observations were made in another testicular cancer study, describing 
a correlation between p53 protein level in vivo and MDM2 mRNA expression (37). Next, 
we detected a concentration-dependent induction of p53 and MDM2 in TC cells following 
cisplatin treatment. The cisplatin concentration-dependent induction of p21 in the TC cell 
lines was much less clear. This finding is in agreement with a recent report in which we des-
cribed that g-radiation but not cisplatin massively induced p21 mRNA and protein expression 
in TC cells (30). Other studies have shown that in addition to g-radiation (30,38), etoposide 
treatment (23) also resulted in an induction of p21 protein in human TC cell lines. These ob-
servations can be explained by a different mechanism of p53 activation after DNA damage 
induced by either g-radiation or etoposide versus cisplatin. 
Several post-translational modification of the p53 protein may play a role in determi-
ning its functional activity. Phosphorylation of p53 at ser15 blocks p53 binding to MDM2 
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leading to the accumulation and activation of p53, whereas phosphorylation of p53-ser46 
positively regulates apoptosis-induction in response to DNA damage (39-43). We only de-
termined basal levels of p53 phosphorylation but did not find any difference between the 
cell lines (results not shown). Furthermore, conflicting data about the importance of these 
modifications have been published (44,45). Other p53 regulatory proteins have been sugge-
sted to be more important such as the related proteins MDM2 and MDM4 (MdmX) (45-47). 
The role of p53-MDM2 interaction in the response of testicular cancer to cisplatin is still not 
conclusive (48,49). However, treatment of the cells with nutlin-3, a small molecule antago-
nist of MDM2, was sufficient to induce apoptosis in TC cells suggesting that p53 activity 
is negatively regulated by MDM2. In addition, it was shown that MDM4 also functions as 
a negative feedback regulator of p53 in some of the TC cell lines (50). When nutlin-3 was 
combined with cisplatin an enhanced reduction in cell survival was observed in TC cells. 
Unfortunately, no causal relation between the effect of nutlin-3 or cisplatin with the presence 
of functional active p53 was established (50).
Table 1. The concentration of cisplatin inhibiting cell survival by 50 % after continuous treatment with 
cisplatin in the MTT assay (ID50 cisplatin) and the protein expression characteristics of TC cell lines.
ID50 Cisplatin p53 MDM2 p21 Fas
(mM)1 (protein expression)2 (membrane)3
Tera 0.7 ± 0.1 + + + +
Tera-CP 2.1 ±0.2 + + + +
833KE 1.0 ± 0.2 ++ ++ + +
Scha 3.3 ± 1.0 ++ ++ ++ +
2102EP 4.1 ± 0,7 ++ ++ ++ +
1) ID50 values are expressed as means ±SD of three independent experiments performed in quadruplicate using the 
    MTT assay. 
2) Protein expression as detected with western blotting and from refs (31,50) 
3) Fas membrane expression levels as detected with flow cytometry
Although clinical analyses of testicular cancers revealed almost no TP53 mutations (20), 
another report showed that mutant p53 was present in a subset of chemoresistant testicu-
lar cancers (24), further supporting the hypothesis of a functional p53 in human testicular 
cancer. A relation between the presence of wild-type p53, the susceptibility for apoptosis-
induction and the chemosensitivity of a panel of TC cell lines has been observed in several 
studies (23,29,51), but these results were challenged by other studies using either a different 
TC cell line panel (25) or p53 inhibition by human papilloma virus type-16 E6 in TC cells 
(13). Therefore, we have used an siRNA approach to investigate the role of p53 in cisplatin-
induced expression of MDM2, p21 and Fas and in cisplatin-induced apoptosis. Although 
p53 suppression reduced expression of these genes in all TC cell lines, an opposite effect 
on cisplatin-induced apoptosis was observed. Down-regulation of p53 led to a decrease in 
cisplatin sensitivity in Tera cells. In the cisplatin-resistant subline Tera-CP, a similar effect 
of p53 was observed but only after prolonged incubation with cisplatin, in line with the me-
chanism of acquired cisplatin-resistance in these cells (6). Our data are in agreement with a 
recent micro-array study from Kerley-Hamilton et al (52) in which the authors demonstrated 
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Figure 7. Proposed simplified model showing the mechanisms 
through which p53 can either be involved in a pro- or anti-
apoptotic response to cisplatin treatment in TC cells. Cisplatin-
induced DNA damage activates p53, which in turn transcribes 
p21 and MDM2, and induces Fas membrane expression. Re-
cently, we have identified the Fas pathway to be involved in 
cisplatin-induced apoptosis in cisplatin-sensitive TC cell lines 
(29). Moreover, we demonstrated that high cytoplasmic p21 
expression inhibits both Fas death receptor mediated apoptosis 
(30) and cisplatin-induced apoptosis (31). Here, we propose the 
following model. In TC cells hardly expressing p21, cisplatin-
induced p53 activation results in enhanced Fas death receptor 
expression and Fas death receptor mediated apoptosis. In ad-
dition, cisplatin-induced activation of p53 may also lead to 
enhanced intrinsic (mitochondrial) apoptosis. Thus, p53 has a 
pro-apoptotic function. In TC cells expressing relatively high 
cytoplasmic p21 levels, cisplatin-induced p53 activation also 
results in enhanced Fas death receptor expression, although to 
a lesser extent. However, the relatively high cytoplasmic p21 
expression levels are strongly depending on p53 transcriptional activity and are blocking both cisplatin-induced 
extrinsic and intrinsic apoptosis. In these cisplatin-resistant TC cells, p53 has an anti-apoptotic function as transcrip-
tional activator of p21 and possibly MDM2. 
that p53 was directly involved in cisplatin sensitivity in Tera cells, as the down-regulation of 
p53 corresponded to the global decrease of several cisplatin-induced genes involved in apop-
tosis and in particular of genes involved in the extrinsic apoptosis machinery, like FAS, Fas 
adaptor LRDD and a gene involved in positive Fas regulation, PHLDA3 (52). Previously, we 
have demonstrated that the Fas/FasL system is active and functional in the cisplatin-sensitive 
TC cell lines, including Tera cells (29). An additional factor sensitizing these TC cells to 
cisplatin and Fas mediated apoptosis is the low expression level of cytoplasmic p21 (30,31). 
Down-regulation of p53 prevented cisplatin-induced Fas surface expression in these cells. 
We therefore, hypothesize that in TC cells with low p21 expression levels, p53 is a pro-apop-
totic determinant of cisplatin-induced apoptosis via the Fas death receptor but p53-mediated 
effects via the intrinsic pathway can not be excluded (Figure 7). In intrinsic cisplatin-resistant 
TC cell lines, expressing high p21 and relatively low levels of Fas, we observed an anti-
apoptotic role for p53. Suppression of p53 resulted in reduced expression levels of both p21 
and Fas. Recently, we have demonstrated that cytoplasmic localized p21 is a key determinant 
of cisplatin-resistance in TC cell lines and in cisplatin refractory testicular cancer patients. 
An important regulatory mechanism of p21 protein expression was identified and involved 
binding of miR-106b seed family members to the 3’-UTR of p21, and thus reduced expres-
sion of p21. Expression levels of miR-106b family members were much higher in cisplatin 
sensitive compared to intrinsic cisplatin-resistant TC cell lines explaining the high p21 pro-
tein levels in the latter (31). Our present results indicate that in intrinsic cisplatin-resistant 
TC cells p53 plays an anti-apoptotic role due to its effect as transcriptional activator on p21 
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 In conclusion, our results suggest a dual role for p53 in transactivation and cisplatin-
induced apoptosis in TC cell lines depending on the cellular context. The observed effect of 
p53 on cisplatin-induced apoptosis may be closely related to p21 and Fas expression levels 
in TC cells.
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Abstract
A major role for p53 in the response and execution of apoptosis after chemotherapy has been 
described for many cancers. Although testicular cancer (TC) often express high levels of p53 
and almost no TP53 mutations are found, resistance to chemotherapy is still observed. In this 
study, we demonstrate that in intrinsic and acquired-cisplatin resistant TC cells p53 resides in 
a complex with murine double minute 2 (MDM2) after cisplatin treatment. Hyper-activation 
of the p53 pathway using the MDM2 antagonist Nutlin-3 in TC cells leads to nuclear lo-
calization of p53 and effective apoptosis induction as single agent. Targeting MDM2 with 
Nutlin-3 or short interfering RNA extremely sensitizes resistant TC cells to cisplatin. The 
observed effects are dependent on the presence of wild-type p53, since mutant p53 expres-
sing TC cells or wild-type p53 suppressed TC cells are resistant to Nutlin-3. These results 
indicate that targeting the p53/MDM2 axis, in combination with standard treatment, appears 
to be a powerful strategy to pursue in cisplatin-resistant or -refractory testicular cancers. 
Specifically, we show that the Fas death receptor pathway plays an important role in MDM2 
antagonist-induced apoptosis in TC cells. Importantly, we have identified a similar mecha-
nism in Hodgkin lymphoma and acute myeloid leukaemia cells, suggesting a common profile 
for Nutlin-3-induced apoptosis, which involves the Fas death receptor pathway.
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Introduction
Most testicular cancer (TC) patients respond well to cisplatin-based chemotherapy, howe-
ver, there is still a subset of these young patients that will die because of chemo-resistant or 
chemo-refractory disease (1-3). Similar to its effects in patients, cisplatin proved to be an 
extremely cytotoxic drug, inducing massive apoptosis in TC cell lines (4-8). An important 
role for p53 in the response to chemotherapeutic drugs and the execution of apoptosis has 
been described (9-13). p53 is a tumour suppressor protein with a dual role in stress response 
by transactivation of genes that induce apoptosis, such as FAS, as well as genes that induce 
cell-cycle arrest, such as CDKN1A (encoding p21cip1/waf1), allowing time for DNA repair. The 
function of p53 is regulated by several mechanisms, acting not only at the transcriptional 
and translational level, but also on stability, post-translational modification, and subcellular 
localization of p53 (14,15).
P53 is the most frequently mutated gene in human cancers (16-19) but surprisingly, in 
human TCs almost no p53 mutations occur and the p53 protein is expressed at high levels 
in the majority of TCs (20-22). Despite the increasing knowledge about p53 as a transacti-
vator and cellular gatekeeper for cell growth and division, the effects of wild-type p53 (and 
mutated p53) on drug sensitivity of human tumours is still not clear. Recently, we showed in 
TC cell lines, that p53 function is related to the response to cisplatin-induced DNA-damage, 
which also involved activation of the Fas death receptor pathway (4). Several studies have 
reported the effect of wild-type p53 expression on chemo-sensitivity of human TC cell lines 
with contrasting and sometimes conflicting results (6,23-31).
Tumours that retain wild-type p53 are supposed to have other defects in the p53 pa-
thway, such as presence of miR-371-373, miR-106b seed family, cytoplasmic p21, lack of 
PTEN expression or increased MDM2 expression (32-36). MDM2, as transcriptional target 
of p53, is the main negative feedback regulator of p53. By binding to the transactivation 
domain of p53, MDM2 is able to regulate p53 activity and stability via several mechanisms 
such as promoting p53 degradation through ubiquitination, stimulating p53 nuclear export, 
and inhibiting acetylation of p53 (15,37,38).
Inhibition of the p53-MDM2 interaction, with small molecules like RITA and Nutlin-3, 
provides an attractive strategy for (re)activating wild-type p53 in a non-genotoxic way. This 
(re)activation leads to cell cycle arrest and or apoptosis in tumour cells with wild-type p53 
(39-43). Restoration of p53 function by Nutlin-3 may thus have profound therapeutic use for 
tumours that have retained wild-type p53, particularly if MDM2 activity is disproportionally 
increased. Recently, Nutlin-3-induced apoptosis was investigated in a small panel of TC cell 
lines, and only additive effects were seen in combination with cisplatin. However, no me-
chanistic insights in Nutlin-3-induced apoptosis were offered (43,44). To further explore the 
potential of MDM2 inhibition as a mean to activate p53 in TC and to determine underlying 
mechanisms, we have determined the role of p53 and MDM2 in cisplatin-induced apoptosis 
using cisplatin-sensitive and -resistant human TC models. Finally, the importance of the Fas 
death receptor pathway in Nutlin-3 induced apoptosis has been studied.
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Materials and Methods
Cell Lines & reagents. A well defined panel of cisplatin sensitive and resistant EC cell lines 833KE, Tera, Tera-CP, 
Scha and 2102EP (all expressing wild-type p53) and NCCIT (mutant p53) were used in this study (4,21,24,45,46). 
Tera, Tera-CP, 2102EP, Scha, 833KE and NCCIT were cultured in RPMI 1640 medium (Gibco, Invitrogen, Me-
relbeke, Belgium) supplemented with 10% fetal calf serum (Bodinco, Alkmaar, the Netherlands) at 37oC in a 
humidified atmosphere with 5% CO2. Tera, Tera-CP and Scha were harvested by scraping, 2102EP and NCCIT by 
treatment with trypsin and 833KE by treatment with 0.005% protease XXIV (Sigma, Amsterdam, the Netherlands). 
The cell lines OCI-AML-3, MOLM-13, HL-60, KM-H2, L540 and L428 were maintained as described previously 
(41,42,47). Cisplatin was purchased from Bristol-Myers Co. (Weesp, the Netherlands), Nutlin-3 from Cayman Che-
mical (Huissen, the Netherlands). To block CD95/CD95L interactions, cells were incubated with anti-CD95L Ab 
Nok-1 (Becton Dickinson, Breda, the Netherlands) and azide free IgG control (Becton Dickinson).
Drug Sensitivity Assay. Drug sensitivity testing was performed with the microculture tetrazolium assay as 
described previously (4).
Immunofluorescence. Cells were seeded on 0.01% poly-L-lycine (Sigma) precoated coverslips. 24h after in-
dicated treatment cells were fixed with Methanol/Acetone (1:1) for 30 min at RT and then blocked with 1% bovine 
serum albumin and 1% normal goat serum in PBS for 30 min at RT. Followed by immunostaining with the corres-
ponding antibodies and counterstained with Alexa-Fluor goat secondary antibodies (Molecular Probes, Invitrogen). 
Finally, cells were stained with Hoechst 33258 (Molecular Probes, Invitrogen) for 5 minutes, washed with PBS, 
and coverslips were mounted on slides with Vectashield (Vector Laboratories, Amsterdam, the Netherlands). After 
staining cells were analyzed using a Quantimet 600S digital analysis system (Leica Microsystems).
Immunoprecipitation. A total of 107 Tera, Tera-CP, Scha and 2102EP cells were cultured for 24h after indi-
cated treatment. Cells were harvested, washed with ice-cold PBS, and subsequently lysed in 500 ml lysis buffer (20 
mM Tris HCl pH 7.6, 150 mM NaCl, 0.2% NP-40, protease inhibitor COMPLETE®, 1 mM PMSF, 1mM NaF and 
1 mM DTT) for 15 minutes on ice. Cell lysates were clarified at 10,000g for 15 minutes; protein concentration was 
equalized with Bradford, and incubated  for 16h with a mixture of agarose conjugated anti p53 (Do1 & FL-393, 
Santa Cruz, CA, USA). Immunocomplexes were washed 5 times and eluted with 0.5 M Glycine/HCl pH 2.4, mixed 
1:1 with standard 2x Western Blot sample buffer and examined by Western blot analysis as described above.
SDS-Polyacrylamide Gel Electrophoresis and immunoblotting. 24h after indicated treatment cells were harve-
sted and lysates were examined by WB as described previously (4,21). The following antibodies were used: mouse 
anti p53 (DO-1, Santa Cruz), mouse anti-Mdm2 (SMP14, Oncogene Research Products, Darmstadt, Germany), 
mouse anti b-Actin (MP Biomedicals, Eindhoven, the Netherlands), mouse anti p21 (F5, Santa Cruz), rabbit anti-
Parp (Roche Diagnostics, Almere, the Netherlands), caspase 8 (1C12, Cell Signalling, MA, USA), and anti-FasL 
(C20, Santa Cruz). The antibody binding was eventually determined using horseradish peroxidase (HRP)-conjuga-
ted secondary antibodies (DAKO, Glostrup, Denmark) and visualised with the POD chemoluminescence kit (Roche 
Diagnostics). WB membranes were imaged with Molecular Imager Gel Doc XR System (Biorad, Veenendaal, the 
Netherlands). Equal protein loading was checked for with the Bradford total protein assay, Ponceau S staining of the 
blots and ß-actin immunobloting.
Apoptosis. Cells were continuously incubated with cisplatin for 24h at various concentrations. Acridine orange 
fluorescent staining of nuclei in unfixed cells was used to distinguish apoptotic from vital cells (4,21,48).
RNA interference. Small-interfering RNA (siRNA) specific for human p53, MDM2, FasL, and negative control 
(scrambled) were purchased from Eurogentec (Maastricht, the Netherlands). TC cells were transfected in 6 well 
plates with 5 ml of 20 mM siRNA duplex or siRNA antisense using Oligofectamine reagent according to the manu-
facturer’s instructions (Invitrogen). After 24h, cells were treated with cisplatin. 24h after the treatment cells were 
harvested for protein isolation. Alternatively, in order to perform an apoptosis assay, at 24h after transfection, cell 
were harvested and plated in 96-well plate. The day after, cells were treated with cisplatin. Sequence for p53 I small 
interfering RNA (siRNA) molecules was 5’-GCA UGA ACC GGA GGC CCA UdTdT-3’ (sense) and 5’-AUG GGC 
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CUC CGG UUC AUG CdTdT-3’ (anti-sense), sequence for p53 II siRNA was 5’-CUU CGA CUU UGU CAC CGA 
GdTdT-3’ (sense) and 5’-CUU ACG CUG AGU ACU UCG AdTdT-3’ (anti-sense), sequence for P21 I siRNA was 
5’-CUU CGA CUU UGU CAC CGA GdTdT-3’ (sense) and 5’-CUU ACG CUG AGU ACU UCG AdTdT-3’ (anti-
sense), sequence for P21 II siRNA was 5’-GAC CAU GUG GAC CUG UCA CdTdT-3’ (sense) and 5’-GUG ACA 
GGU CCA CAU GGU CdTdT-3’ (antisense) , sequence for FasL siRNA was 5’-CTG GGC TGT ACT TTG TAT 
AdTdT-3’ (sense) and 5’-TAT ACA AAG TAC AGC CCA GdTdT-3’ (anti-sense).
Fas-membrane expression. TC cells were treated as indicated and eventually stained with a phycoerythrin 
(PE)-conjugated Ab against Fas (DX2, Becton Dickinson) for 1 hour at room temperature. Subsequently, cells were 
washed and analyzed by flow cytometry (FACS-Calibur; Becton Dickinson). The mean fluorescence intensity was 
determined by comparison of the fluorescence intensity of unlabeled cells.
Statistical Analysis. Results of at least 3 experiments are expressed as mean ± SD. Student’s unpaired t test 
was used to compare values of test and control samples. All tests were 2-sided and differences were considered to 
indicate significance when p <0.05
Results
P53 and MDM2 cellular localization and cisplatin response in TC cells. We used a panel 
of cisplatin-sensitive and -resistant wild type p53 expressing TC cell lines to compare cis-
platin responses (Table 1) with the cellular localization of p53 and MDM2 and p53-MDM2 
complex formation (Figure 1A-C, Supplemental Figure 1). Using immunofluorescence, we 
have observed that p53 predominantly localized to the cytoplasm, while MDM2 was mainly 
present in the nucleus in all four cell lines (Figure 1A & Supplemental Figure 1). Following 
exposure to 8 mM cisplatin, nuclear localization of p53 became more pronounced in cispla-
tin-sensitive cell lines Tera (Figure 1A) and 833KE (data not shown). In contrast, MDM2 
expression was observed in both the nucleus and the cytoplasm of Tera cells upon cisplatin 
treatment (Figure 1A). In the intrinsically cisplatin-resistant TC cell lines, Scha and 2102EP, 
and in Tera-CP, an acquired cisplatin-resistant subline of Tera, sustained cytoplasmic p53 
was observed at 8 mM cisplatin (Supplemental Figure 1). Only at higher cisplatin concentra-
tions p53 became more nuclear localized (results not shown). In the cisplatin-resistant cell 
lines, MDM2 retained its nuclear localization after treatment with 8 mM cisplatin and became 
cytoplasmic only at high cisplatin concentrations. Immunoprecipitation (IP) was used to de-
termine whether the observed shift in cellular localization of p53 and MDM2 after cisplatin 
treatment affected p53-MDM2 complex formation (Figure 1B). Note that we used lower cis-
platin concentrations for Tera compared to the other cell lines. Despite the strong induction 
of both p53 and MDM2 in Tera with increasing concentrations of cisplatin (Figure 1C), IP 
experiments showed a decrease of p53-MDM2 complexes at cisplatin concentrations above 2 
mM (Figure 1B). In cisplatin-resistant TC cell lines, we still observed sustained p53-MDM2 
complexes even at relatively high (up to 8 mM) cisplatin concentrations. Eventually, p53-
MDM2 complexes in these cells were partially lost at cisplatin concentrations above 16 mM 
(Figure 1B). Taken together, our results suggest that high sensitivity for cisplatin cytotoxicity 
and cisplatin-induced apoptosis is related to loss of p53-MDM2 complex formation and a 
change in p53 cellular localization.
Apoptosis induction by inhibition of the p53-MDM2 interactions depends on wild-type 
p53. To investigate the importance of p53-MDM2 complex formation in preventing apop-
tosis in TC, we used the small molecule inhibitors RITA and Nutlin-3 to inhibit the p53-
MDM2 interaction. RITA induced massive apoptosis at nanomolar concentrations in the 
absence of transcriptional activation of any of the p53 targets tested (p53, MDM2, p21 and 
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Fas). Furthermore, downregulation of p53 with siRNA did not interfere with apoptosis in-
duction by RITA (Supplemental Fig 2A). Moreover, treatment with RITA induced caspase-
dependent apoptosis in the TC cell line NCCIT expressing mutant p53 (Supplemental Fig 
2A). These results indicate that, at least in TC cells, RITA induces apoptosis independently 
of wild-type p53. We therefore focused on the effects of the small molecule inhibitor Nut-
lin-3 in wild-type p53 expressing TC cells.
Figure 1. Loss of complex formation between p53 and MDM2, in cisplatin-sensitive TC cells (A) Immunofluores-
ence showing that p53 localizes in the nucleus, whereas MDM2 resides in the cytoplasm after cisplatin treatment in 
the cisplatin-sensitive TC cell line Tera, representative example of three independent experiments. (B-C) Note that 
we used lower cisplatin concentrations for Tera compared to the other TC cell lines. TC cells were harvested 12h 
after indicated cisplatin treatment. (B) Cell lysates were subjected to p53 immunoprecipitation (IP). Immunoblotting 
was performed using anti-p53 and anti-MDM2 antibodies. In the cisplatin-resistant TC cell lines Tera-CP, 2102EP 
and Scha, p53 was maintained in a complex with MDM2 after cisplatin treatment, while the cisplatin-sensitive Tera 
cells showed a loss of p53-MDM2 complex formation at low cisplatin concentrations. Relative levels of p53 and 
MDM2 were calculated with image J1.41 (National Institutes of Health) normalized and divided p53/MDM2. (C) 
Immunoblotting showing levels of p53, MDM2 and actin from lysates used for IP as indicated.
Treatment of cisplatin-sensitive Tera and 833KE or cisplatin-resistant Tera-CP, Scha 
and 2102EP cells, all expressing wild-type p53, with Nutlin-3 resulted in a dose-dependent 
reduction in cell survival, while no effect of Nutlin-3 on survival of NCCIT cells, that express 
a p53 mutant, was observed (Figure 2A). The reduced survival after Nutlin-3 treatment was 
caused by a dose-dependent induction of apoptosis, which is caspase-dependent as shown by 
increased PARP cleavage (Figure 2B-C). Although Nutlin-3 induced apoptosis in all wild-
type p53 cell lines, low dose Nutlin-3 treatment (4 mM) led to a less prominent apoptotic 
response in the cisplatin-resistant compared to the cisplatin-sensitive cell lines (Figure 2B). 
Immunoblotting demonstrated specific upregulation of p53 after treatment of the various 
cell lines with Nutlin-3 and a dose-dependent increase in the expression levels of the p53 
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Nutlin-3 treatment (Figure 2C). Furthermore, Nutlin-3 treatment led to a more pronounced 
nuclear localization of p53 in all p53 wild-type cells (Supplemental Figure 2B). The mutant 
p53 NCCIT cell line was unaffected after treatment with Nutlin-3, further demonstrating the 
wild-type p53-dependent effect of Nutlin-3 (Figure 2B-C).
Figure 2. Nutlin-3 induced apoptosis in TC cells (A) Survival of TC cells after 96h of continuous Nutlin-3 treatment 
as indicated; values are the mean ± SD of three independent experiments. (B) Apoptosis induction was analyzed af-
ter Nutlin-3 treatment for 24h, by fluorescence microscopy on acridine orange stained TC cells; values are the mean 
± SD of three experiments. (C) Immunoblot analysis showing upregulation of p53, MDM2 and p21 and enhanced 
cleavage of PARP and caspase-8 in wild-type p53 TC cells 24h after Nutlin-3 treatment. The data presented are 
representative of three independent experiments.
We further proved that the observed transcriptional activity and apoptosis induction af-
ter Nutlin-3 treatment was p53-dependent, since p53 downregulation  by siRNA, prevented 
the upregulation of MDM2 and p21 levels after Nutlin-3 treatment (Figure 3D). In addition, 
p53 siRNA transfection, reduced the apoptotic response compared to scrambled siRNA after 
Nutlin-3 treatment in all wild-type p53 expressing cells (Figure 3A-C & Supplemental Figure 
3A).
Increased Fas death receptor expression after Nutlin-3 treatment in TC cells. In line 
with our previous results (4), we found elevated Fas membrane expression levels after cis-
platin treatment in Tera cells, less in Tera-CP cells and only minor changes in 2102EP and 
Scha cells (Figure 4A,B). Interestingly, Nutlin-3 treatment led to a robust upregulation of Fas 
membrane expression in all wild-type p53 expressing TC cell lines to a level significantly 
higher than solvent or cisplatin treatment (Figure 4A,B). Fas is induced in a p53-dependent 
manner in TC cells (4,8,21,49-52), which is further supported by our observation that no in-
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NCCIT after either cisplatin or Nutlin-3 treatment (Supplemental Figure 3B). Additionally, 
Nutlin-3 treatment of p53-suppressed wild-type p53 TC cells prevented the induction of Fas 
membrane expression (Figure 4C). These results indicate that the observed upregulation of 
Fas membrane expression after Nutlin-3 treatment is wild-type p53 dependent as well. Pre-
viously, we have shown that cisplatin-induced apoptosis is depending on activation of the 
Fas/FasL system in the cisplatin-sensitive Tera and 833KE cells, while activation of the Fas/
FasL system is inhibited in the cisplatin-resistant Tera-CP and Scha cells (4). We observed 
a significantly higher Fas membrane expression in all wild-type p53 cell lines, compared 
to solvent or cisplatin, suggesting the involvement of the Fas death receptor pathway in 
apoptosis-induction by Nutlin-3.
Figure 3. Wild-
type p53 is neces-
sary for the Nut-
lin-3 response 
(A-C) Downre-




ment in wild-type 
p53 expressing 




scr) or with p53 
siRNA (siRNA p53) for 24h. Values are the mean ± SD of three experiments; #p < 0.05; *p < 0.01; **p < 0.005. 
(D) Successful downregulation of p53 using siRNA, decreased the expression of MDM2 and p21, and decreased 
cleavage of PARP in p53-suppressed Nutlin-3 treated TC cells compared to control; a representative example of 
three independent experiments is shown.
Fas-dependent apoptosis after Nutlin-3 treatment. To further investigate the importance 
of Fas up-regulation for Nutlin-3-induced apoptosis, we inhibited the Fas/FasL interaction by 
either FasL blocking with Nok-1 antibody or using siRNA targeting FasL. Both blocking of 
FasL and suppression of FasL dramatically reduced the apoptotic response after high doses 
Nutlin-3 in all TC cell lines (Figure 4D), as visualized by a significant decrease in active, 
cleaved caspase-8 as well as a decrease in PARP cleavage (Figure 4E-F). Downregulation of 
FasL with siRNA was confirmed by immunoblotting (Figure 4E-F & Supplemental Figure 
3C). Blocking or suppression of FasL, however, had no effect on the induction of p53 by 
Nutlin-3 (Figure 4E-F & Supplemental Figure 3C). These results indicate that the massive 
apoptosis induction in TC cells after Nutlin-3 treatment is to a large extent dependent on 
activation of the Fas death receptor pathway.
We recently established an important role for high cytoplasmic levels of p21 in inhibiting 
cisplatin-induced Fas-mediated apoptosis in TC (Spierings et al. 2004; Koster et al. 2010). 
Because of the reduced apoptotic response at the lowest Nutlin-3 dose (4µM) in the intrin-
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sically cisplatin-resistant Scha and 2102EP cells, expressing high p21 levels, compared to 
the cisplatin-sensitive Tera and 833KE cells, expressing low levels of p21, (Figure 2B) we 
defined the importance of p21 in inhibiting Nutlin-3-induced apoptosis. Down-regulation of 
p21 using an siRNA approach (Supplemental Figure 3D) led to an increase in Nutlin-3-indu-
ced apoptosis 3 in Scha and 2102EP cells, as demonstrated by an increase in PARP cleavage 
(Supplemental Figure 3D).  We, thus, show that p21 plays a role in inhibiting Nutlin-3 indu-
ced apoptosis as well, but only after treatment with relatively low Nutlin-3 concentrations.
Figure 4. Fas-dependent apoptosis after Nutlin-3 treatment in TC cells (A) Following the indicated treatment, TC 
cells were harvested and Fas membrane expression was determined by flow cytometry. Values were depicted as 
mean fluorescence intensity (MFI). Values are the mean ± SD of three experiments. (B) TC cells were treated as in-
dicated and Fas-membrane expression was determined by immunofluorescence. (C) Downregulation of p53 reduced 
Fas membrane expression after Nutlin-3 treatment in wild-type p53 expressing TC cells, compared to control; values 
are the mean ± SD of three experiments; #p < 0.05; *p < 0.01; **p < 0.005. (D) Decreased apoptotic response after 
blocking or suppression of FasL, in TC cells treated with Nutlin-3; values are the mean ± SD of three experiments. 
(E-F) Fas acts pro-apoptotic after 24h Nutlin-3 treatment in TC cells. After successful downregulation of FasL or 
blocking of FasL, with NOK-1, a decrease in PARP cleavage and active caspase-8 was observed in Tera (E) and 
2102EP (F); a representative example of three independent experiments is shown.
Next, we addressed the question, if the Fas death receptor pathway also plays an impor-
tant role in Nutlin-3-induced apoptosis in other, non-testicular tumour cell types. To this end, 
we analyzed Hodgkin lymphoma and AML cell lines, which are also known to be sensitive 
to Nutlin-3 (41,42,53). Blocking of FasL with Nok-1 considerably reduced the apoptotic res-
ponse and PARP cleavage after Nutlin-3 treatment in the wild-type p53 expressing Hodgkin 
lymphoma cell lines KM-H2 and L540 (Figure 5A) as well as in the wild-type p53 expressing 
MOLM-13 AML cells (Figure 5B). In addition, no effect of either Nutlin-3 treatment or bloc-
king of the Fas/FasL interaction was observed in mutant p53 Hodgkin lymphoma and AML 
cell lines, L428 (Figure 5A) and HL-60 (Figure 5B), respectively. These results indicate that 
the Fas death receptor pathway also plays an important role in Nutlin-3 induced apoptosis in 
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Figure 5. Fas-dependent apop-
tosis after Nutlin-3 treatment 
in Haematological Neoplasm 
(A-B) Decreased apoptotic 
response and decreased PARP 
cleavage after blocking of 
FasL in wild-type p53 expres-
sing Hodgkin lymphoma cells 
(A) and AML cells (B) after 
Nutlin-3 treatment. Values are 
the mean ± SD of three expe-
riments; #p < 0.05; *p < 0.01; 
**p < 0.005. A representative 
example of three independent 
experiments is shown.
Synergistic effect of Nutlin-3 and cisplatin is Fas death receptor- and p53-dependent.
Finally, we tested the cytotoxicity of cisplatin in combination with minimally toxic con-
centrations of Nutlin-3 in TC cells. Treatment for 96h with the combined drugs led to much 
stronger reductions in survival of all wild-type p53 TC cell lines tested as compared to single 
drug treatment with cisplatin or Nutlin-3 (Figure 6A, Supplemental Figure 4A). The stron-
gest decrease in survival combining the two drugs was observed in the intrinsic and acquired 
cisplatin-resistant cell lines (Figure 6A, Supplemental Figure 4A & Table 1). As expected, 
the combination with Nutlin-3 had no potentiating effect on cisplatin-induced cytotoxicity in 
the mutant p53 cell line NCCIT (Supplemental Figure 4B).
The reduction in survival of TC cells after the combined treatment with Nutlin-3 and 
cisplatin was related to the enhanced induction of apoptosis (Figure 6C & Supplemental Fi-
gure 6B). Immunoblotting showed enhanced upregulation of p53 and MDM2 after combined 
treatment with Nutlin-3 and cisplatin compared to either cisplatin or Nutlin-3 treatment alone 
(Figure 6B & Supplemental Figure 6A). The increase in PARP cleavage demonstrated the 
enhanced activation of effector caspases by the combined treatment (Figure 6B & Supple-
mental Figure 6A). Next we addressed the question, if the Fas death receptor pathway also 
plays an important role in apoptosis-induction after the combined treatment. Therefore, we 
first determined Fas membrane expression levels after the combined treatment. Fas mem-
brane expression was in the combination with cisplatin, compared to Nutlin-3 alone, even to 
a greater extent upregulated in all wild-type p53 TC cell lines (Figure 6D & Supplemental 
Figure 5C), while no induction of Fas membrane expression was observed in the mutant p53 
expressing NCCIT (Supplemental Figure 3B). Additionally, blocking of FasL reduced the 
apoptotic response of wild-type p53 TC cells to the combined treatment with Nutlin-3 and 
cisplatin, in particular at the lower cisplatin concentration (Figure 6E & Supplemental Figure 
5D). Suppression of MDM2 with siRNA extremely sensitized TC cells to cisplatin treatment, 
almost similar to our observations with Nutlin-3.  This demonstrates that the release of the 
negative feedback on p53 by MDM2 is the important event in the induction of apoptosis 
in TC cells (Figure 6B-C). Moreover, p53 expression and Fas membrane expression were 
strongly upregulated after treatment with MDM2 siRNA, especially in combination with 
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These observations indicate that targeting MDM2 in combination with cisplatin treat-
ment might potentially overcome both intrinsic as well as acquired-resistance to cisplatin in 
wild-type p53 TC, and is largely dependent on activation of the Fas death receptor pathway.
Figure 6. Synergistic effect of cisplatin and inhibition of the p53-MDM2 interaction (A) Survival of TC cells after 
96h of continuous Nutlin-3 (Nut-3) treatment as indicated, in combination with increasing cisplatin concentration. 
IC50 values are depicted for cisplatin as well as the combination with 1 mM Nutlin-3; values are the mean ± SD. (B) 
Increased levels of p53 and increased PARP cleavage after targeting the p53/MDM2 axis; a representative example 
of three independent experiments is shown. (C) Increased apoptosis after targeting the p53/MDM2 axis with either 
siRNA against MDM2 or Nutlin-3 (Nut-3) in combination with cisplatin; values are the mean ± SD of three ex-
periments; #p < 0.05; *p < 0.01; **p < 0.005. (D) Following indicated treatment TC cells were harvested and Fas 
membrane expression was determined by flow cytometry. Values were depicted as mean fluorescence intensity 
(MFI). Values are the mean ± SD of three experiments (E) Decreased apoptotic response after blocking of FasL, 
with NOK-1, in TC cells treated with the combination of cisplatin and Nutlin-3 as indicated; values are the mean ± 
SD of three experiments; #p < 0.05; *p < 0.01; **p < 0.005.
Discussion
In the present study, we demonstrate that wild-type p53 is sustained in complex with MDM2 
in cisplatin-resistant TC cell lines following treatment with therapeutically-relevant cisplatin 
concentrations. Our results indicate that interfering in the p53-MDM2 interaction through the 
small molecule compound Nutlin-3 sensitizes wild-type p53 TC cells for apoptosis. Combi-
ning Nutlin-3 with cisplatin, the most important therapeutic drug in the treatment of testicular 
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cancer patients, results in hyper-activation of the p53 pathway and largely sensitizes both 
intrinsic as well as acquired cisplatin-resistant TC cells to apoptosis via the Fas/FasL death 
receptor pathway and strongly reduces cell survival. These results indicate that targeting the 
p53/MDM2 axis, in combination with standard chemotherapeutic treatment, appears to be 
an attractive therapeutic strategy to pursue for cisplatin-resistant/refractory testicular cancer 
(Figure 7).
Figure 7. Simplified model sho-
wing the role of the MDM2/p53 
axis in regulating the sensitivity 
to cisplatin and Nutlin-3 in wild-
type p53 expressing TC cells. P53 
is a transcriptional activator of 
p21, Fas and MDM2. Cisplatin 
sensitive TC cells have low levels 
of p21 and cisplatin-resistant TC 
cells high levels of cytoplasmic 
p21, which is a key determinant of 
cisplatin-induced apoptosis (36). 
Cisplatin-induced apoptosis in TC 
cells also involves activation of 
the Fas death receptor pathway via 
elevated Fas membrane expres-
sion. High cytoplasmic p21 levels 
inhibit Fas death receptor media-
ted apoptosis in cisplatin-resistant 
TC cells (21). Moreover, cisplatin-
induced DNA damage activates 
p53 and enhances release of p53 
from p53-MDM2 complex, while 
sustained p53-MDM2 complex 
formation is found in cisplatin resistant cells.  Interfering in p53-MDM2 complex formation by Nutlin-3 treatment 
(or suppression of MDM2) substantially induced Fas expression, resulting in apoptosis of both cisplatin sensi-
tive and resistant TC cells. Cisplatin in combination with Nutlin-3 further enhanced Fas expression and sensitized 
cisplatin-sensitive and resistant TC cells to cisplatin-induced apoptosis.
P53-interacting proteins, such as MDM2, are important regulators of wild-type p53 func-
tionality (39,54-60). The lack of TP53 mutations in TC led to the hypothesis that constituti-
vely expressed p53 is functionally inactive (61-63). Surprisingly high levels of wild-type p53 
have been frequently observed in TC that are correlated with expression levels of the p53 
transcriptional target MDM2, suggesting that p53 is functional in TC (20,26,29,34,64). Here, 
we show that treatment with the selective MDM2 antagonist Nutlin-3 caused a high induc-
tion of both p53 and MDM2, a massive induction of apoptosis, and a strong reduction in cell 
survival in cisplatin-sensitive as well as cisplatin-resistant TC cell lines. In addition, siRNA 
targeting MDM2 had similar effects as Nutlin-3 treatment, indicating an important role of 
MDM2 as a negative-feedback regulator of p53 activity, and excluding a role for Nutlin-3 
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induced release of MDM2 in the observed apoptosis. These results suggest a tight regulation 
of p53 interacting with MDM2. Several in vitro and in vivo studies suggest an important role 
for p53 in TC cisplatin responses (26,31,63,65-67). In contrast, other studies have failed to 
support a role for p53 in TC responses (29), although the involvement of the p53-MDM2 
complex in the response to chemotherapy had not been thoroughly assessed (29,30). The 
present study indicates that p53 function is impeded by the interaction with MDM2 and the 
subsequent sequestration of p53 in the cytoplasm of TC cells following cisplatin treatment. 
The strong sensitization to cisplatin by low doses of Nutlin-3 further demonstrates the impor-
tance of MDM2 in controlling p53 following DNA damage.
Table1 – IC50 values and p53 status of the cell lines used in this study
Cell line IC50 Cisplatin (mM)
1 IC50 Combination (mM)
2 Enhancement Ratio3 P53 status4
Tera 0,69 ± 0,11 0,07 ± 0,01 9,9 wt/wt
Tera-CP 2,14 ± 0,17 0,11 ± 0,02 19,5 wt/wt
833KE 1,04 ± 0,10 0,13 ± 0,03 8,0 wt/wt
Scha 2,91 ± 0,84 0,28 ± 0,08 10,4 wt/wt
2102EP 4,05 ± 0,66 0,39 ± 0,21 10,4 wt/wt
NCCIT 2,15 ± 0,34 2,25 ± 0,59 1,0 mt/-
1) The IC50 (drug concentration reducing cell survival by 50%) for cisplatin was calculated from the graphs in Figure 
6A and Supplemental Figure 6A-B. The mean IC50 ± SD was determined in three experiments, each performed in 
quadruplicate.
2) The IC50 (drug concentration reducing cell survival by 50%) for cisplatin in combination with 1 mM Nutlin-3 was 
calculated from the graphs in Figure 6A and Supplemental Figure 6A-B. The mean IC50 ± SD was determined in 
three experiments, each performed in quadruplicate.
3) Nutlin-3 enhancement ratios were calculated by dividing the IC50 for cisplatin alone by the IC50 for the combina-
tion with cisplatin and 1 mM Nutlin-3.
4) p53 status of the cells was previously described (21,24).
Induction of FasL and upregulation of the Fas receptor in a p53-dependent manner has 
been observed in several tumour cell lines after treatment with chemotherapeutic drugs, such 
as cisplatin, and is related to apoptosis induction (4,8,21,49-52). Previously, we have repor-
ted that the Fas/FasL system is active and functional in cisplatin-sensitive but almost inactive 
in cisplatin-resistant TC cell lines (4). In the present study, we show that Nutlin-3 treatment 
strongly enhanced Fas membrane expression levels in TC cells. Fascinatingly, blocking of 
the Fas/FasL death receptor pathway in TC cells impairs apoptosis induction by Nutlin-3 
as well as combined treatment with Nutlin-3 and cisplatin. However, involvement of other 
genes in this pathway cannot be excluded, because p53 has been shown to transcriptionally 
activate several other genes involved in apoptosis via the Fas/FasL system after cisplatin 
treatment. In the cisplatin-sensitive Tera cells, besides FAS, the Fas adaptor LRDD and a 
gene implicated in positive Fas regulation, PHLDA3 were found to be regulated by p53 upon 
cisplatin treatment (31). Importantly, we observed that the Fas/FasL death receptor pathway 
also plays an important role in Nutlin-3-induced apoptosis of wild-type p53-expressing AML 
and Hodgkin cell lines. Interestingly, the wild-type p53-expressing cell line OCI-AML-3 
did not show Nutlin-3-induced apoptosis. These latter results, however, can be explained by 
observations that Nutlin-3-induced apoptosis was independent of transcriptional activation 
of p53 in these cells (42). These results indicate a major role for the Fas/FasL death receptor 
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pathway in response to Nutlin-3 in wild-type p53 TC, AML and Hodgkin cell lines.
Recently, we have defined the important protective role of high, cytoplasmic localized 
p21 levels against cisplatin-induced Fas receptor-mediated apoptosis in cisplatin-resistant 
TC cells (21,36). The present results indicate that p21 only blocks Nutlin-3-induced apopto-
sis in cisplatin-resistant TC cells at relatively low Nutlin-3 concentrations. Treatment with 
higher Nutlin-3 concentrations led to a strong induction of p53 and a further increase in 
Fas membrane expression in testicular cancer cells, whereas p21 mRNA and protein levels 
remained relatively low after either Nutlin-3 or cisplatin treatment in these cells (4,21,36,44). 
Non-apoptotic genes, such as CDKN1A, constitutively harbour high levels of the poised RNA 
polymerase II (RNAPII) initiation complex at their core promoters, which are converted 
into elongated forms shortly after stress, but reinitiate very poorly. In contrast, pro-apoptotic 
genes, including FAS, have low levels of bound RNAPII but undergo damage-induced acti-
vation through multiple rounds of efficient reinitiation (68-70). Additionally, the co-factors 
ASPP1/2, JMY, HAUSP, and NF-Y enhance p53 apoptotic activity by facilitating its binding 
to pro-apoptotic promoters (69-73). For instance, NF-Y is known to be an essential positive 
regulator of FAS transcription, while it represses CDKN1A promoter activity (69,70). Inte-
restingly, p53 occupancy of the p21 promoter in testicular cancer cells was similar to the 
levels observed in U2OS and HCT116 cells, whereas much less p21 expression was found 
in testicular cancer cells (44). Therefore, it is tempting to speculate that the Nutlin-3 induced 
release of the negative feedback on p53 by MDM2 further shifts the balance toward transcri-
bing pro-apoptotic genes (involved in the Fas death receptor pathway).
Combining Nutlin-3 with other cytotoxic agents enhanced the activity of these agents in 
wild-type p53 leukaemia cells (47,74,75). Our results showed that combining non-toxic con-
centrations of Nutlin-3 with cisplatin sensitized both intrinsic as well as acquired cisplatin-
resistant TC cells to low concentrations of cisplatin. Of interest, MDM2 inhibitors in contrast 
to cisplatin might be considered non-genotoxic, as demonstrated with Nutlin-3a in mice (76). 
Nutlin-3a has even shown protective activity in normal kidney cells against cisplatin-induced 
apoptosis (77). MDM2 inhibitors are in phase I clinical trials in haematological malignancies 
and solid tumours. Based on the present results, clinical trials using MDM2 inhibitors such 
as Nutlin-3 in combination with cisplatin to treat cancer patients with wild-type p53, for ins-
tance refractory TC patients, may be of great importance.
In conclusion, we demonstrate that the negative feedback regulator MDM2 plays an 
important role in the sensitivity of wild-type p53 testicular cancer to Nutlin-3 and cisplatin. 
These findings indicate that targeting the p53/MDM2 axis in combination with standard tre-
atment enhances Fas death receptor-mediated apoptosis, is a therapeutic strategy warranted 
to pursue in cisplatin-resistant/refractory testicular cancers. 
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Supplemental Figure 1. Immunofluorescence showing that p53 becomes more pronounced nuclear localized, while 
MDM2 stays nuclear localized after cisplatin treatment (8 mM) in the cisplatin-resistant TC cell line Tera-CP, Scha 
and 2102EP; a representative example of three independent experiments is shown.
Supplemental Figure 2. (A) No induction of p53 after treatment with RITA. Suppression of p53 with a specific 
siRNA did not interfere with the apoptosis induction by RITA as visualised by PARP cleavage; a representative 
example of three independent experiments is shown. (B) Immunofluorescence showing that p53 is more nuclear 
localized after Nutlin-3 treatment in the cisplatin-sensitive TC cell line Tera and the intrinsically resistant cell line 
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Supplemental Figure 3. (A) Successful downregulation of p53 using siRNA targeting p53, decreased cleavage of 
PARP in p53-suppressed Nutlin-3 treated TC cells compared to control; a representative example of three inde-
pendent experiments is shown.  (B) Following the indicated treatment no effect was observed on Fas membrane 
expression of the mutant p53 cell line NCCIT; a representative example of three independent experiments is shown. 
(C) After successful downregulation of FasL or blocking of FasL, with NOK-1, a decrease in PARP cleavage was 
observed in Tera-CP and Scha; a representative example of three independent experiments is shown. (D) Downre-
gulation of p21 increased the apoptotic response of the intrinsically ciplatin-resistant cells Scha and 2102EP after 
Nutlin-3 treatment; a representative example of three independent experiments is shown. 
Supplemental Figure 4. (A-B) Survival of TC cells after 96h of continuous Nutlin-3 treatment as indicated, in com-
bination with increasing cisplatin concentration. IC50 values are depicted for cisplatin as well as the combination; 
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Supplemental Figure 5. (A) Increased levels of p53 and increased PARP cleavage after targeting the p53/MDM2 
axis; a representative example of three independent experiments is shown. (B) Increased apoptosis after targeting the 
p53/MDM2 axis with either siRNA against MDM2 or Nutlin-3 (Nut-3) in combination with cisplatin; values are the 
mean ± SD of three experiments. (C) Following the indicated treatment TC cells were harvested and Fas membrane 
expression was determined by flow cytometry. Values were depicted as mean fluorescence intensity (MFI). Values 
are the mean ± SD of three experiments (D) Decreased apoptotic response after blocking of FasL, with NOK-1, in 
TC cells treated with the combination of cisplatin and Nutlin-3; Values are the mean ± SD of three experiments.
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Abstract
Testicular cancers are the most frequent solid malignant tumor in men 20–40 years of age and 
the most frequent cause of death from solid tumors in this age group. At the time of diagnosis 
up to 50% of the patients suffer from metastatic disease, while the majority of metastatic 
testicular cancer patients, in contrast to most other metastatic solid tumors, can be cured with 
highly effective cisplatin-based chemotherapy. Therefore testicular cancer is considered the 
paradigm of curable solid tumor and an ideal model to investigate and unravel the molecular 
determinants of chemotherapy sensitivity (and resistance) of solid tumors. This review aims 
to summarize the current knowledge on the biological basis of cisplatin-induced apoptosis 
and response to chemotherapy in testicular cancer. Moreover, the fact that testicular cancer 
sustains high basal levels of wild-type p53 is discussed. In turn, presence of wild-type p53 is 
causative for the exquisite sensitivity to cisplatin of testicular cancers. Resistance to cispla-
tin occurs via a shift in the balance between key-players, such as p21Waf1/Cip1 (p21), Fas and 
MDM2, acting upon cisplatin-induced activation of the p53-pathway. Recent studies suggest 
that high levels of cytoplasmic localized p21 and tight negative feedback regulation of p53 
by MDM2 protect testicular cancer cells against cisplatin-induced apoptosis. Drugs target-
ing either cytoplasmic localized p21 or the p53/MDM2 axis showed, at least pre-clinically, 
a sensitizing effect to cisplatin treatment. Further clinical development of such type of drugs 
may lead to new treatment options for platinum resistant disease.
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Introduction
Testicular cancers represent the most frequent solid malignant tumor in men 20-40 years of 
age and incidence is still rising world-wide (1). Based on histology, biochemical and clini-
cal features these tumors can be divided in seminomatous and nonseminomatous testicular 
cancer. Non-seminomas do metastasize more widely and are less sensitive to radiotherapy 
than seminomatous testicular cancer, which has consequences for prognosis and treatment 
strategies. Nonseminomas display various stages of differentiation, ranging from the undif-
ferentiated embryonal carcinoma (EC), the more differentiated extra-embryonic components 
like yolk sac carcinomas (YS) and choriocarcinomas (Chc), to the highly differentiated tera-
toma (T) component (2,3). Note, that most human cancer cell lines commonly used as model 
for testicular cancer are of EC origin.
Platinum-based chemotherapy is the cornerstone of treatment of many cancers and used 
as first-line therapy for testicular, bladder, lung, ovarian cancers. In case of bladder, lung and 
ovarian cancer there is often responsiveness to platinum-based chemotherapy, however the 
majority of these cancer patients will eventually relapse with platinum-resistant disease. In 
contrast, an enormous improvement has been obtained in outcome and survival of testicular 
cancer patients, even in case of extensive metastatic disease, by the introduction of cisplatin 
as anticancer drug in the mid 1970s (4,5). Testicular cancer is therefore considered as para-
digm of platinum-sensitive solid tumors.
A relatively unique feature of testicular cancers is the expression of high levels of wild-
type p53 (6-8) that is otherwise frequently mutated in other tumor types (9-12). Mutations in 
TP53 that compromise p53 function occur in ~50% of human cancers (9-12). The mutation 
rate of p53 varies dramatically between different tumor types ranging from 10–12% in leu-
kemias, to 38–70% in lung cancers and 43–60% in colon cancers, while in human testicular 
cancers surprisingly less than 1% of TP53 mutations occur (13). TP53 is a tumor suppressor 
gene, of which the protein has a dual role in stress response. It trans-activates a number of ge-
nes including p21Waf1/Cip1 (p21), MDM2 and Fas (14) that coordinately direct cells into either 
cell cycle arrest or apoptosis. The p53 pathway is crucial for effective tumor suppression in 
humans and a major role for p53 in the response to chemotherapeutic drugs, such as cisplatin, 
and the execution of apoptosis has been described (15-19).
This review will briefly give an overview of common pathways activated by cisplatin-
induced DNA-damage and thereafter mainly focuses on the functionality of wild-type p53, 
the p53-apoptotic pathway and downstream targets Fas, MDM2 and p21 and their role in 
determining the response to cisplatin-induced apoptosis in testicular cancer. Unfortunately, 
in the group of patients diagnosed with testicular cancer, a subset of patients with extensive 
metastatic spread belonging to the intermediate or poor risk group will not achieve a durable 
complete remission after initial treatment and eventually die from their disease (20). In depth 
understanding why most testicular cancer patients are curable with chemotherapy could lead 
to the development of more effective treatment of refractory testicular cancers and other less 
chemo-sensitive solid tumor types.
Response to cisplatin-induced DNA-damage. Cisplatin becomes activated intracellu-
larly by the aquation of one or both of the two chloride groups before it covalently binds to 
DNA, forming DNA adducts (21). These adducts cause inter- and intrastrand DNA cross-
links and distortions in DNA, including unwinding and bending, which are recognized by 
several cellular proteins (21,22). This process activates various signal-transduction pathways 
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involved in DNA-damage recognition (DDR) leading to cell-cycle arrest and DNA repair 
or apoptosis (21-23). DNA damage activates the ATM/ATR protein-kinase family. ATM/
ATR in turn induces a range of differential posttranslational modifications of p53 (24-26), 
although conflicting data about the importance of these modifications, including p53 phosp-
horylation, have been published (27,28). P53 regulating proteins, such as the closely related 
proteins MDM2 and MDMX, have been suggested to be of great importance in tailoring the 
p53-mediated DNA damage response (27-31). ATM directly and indirectly induces MDM2 
phosphorylation, resulting in decreased activity and stability of MDM2 (31-33) and, conse-
quently, loss of the negative feedback on p53. Upon DNA damage induction, for example 
by cisplatin, p53 is activated and co-factors facilitate p53-mediated trans-activation of ge-
nes. Co-factors such as ASPP1/2, JMY, HAUSP and NF-Y seem to enhance p53 apoptotic 
activity by facilitating its binding to pro-apoptotic promoters (e.g. induction of Fas, TRAIL 
Death Receptor 5 and bax) (31,32,34-38), while co-factors such as c-abl, hnRNP K and Miz-
1 facilitate cell cycle arrest, especially by enhancing p21 transcription, which allows time for 
DNA repair (34,39,40).
P21 was initially identified as an important mediator of p53-dependent tumor growth 
suppression, (41) functioning as an inhibitor of especially G1 cyclin kinases (42). P21 be-
longs to the Cip/Kip family of CDK inhibitors including p27 and p57. Each family member 
inhibits the kinase activity of broad but not identical classes of CDK–cyclin complexes, cau-
sing hypo-phosphorylation of retinoblastoma protein (pRb) (43,44). Hypo-phosphorylated 
pRb prevents the release of E2F (43-45), leading to the repression of E2F-dependent trans-
cription and to a G0/G1 arrest (46,47). However, more recent investigations have shown that 
p21, besides inhibiting the cell cycle, might also play a role in promoting cell cycle transition 
(17,48-51), differentiation (52-54) and preventing apoptosis (55). 
Lack of mutations in TP53 in TC. Aforementioned, a surprisingly low percentage of 
TP53 mutations are found in testicular cancer (TC). Lack of mutations in TP53 might be 
explained by expression of microRNAs (miRs), which can inhibit translation of genes, in-
cluding downstream targets of p53, through interaction with the 3’untranslated region (UTR) 
of the messenger RNA (mRNA). In TC, high expression of the miR-371~373 cluster was 
observed, which mimics mutated p53 by targeting the tumor suppressor gene protein LATS-
2, involved in the regulation of G1-S transition in the cell cycle (56). Additionally, TCs are 
supposed to have a deregulated G1/S checkpoint (57-60), since p21 and pRB are almost not 
detectable in seminomas and embryonal carcinomas, while p27, cyclin E and cyclin D2 are 
over-expressed (57-63). Furthermore, p27 and p21 (if expressed) are mainly cytoplasmic 
localized in TC cell lines due to PI3K/Akt phosphorylation of the nuclear localization signal 
(NLS) domain of these proteins (64,65). Activated Akt TC might be due to the lack of PTEN 
(phosphatase and tensin homolog) (65) a negative regulator of the PI3K/Akt pathway. In 
turn, cytoplasmic p21 and p27 actually promote cell cycle progression from G1 into S phase, 
by regulating the assembly and activation of Cyclin/CDK complexes, a mechanism that has 
not been demonstrated in TC cells yet (17,48-51). Moreover, in TC, in contrast to other solid 
tumor types, the DDR machinery is rarely activated spontaneously (66,67). Therefore, no 
selective pressure on aberrations of the DDR genes, such as ATM/ATR, Chk2 and TP53 
are necessary, whilst the intact state of the DDR machinery may contribute to the exquisite 
cisplatin-sensitivity of these tumors (66,67).
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The role of wild type p53 in cisplatin-induced DNA damage and apoptosis in TC. 
High levels of wild-type p53 are positively correlated with MDM2 expression levels in vivo 
and in vitro in TC (6,62,68-70). MDM2 is an important negative feedback regulator of p53 
(27-31), and activity towards p53 is regulated by phosphorylation of MDM2 (31,33,71,72). 
p-Akt can bind to and phosphorylate MDM2, leading to nuclear localization of MDM2 and 
consequently enhancing MDM2-mediated ubiquitination and degradation of p53 (71,72). 
Alternatively, p-ATM mediated phosporylation of MDM2 inhibits the ability of MDM2 to 
poly-ubiquitinate p53, and is likely to be the key step in causing p53 stabilization (31,33). 
Therefore, tight regulation of p53 by MDM2 may be of importance for the response to cis-
platin in TC.  In contrast to many other tumor cell types, in TC cell lines cisplatin treatment 
led to an upregulation of p53, MDM2 and Fas, while levels of p21 were much less affected 
Chapters 1-4 & refs (7,73). Moreover, we showed that cisplatin-induced apoptosis as well 
as trans-activation of MDM2, Fas en p21 were depending on p53 (Chapter 3). In cisplatin-
sensitive TC cells, p53 downregulation strongly reduced sensitivity to cisplatin (Chapter 
3). Interestingly, previous results from our group have demonstrated that cisplatin induces 
apoptosis mainly in as Fas-dependent manner in cisplatin-sensitive TC cells (73). In the 
cisplatin-sensitive Tera cells, besides FAS, the Fas adaptor LRDD and a gene implicated in 
positive Fas regulation, PHLDA3 were found to be regulated by p53 upon cisplatin treatment 
(74). The pro-apoptotic role of CDK2 in TC has been recently established and is strongly 
connected to the Fas apoptosis route (64). CDK2 can be induced in a caspase-dependent way 
following activation of the Fas pathway (75), leading to depolarization of the mitochondrial 
membrane (76) by cytoplasmic CDK2 mediated translocation of Bax to the mitochondria 
(76,77). Alternatively, after the induction of DNA damage, functional interaction of CDK2 
with FOXO1 can be an important mechanism to enhance, among others Fas ligand expres-
sion, and thus promotes activation of the Fas pathway (78). In contrast to the protective 
effect of p53 downregulation on cisplatin-induced apoptosis observed in cisplatin-sensitive 
TC cells, p53 suppression strongly sensitized intrinsic cisplatin-resistant TC cells to cisplatin 
(Chapter 3). The anti-apoptotic role of p53 may be due to its role as transcriptional activator 
of p21, a protein that was predominantly expressed in the intrinsic resistant TC cells (Chapter 
3). In addition, in cisplatin-resistant TC cells p53 function is impeded by the interaction with 
MDM2 and the subsequent sequestration of p53 in the cytoplasm (Chapter 4). The impor-
tance of p21 and MDM2 in cisplatin-resistance of TC cells is discussed hereafter.
Cytoplasmic p21 as an inhibitor of cisplatin-induced apoptosis in TC. Recent studies 
on cisplatin and irradiation induced p21 in TC cell lines showed that irradiation, in contrast 
to cisplatin, strongly induced p21 mRNA and protein expression in these cells. Surprisingly, 
p21 was not present in the nucleus but in the cytoplasm. Functional analysis of irradiation-
induced cytoplasmic p21 revealed its involvement in protecting TC cells against Fas-induced 
apoptosis (7). Whether differences in basal p21 levels are important in determining cispla-
tin sensitivity in TC cell lines, was, however, not studied. We have now reported that in 
cisplatin-sensitive TC cells lower basal levels of cytoplasmic localized p21 were detectable 
compared to intrinsically cisplatin-resistant TC cells (64). Moreover, ectopic expression of 
cytoplasmic localized p21, using a p21-D-NLS construct, rendered cisplatin-sensitive Tera 
cells resistant to cisplatin treatment. While p21 suppression of intrinsic cisplatin-resistant TC 
cells led to an increase in apoptosis upon cisplatin treatment (64). Clinical relevance of these 
cell line based findings was also demonstrated. As stated before, p21 is not commonly ex-
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pressed in EC components of chemo-sensitive TC patients. In contrast, cytoplasmic localized 
p21 is detectable in the EC component of the majority of refractory testicular cancer patients 
suggesting a role for cytoplasmic p21 in the chemo-resistance of testicular cancers, probably 
via apoptosis inhibition. In two p21 positive, refractory TC patients only the EC component 
was present, which is further strengthening the in vitro observations with respect to the cyto-
plasmic p21 dependent mechanism of cisplatin resistance (64).
Cytoplasmic p21 antagonizes the pro-apoptotic function of proteins. The mechanism 
by which cytoplasmic p21 can inhibit apoptosis in TC is becoming more clear. Several pos-
sible anti-apoptotic functions of high cytoplasmic p21 levels have been described that are 
strongly related to Fas-induced apoptosis. ASK-1 is a mediator of Fas-induced apoptosis: 
upon Fas activation, Fas is trimerized and induces recruitment of Daxx that interacts with 
ASK1, resulting in activation of JNK/SAPK and p38, and concomitantly apoptosis induc-
tion. This process is blocked by cytoplasmic p21 binding to ASK1 (79-81). In fact, we have 
recently demonstrated that cytoplasmic p21 forms a complex with ASK-1 in TC (64). Ad-
ditionally, cytoplasmic p21 can inhibit Rho-kinase activity (82,83), which in turn is involved 
in Fas-induced apoptosis by enhancing Fas/FasL clustering in lipid rafts and Fas receptor 
capping, a mechanism that has not been demonstrated in TC cells yet (84-86). Interaction 
of cytoplasmic localized p21 with caspase 3 can lead to reduced Fas-induced apoptosis, ho-
wever in TC cells the interaction between cytoplasmic p21 and caspase 3 was not detected 
(7,64,87). CDK2 activity can be induced in a caspase-dependent way following activation 
of the Fas pathway (75). We have reported that CDK2 was in complex with p21 in intrinsic 
cisplatin-resistant TC cells (64). Furthermore, the high levels of cytoplasmic localized p21 
in intrinsic cisplatin-resistant TC cells were essential to protect these cells for the cisplatin-
induced pro-apoptotic effect of CDK2 (64). Therefore, we conclude that one key determinant 
of cisplatin-resistance in TC cells is high cytoplasmic expression of p21.
Regulation of p21 protein levels in TC. A recent study has provided novel insight in 
the mechanism causing the low p21 levels in cisplatin-sensitive versus the high p21 levels 
in cisplatin-resistant TC (64). Involvement of the miR-106b seed family in regulating p21 
expression and cell cycle control has previously been demonstrated (88,89). Additionally, it 
has been described that miR-17-5p, miR-106a and miR-20a belonging to the miR-106b seed 
family are under transcriptional control of Oct4 in murine ES cells (90). Our study shows that 
in cisplatin-resistant in human TC cells, high expression of p21 is related to low expression 
of Oct4 and miR-106b seed family members, while transfection with pre-miRs led to p21 
suppression and to a concomitant increase in cisplatin sensitivity (64). Suppression of Oct4 
in a cisplatin-sensitive TC cell line Tera lowered the expression level of miR-106a, miR-
17-5p and miR-20a resulting in enhanced p21-3’UTR dependent luciferase translation and 
robustly induced p21 protein expression (64). This was accompanied by a strong reduction 
in cisplatin induced apoptosis. Interestingly, in chemo-refractory TC patients almost no miR-
17-5p, miR-106a and Oct4 staining was observed in EC components, with clearly detectable 
p21, while high levels of these miRs and Oct4 were detected in the EC component of chemo-
sensitive TC patients.
Cytoplasmic p21, differentiation and cisplatin sensitivity in testicular cancer. Several 
studies have demonstrated that more differentiated TCs, such as teratomas, in contrast to 
EC, abundantly express p21 (58,59,61,62,91). Teratomas predominately show a nuclear lo-
calization of p21 and are neither growing, possibly via p21-mediated cell cycle arrest, nor 
responsive to treatment with cisplatin (3,8,63,91). After treatment with cisplatin-based che-
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motherapy residual vital mature teratoma is found in 30-40 percent of the patients, implying 
a selection for more differentiated components that are less chemosensitive (63,92). Howe-
ver, occasionally an enlarging mature teratoma arises during or after chemotherapy (63,93), 
indicating a loss of cell cycle arrest. This is called the growing teratoma syndrome. These 
growing teratomas appeared to be responsive to a selective CDK4/6 inhibitor, PD0332991 
(63). It is tempting to speculate about a possible redistribution of p21 from the nucleus to 
the cytoplasm in this syndrome, but so far no data are available. In contrast to teratomas, 
primary ECs hardly express any p21 (58,59,61,62). ECs are characterized by a capacity to 
differentiate, which is observed both in vitro and in vivo (94-98). Moreover, ECs share many 
similarities with embryonic stem cells (3,99) including their miRNA expression profile (99) 
and mRNA expression of a cassette of pluripotency genes, such as Oct4, Nanog and Stellar 
(3,99,100). In addition, retinoic acid (RA) treatment of the TC/EC cell line Tera resulted in 
repression of Oct4, Nanog and Stellar. Oct4 suppression has a similar effect as RA treat-
ment, since RA treatment as well as Oct4 knockdown induced differentiation of Tera cells 
(100,101), and concomitantly induced resistance to cisplatin (102,103). Interestingly, after 
RA treatment or Oct4 suppression downregulation of miR-106 seed family members was 
observed (64,104). The miR-106b seed family is potentially oncogenic (105) and has been 
implied in embryonal stem cells maintenance, control of differentiation (106) and fine-tuning 
of p21 expression, via inhibition of p21 translation by binding to the p21’3UTR (64,88,89). 
Therefore, it is not surprising that the onset of differentiation in Tera cells leads to enhanced 
expression of p21 (107-109) that is mainly cytoplasmic localized 2 days after RA treatment 
or Oct4 suppression (64).
Together these observations show a direct correlation between cytoplasmic p21 expres-
sion, regulated by Oct4, miR-106b seed family members, and resistance of testicular cancers 
to cisplatin. In addition, these data strongly suggest a link between cytoplasmic p21 and onset 
of differentiation.
How to translate this knowledge to better therapeutic possibilities. P53 function is im-
peded by the interaction with MDM2 and the subsequent sequestration of p53 in the cyto-
plasm in cisplatin-resistant testicular cancer cells (Chapter 4). Therefore, targeting the p53/
MDM2 axis may sensitize TC cells to cisplatin. Nutlin-3 inhibits the interaction between 
MDM2 and p53 by binding MDM2 in the p53-binding pocket leading to stabilization of p53 
(29). Treatment with Nutlin-3 as a single agent induced apoptosis and at minimally cyto-
toxic concentrations nutlin-3 sensitized testicular cancer cells to cisplatin (Chapter 4 & refs 
110,111). Both Nutlin-3 and siRNA against MDM2, caused a high induction of p53 and Fas 
membrane expression, a massive apoptosis induction, and a strongly reduced survival in both 
cisplatin-resistant and -sensitive testicular cancer cell lines (Chapter 4). Combining non-toxic 
concentrations of Nutlin-3 with cisplatin leads to a further activation of the p53 pathway 
and the Fas/FasL death receptor pathway and sensitizes both intrinsic as well as acquired 
cisplatin-resistant testicular cancer cells even to low concentrations of cisplatin (Chapter 4). 
Blocking of the Fas/FasL death receptor pathway impairs apoptosis induction of Nutlin-3 as 
well as Nutlin-3 combined with cisplatin in testicular cancer cells (Chapter 4). After Nutlin-3 
treatment or cisplatin treatment, p21 mRNA and protein levels remained relatively low in 
testicular cancer cells (7,73,110). Though occupancy of p53 on the p21 promoter in testicular 
cancer cells showed similar levels compared to U2OS and HCT116 cells, a clear difference 
in p21 expression was observed between testicular cancer cells and non-testicular cancer 
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cells (110). Therefore, it is legitimate to assume that the release of negative feedback on p53 
turns the balance in favor of transcribing pro-apoptotic genes, such as proteins involved in 
the Fas death receptor pathway. The results discussed herein suggest that the activation of 
the complex DNA damage-induced p53 pathway, with MDM2 as feedback mechanism fine-
tuning the p53 response, seems to play a crucial role in balancing chemotherapy response of 
testicular cancers. Moreover, efficient activation of the p53-induced pro-apoptotic pathway 
by antagonizing MDM2 overrules the anti-apoptotic effect of p21 in response to cisplatin-
induced DNA damage in testicular cancers.
Increased levels of cytoplasmic localized p21 is a key determinant of cisplatin-resistance 
in TC cells (64). Cytoplasmic localization of p21 is caused by PI3K/Akt mediated phosp-
horylation of p21 (64). Cytoplasmic localized p21 can be re-localized towards the nucleus 
by dephosphorylation of p21, using Triciribine, an Akt inhibitor currently in phase 1 trial, 
siRNA against Akt or the PI3K inhibitor LY294002. Relocalization of p21 caused a loss of 
complex formation of p21 with pro-apoptotic CDK2 and sensitized cisplatin-resistant TC 
cells for cisplatin-induced apoptosis (64). Therefore, a therapeutically interesting approach 
would be targeting Akt phosphorylation with the use of PI3K/Akt inhibitors (112). Whether 
PI3K/Akt inhibitors currently in clinical trial, such as Triciribine, SF1126, BKM120, PX-
866, BEZ235 and GDC-0941 are effective, needs to be elucidated.
Conclusions
Testicular cancer is considered a paradigm for curable advanced malignancy and therefore, 
an informative model to investigate and understand the molecular determinants of chemo-
therapy sensitivity (and resistance) of solid tumors. Extensive knowledge about mechanisms 
involved in sensitivity and resistance of testicular cancer to DNA-damaging agents contri-
butes to the design of new treatment strategies to overcome cisplatin resistance of refractory 
testicular cancers and of other human cancers. Based on our own studies and literature pre-
sented, we conclude that presence of wild-type p53, almost no p21 induction, and activation 
of the Fas apoptotic pathway is important for the exquisite sensitivity of TC cells to cisplatin. 
The reduced levels of p21 are caused by high expression of Oct4 and miR-106b seed family 
members. In cisplatin-resistant TC cells, resistance is caused by high levels of cytoplasmic 
p21 and tight regulation of p53 by MDM2. P21 is predominantly localized in the cytoplasm 
and does not induce cell cycle arrest, but antagonizes the pro-apoptotic function of proteins 
downstream of Fas, such as Ask1 and CDK2 in these cisplatin-resistant TC cells. To overco-
me cisplatin resistance of TC cells, two main strategies have been identified. Relocalization 
of cytoplasmic p21, using inhibitors of the PI3K/Akt pathway, resulted in a strong sensitiza-
tion to cisplatin. Alternatively, antagonizing the MDM2-mediated negative feed-back of p53 
with nutlin-3 also largely enhanced cisplatin sensitivity in TC cells.
Wild-type p53 is present in most tumors of TC patients, while recent data showed that 
high levels of cytoplasmic p21 and low levels of Oct4 and miR106-b family members were 
features of EC tumors of refractory TC patients. Therefore, enhanced efficacy in the treat-
ment of refractory testicular cancers may be achieved by the combination of conventional 
chemotherapy with MDM2 antagonists or PI3K/Akt-inhibitors. This needs to be further stu-
died in preclinical and clinical settings. Gaining those insights may direct novel therapeutic 
approaches in other p21-expressing solid tumors with wild-type p53 as well.
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Figure 1. The role of wild-type p53, MDM2, p21 and Fas in cisplatin sensitivity and strategies to enhance cisplatin 
sensitivity in testicular cancer. (A) Schematic overview of connected pathways, which are causative for the sus-
tained presence of wild-type p53 in testicular cancer. Solid lines represent active, while dotted lines represents in-
active signaling. (B) Cisplatin-induced DNA damage activates p53, which in turn transcribes MDM2 and p21, and 
activates the Fas apoptosis pathway and the mitochondrial apoptosis pathway. MDM2 is important for regulating 
p53 trans-activational activity, p-Akt is important for dynamic shuttling of p21 from the nucleus towards the cyto-
plasm, while cytoplasmic p21 can block apoptosis. Oct4 regulated miR-106b seed family members (miR-106b fam) 
are involved in regulating p21 expression levels. Cisplatin-sensitive cells are characterized by high levels of Oct4 
and miR-106b family members and as a consequence low amounts of cytoplasmic p21, resulting in cisplatin-indu-
ced apoptosis. Cisplatin-resistant cells have lower levels of Oct4 and miR-106b family members and high amounts 
of cytoplasmic p21, resulting in CDK2 inhibition and concomitantly moderate levels of cisplatin-induced apoptosis. 
Grey lines represent anti-apoptotic response and black lines represent pro-apoptotic response to cisplatin-induced 
DNA damage. (C) Deactivation of Akt with LY294002, Triciribine or siRNA against Akt sensitizes cisplatin-re-
sistant cells. Deactivation of Akt leads to nuclear localization of p21, which in turn is no longer capable of blocking 
cisplatin-induced apoptosis. Dotted grey lines represent inactivated signaling, due to treatment. (D) Interfering in 
p53-MDM2 complex formation by Nutlin-3 treatment (or suppression of MDM2) substantially induced Fas expres-
sion, resulting in apoptosis of both cisplatin-sensitive and -resistant TC cells. Cisplatin in combination with Nutlin-3 
further enhanced Fas expression and sensitized cisplatin-sensitive and -resistant TC cells to cisplatin-induced apop-
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Abstract
Bleomycin is an essential component of cisplatin-based chemotherapy regimens for patients 
with disseminated testicular cancer (TC), the paradigm of chemotherapy-sensitive solid tu-
mors. However, a subset of these young patients still die because of chemo-resistant disease. 
Bleomycin hydrolase (BLMH) is an enzyme capable of metabolic inactivating of bleomy-
cin. Increased enzymatic activity and elevated expression of BLMH have been observed in 
bleomycin-resistant human tumor cell lines. Besides, the homozygous variant G/G of the 
SNP A1450G in BLMH, thought to be involved in controlling the enzymatic activity, was 
associated with reduced survival and chemo-resistant disease in testicular cancer patients. 
In this study, we used a TC cell line panel, all homozygous wild-type A/A for the SNP 
A1450G, consisting of Tera, the acquired cisplatin-resistant subline Tera-CP, and the intrin-
sic cisplatin-resistant Scha cell line. Therefore, differences in enzymatic properties of BLMH 
due to different SNP genotypes of the cell lines used in the present study could be excluded. 
Highest BLMH levels were detected in the 10-fold bleomycin-resistant Scha cells. Tera and 
Tera-CP had similar BLMH levels indicating that acquired cisplatin-resistance is not related 
to bleomycin-resistance. High levels of BLMH coincided with a decreased sensitivity to 
bleomycin and a decrease in bleomcyin-induced apoptosis. Moreover, suppression of the 
high BLMH level using siRNA sensitized Scha cells to bleomycin-induced apoptosis but not 
to cisplatin. In conclusion, the level of BLMH is an important determinant of sensitivity to 
bleomycin in TC cells.
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Introduction
Testicular cancer (TC) is the most common types of malignancy in men from 20-40 years 
of age, with a still increasing worldwide incidence (1). The mortality rate of TC has decre-
ased, leading to a long-term survival of over 80% (2,3). This improvement in survival is 
related to the introduction of cisplatin for the treatment of disseminated TC in the late 1970s 
and the further development of cisplatin-based regimens (4-6). Bleomycin has proven to be 
an important and essential component of cisplatin-based chemotherapy regimens, like PVB 
(Cisplatin, Vinblastin, Bleomycin) and the currently used standard treatment regimen BEP 
(Bleomycin, Etoposide and Cisplatin), to treat patients with  TC (7-9). In addition bleomycin 
is used in combination with other cytotoxic drug in the treatment of Hodgkin’s disease.
However, the use of bleomycin as an anticancer drug is limited by bleomycin-indu-
ced pulmonary inflammation and fibrosis (pneumonitis) and tumor resistance to bleomycin. 
Pneumonitis is a bleomycin treatment related complication that occurs in approximately 10% 
of TC patients and is fatal in about 1% of the patients (10-13). Toxicity to bleomycin might 
be influenced by decreased drug clearance, repair of bleomycin-induced DNA lesions and/or 
inactivation of bleomycin (14-16). Bleomycin hydrolase (BLMH) is an enzyme capable of 
metabolically inactivating bleomycin (15) that shows low expression levels in human lungs 
and skin (17). In mice, lack of enzymatic activity of BLMH is associated with increased 
bleomycin-induced pulmonary toxicity (18,19). Moreover, increased enzymatic activity and 
elevated expression of BLMH in bleomycin-resistant human non-testicular tumor cell lines 
were observed (15,17,20,21), suggesting that activity and or levels of BLMH influence toxi-
city and antitumor efficacy of bleomycin. Recently we have defined that the homozygous 
variant G/G of the BLMH gene SNP A1450G is associated with reduced survival and higher 
chemo-resistant disease in patients with testicular cancer treated with cisplatin-bleomycin 
containing chemotherapy (22).
In the presented study we investigated the sensitivity of TC cell lines to bleomycin and 
cisplatin, and related the sensitivity to BLMH protein levels (and genotype). Moreover, we 
suppressed the cells for BLMH with siRNA to interfere with the cytotoxic response to bleo-
mycin. 
Materials and Methods
Chemicals. RPMI 1640, Optimem medium, HAM, F12-DMEM and Oligofectamine reagent were obtained from 
Invitrogen (Merelbeke, Belgium). Fetal calf serum (FCS) was purchased from Bodinco (Alkmaar, the Netherlands) 
and MTT (3-(4,5-dimethylthiazol-2-yl)-2,5diphenyl-tetrazoliumbromide), trypsin, and acridine orange from Sigma-
Aldrich (Amsterdam, the Netherlands). Dimethyl sulfoxide (DMSO) was obtained from Merck (Darmstadt, Ger-
many). Bleomycin and cisplatin were obtained from Pharmachemie (Haarlem, the Netherlands). Polyvinylidene 
difluoride (PVDF) membranes were obtained from Millipore BV, Etten-Leur, the Netherlands. The monoclonal 
antibody against BLMH was obtained from Abcam (Cambridge, UK) and the monoclonal antibody against beta-
actin from (MP Biomedical, the Netherlands). The horseradisch peroxidase (HRP)-conjugated secondary rabbit 
anti-mouse antibody was from Dako (Glostrup, Denmark) and the Lumi-light PLUS western blot substrate kit from 
Roche Diagnostics (Almere, the Netherlands).
Cell Lines. The human germ cell tumor cell lines Tera, its cisplatin resistant sub-line Tera-CP, and the intrinsic 
cisplatin resistant Scha were used (23,24). All cell lines were cultured as monolayers in RPMI 1640 medium with 
10% heat-inactivated FCS and harvested by scraping. Cells were cultured at 37°C in a humidified atmosphere con-
taining 5% CO2. BLMH genotype, of the cell lines used in this study, was determined by polymerase chain reaction 
(PCR) and a restriction fragment length polymorphism technique, according to the previously described procedure 
(22).
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Cytotoxicity. Sensitivity to bleomycin and cisplatin was tested with the microculture tetrazolium assay as 
described before (25). Cells were continuously incubated with the drugs in 96-wells tissue-culture plates in HAM/
F12-DMEM medium (1:1) supplemented with 20% FCS. After a culture period of 4-days, 20 µl MTT solution (5 
mg/ml) was added to each well for 225 min; then the plates were centrifuged, the supernatant was aspirated, and 
the formed formazan crystals were dissolved in 200 µl DMSO, after which the extinction was read at 520 nm using 
a Benchmark Microplate Reader (Biorad, Veenendaal, the Netherlands). The percentage of cell survival was cal-
culated by dividing the mean of the test sample by the mean of the untreated samples. Controls consisted of media 
without cells (background extinction) and cells incubated with medium without drugs (growth control). At least 
three independent experiments were performed.
SDS-Polyacrylamide gel electrophoresis (SDS-PAGE) and Western blotting. Levels of the BLMH protein 
were determined by SDS-PAGE followed by western blotting. Cells were harvested as described above, washed 
once with cold phosphate buffered saline (PBS: 6.4 mM Na2HPO4, 1.5 mM KH2PO4, 0.14 M NaCl, 2.7 mM 
KCl, pH 7.2), lysed by standard Western blot sample buffer (50 mM Tris-HCl, pH 6.8, 2% SDS, 10% glycerol, 5% 
2-β-mercaptoethanol, 0.002% bromophenol blue) and boiled for 5 min to denaturize the proteins. Protein concentra-
tions were determined according to Bradford(26). Total cell lysates were size-fractionated by electrophoresis (SDS-
PAGE, Biorad, Veenendaal, the Netherlands) and transferred onto activated PVDF membranes using a tank-blot 
system (Biorad). Upon staining, the membranes were washed in Tris-buffered saline (TBS: 100 mM Tris-HCl, 137 
mM NaCl, pH 7.8) and blocked for 1h in TBS supplemented with 5% milk powder and 0.05% Tween-20 (TBSt-
milk). Immunodectection of BLMH was performed by incubation with the mouse anti-human BLMH (2079C4a 
1:800 diluted in TBSt-milk) overnight at 4°C. Finally antibody binding was determined using HRP-conjugated 
secondary rabbit anti-mouse antibody and visualization was performed with the Lumi-light PLUS western blot 
substrate kit. Immunostaining of beta-actin (C4, 1:10000 diluted in TBSt-milk) was performed as a control for equal 
protein loading.
Apoptosis. Staining with acridine orange was used to distinguish apoptotic cells from vital cells (27). In the 
apoptosis experiments, 5,000-10,000 cells per well were pre-incubated with siRNA for 24h followed by incubation 
with bleomycin or cisplatin for 4h (short/high treatment) or 24 h (long/low treatment) in 96-wells micro-culture 
plates in a total volume of 200 µl. Untreated cells served as control. After 48 h of incubation at 37°C, acridine orange 
was added to a final concentration of 5 µg/ml and cells were incubated at 37°C for a further 10 min. Thereafter, 125 
µl of the supernatant was carefully removed before proceeding with cell counting using a fluorescent microscope 
(Olympus IM, Japan) at 535 nm. The percentage of apoptotic cells was calculated by dividing the amount of apop-
totic cells by the total amount of cells counting at least 300 cells per well. 
Downregultation BLMH by RNA interference. Small interfering RNAs (siRNAs) were used for down-regu-
lation of BLMH. Double-stranded BLMH siRNA molecules 5’-GCU CUG AUA CAG AAA CUG AAU dTdT-3’ 
(sense) and 5’-AUU CAG UUU CUG UAU CAG AGC dTdT-3’ (antisense) were designed and synthesized by Eu-
rogentec (Maastricht, the Netherlands).  Scrambled oligonucleotides, from Eurogentec (Maastricht, the Netherlands) 
served as negative control. Cells were plated in 6-wells or 96-wells plates in unsupplemented Optimem medium and 
transfected with 0.12 mM siRNA using Oligofectamine reagent according to the manusfacturer’s protocol (Invi-
trogen) for respectively protein and apoptosis measurements.
Statistics. Statistical analysis consisted of a (un-)paired Student t-test. A double sided p-value < 0.05 was 
considered to indicate significance.
Results
High BLMH levels are associated with reduced bleomycin cytotoxicity and apoptosis-in-
duction in TC cells. We used a TC cell line panel consisting of Tera, an acquired 3.1 fold 
cisplatin-resistant subline Tera-CP, and the intrinsic 13-fold cisplatin-resistant Scha cell line. 
Figure 1A shows the survival curve of Tera, Tera-CP and Scha after continuous incubation 
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with cisplatin for 96h with IC50 (concentration inhibiting survival by 50%) values indicated 
in Table 1. No difference in sensitivity to bleomycin after incubation for 96 h was observed 
between Tera and Tera-CP, whereas Scha showed to be 10-fold resistant to bleomycin com-
pared to the Tera and Tera-CP (Figure 1B & Table 1).
Next, we determined BLMH expression levels in the TC cell lines by Western Blot ana-
lysis. Almost no difference in BLMH protein levels between Tera to Tera-CP was observed, 
while Scha expressed approximately 4-fold higher BLMH levels compared to Tera (Figure 
1C). Cell lines were screened for a single nucleotide polymorphism (SNP) A1450G in the 
BLMH gene that is thought to be involved in controlling the enzymatic activity. All three TC 
cell lines showed to be wild type (A/A) for the SNP A1450G.
Figure 1. BLMH levels are associated with the response to bleomycin (A-B) Survival of TC cells after 96h of 
continuous cisplatin treatment (A) and bleomycin treatment (B) as indicated; values are the mean ± SD of three 
independent experiments; *p < 0.05; **p < 0.01; ***p < 0.005 Tera-CP or Scha compared to Tera for cisplatin and 
Scha compared to Tera/Tera-CP for bleomycin. (C) Western blot analysis showing the levels of BLMH of the TC 
cell lines Scha, Tera and Tera-CP. Actin was used as loading control; data are representative of three independent 
experiments. (D) Apoptotic response after 24h of treatment with bleomycin as indicated; values are the mean ± SD 
of three independent experiments; *p < 0.05; **p < 0.01; ***p < 0.005 Tera-CP or Scha compared to Tera.
We compared bleomycin-induced apoptosis in the TC cell lines. In Tera and Tera-CP, 
an almost similar concentration-dependent apoptotic response was observed after bleomycin 
treatment. In Scha, in contrast, bleomycin-induced apoptosis was strongly reduced compared 
to Tera and Tera-CP reflecting the results in the survival assay and indicated a relation with 
BLMH levels (Figure 1D).
High levels of BLMH protect TC cell line Scha for bleomycin-induced apoptosis. To 
investigate the importance of high levels of BLMH, TC cells were depleted of BLMH. Only 
treatment with specific siRNAs for BLMH showed a clear down-regulation of the target 
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higher apoptosis levels in Scha cells upon bleomycin treatment compared to Scha cells trans-
fected with scrambled siRNA (Figure 2B). In Tera cells, expressing low endogenous BLMH 
levels, no significant effect of BLMH suppression on bleomycin-induced apoptosis levels 
was observed (Figure 2B). No effect on cisplatin-induced apoptosis was observed in Tera and 
Scha cells suppressed for BLMH (data not shown).
The effect of BLMH levels on apoptosis was further investigated using a short incuba-
tion time (4h) with higher doses of bleomycin. In BLMH suppressed Scha cells bleomycin 
treatment even doubled the induction of apoptosis compared to control (Figure 2C). No ef-
fect of down-regulation of BLMH on cisplatin-induced apoptosis was observed in Scha cells 
using high doses and short treatment time (Figure 2D).
Figure 2. BLMH suppression sensitizes TC cells to bleomycin. (A) Successful downregulation of BLMH in the TC 
cells Tera and Scha. Data are representative of three independent experiments. (B) Suppression of BLMH incre-
ased the apoptotic response of the high BLMH expressing Scha cells 24h after continues bleomycin treatment as 
indicated, while no significant increase in the apoptotic response was observed in the low BLMH expressing Tera 
cells; values are the mean ± SD of three independent experiments; *p < 0.05; **p < 0.01; ***p < 0.005 Scha siRNA 
BLMH versus Scha siRNA Scr. (C) Suppression of BLMH increased the apoptotic response after a short incubation 
time (4h) and higher doses of bleomycin, as indicated, in Scha cells. While no significant increase in the apoptotic 
response was observed after short/high treatment with cisplatin in Scha cells; values are the mean ± SD of three 
independent experiments; *p < 0.05; **p < 0.01; ***p < 0.005 Scha siRNA BLMH versus Scha siRNA Scr.
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Discussion
BLMH deaminates bleomycin and consequently converts bleomycin into the metabolite 
desamido-bleomycin, which in contrast to bleomycin poorly cleaves DNA and lacks cyto-
toxicity (18,28). Bleomycin is an essential component of the cisplatin-based chemotherapy 
regimens for treatment of TC. Since metabolic inactivation of bleomycin by BLMH appears 
to be associated with human tumor resistance to bleomycin (15), we investigated whether 
BLMH levels influence survival and apoptotic response in TC cell lines treated with bleomy-
cin. Here, we show that high levels of BLMH are associated with a diminished apoptotic and 
cytotoxic response to bleomycin. No association between cisplatin sensitivity and BLMH 
levels was observed. Furthermore, suppression of BLMH sensitized the high BLMH expres-
sing cells to bleomycin, but not to cisplatin.






Rel. BLMH expression3 BLMH genotype
Tera 0.35 ± 0.06 (RF 1.0) 0.10 ± 0.02 (RF 1.0) 1 A/A
Tera-CP 1.07 ± 0.28 (RF 3.1) 0.09 ± 0.04 (RF 0.9) 1.25 A/A
Scha 4.81 ± 0.57 (RF 13) 0.95 ± 0.26 (RF 9.5) 4.01 A/A
1) The IC50 (drug concentration reducing cell survival by 50%) for cisplatin was calculated from the graph in Figure 
1A. The mean IC50 ± SD was determined in three experiments, each performed in quadruplicate. Resistant factor 
(RF) was calculated by dividing the IC50 of the cell lines by the IC50 of Tera.
2) The IC50 for bleomycin was calculated from the graphs in Figure 1B. The mean IC50 ± SD was determined in 
three experiments, each performed in quadruplicate. RF was calculated by dividing the IC50 of the cell lines by the 
IC50 of Tera. 
3) Relative BLMH expression (Rel. BLMH expression) was calculated with image J1.41 (National Institutes of 
Health) by dividing BLMH/Actin and normalized against Tera.
Other substrates of BLMH, besides bleomycin, homocysteine and probably amyloid 
precursor protein (29-31), are currently unknown. BLMH is supposed to have a conserved 
cellular function (17,19,32) and is suggested to play a role in protein processing and degra-
dation, since it resembles a proteasome-like structure (33,34). Consequently, BLMH might 
influence degradation of proteins involved in the apoptotic response to cytotoxic drugs other 
than bleomycin, including cisplatin. Our results suggest that BLMH is not involved in regu-
lating intracellular response pathways to cisplatin in TC.
The observed importance of BLMH levels in determining sensitivity to bleomycin is in 
agreement with previous studies on normal tissue and cancers discussed below. The sensiti-
vity of  lungs to bleomycin can best be explained by the lack of BLMH activity (18), due to 
low expression levels of BLMH observed in human lung tissue (17). High BLMH activity in 
lung tissue of rabbits actually protected the lungs against the toxic effects of bleomycin (18). 
High BLMH expression levels were observed in several bleomycin-resistant human tumor 
cell lines, including cell lines originating from Burkitt lymphomas, colorectal adenocarcino-
mas and leukemias (15,17,20,21). In contrast, low or undetectable levels of BLMH were ob-
served in Hodgkin’s disease (21), which is considered bleomycin-sensitive. Of interest, E-64, 
a cysteine proteinase specific inhibitor that inhibits BLMH activity, sensitized Daudi lymp-
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homa and Colo-205 cells to bleomycin in vitro and in vivo (15,20). Whether pharmacological 
inhibition of BLMH is a therapeutic option for TC patients needs to be further investigated, 
since inhibition of BLMH might increase bleomycin-induced pulmonary toxicity as well.
Recently, we observed that the somatic homozygous variant G/G of BLMH SNP 
A1450G is associated with reduced survival and a higher prevalence of early relapses in 
TC patients treated with bleomycin-containing chemotherapy (22). It is plausible that this 
specific polymorphism in the BLMH gene might affect bleomycin metabolism and thus in-
fluence bleomycin toxicity and/or anti-tumor efficacy, because it is located in the C-terminal 
region that intrudes the active-site cleft of BLMH (32,35,36). Although the involved amino 
acid substitution would unlikely lead to change in protein conformation, the involved region 
forms a likely candidate for interaction with a protein regulating the positioning of the C-
terminal arm (32) that intrudes the active-site cleft of BLMH and thereby influences substrate 
specificity as observed for a yeast BLMH homolog (32,35,36).  In the present study, we used 
TC cell lines that were homozygous wild-type A/A for this SNP. Therefore, we can exclude 
SNP-dependent differences in enzymatic properties of BLMH in the cell lines used in the 
present study. Future studies on biomarkers for bleomycin efficacy in TC patients may not 
only focus on the presence of the G/G variant of the BLMH SNP A1450G but also on BLMH 
expression levels in testicular tumors.
In conclusion, our results suggest that BLMH is an important determinant of cellular 
metabolism of and consequently resistance to bleomycin in high BLMH expressing TC cells. 
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Summary
Testicular cancers (TC) represent the most frequent solid malignant tumor in men 20-40 
years of age and the incidence of testicular cancer has been arising world-wide (1). Platinum-
based chemotherapy has improved outcome of testicular cancer enormously. In other tumor 
types, for instance bladder, lung and ovarian cancer, responsiveness to platinum-based che-
motherapy is often observed, but most of these patients eventually will relapse and die from 
platinum-resistant disease. Testicular cancers are cured at a rate of greater than 80% with 
conventional cisplatin-based chemotherapy even when highly advanced (1-2). Testicular 
cancer is, therefore, considered to be a paradigm of a platinum-sensitive solid tumor. Howe-
ver, the remaining 10~20% of patients are refractory to treatment and most will eventually 
die from progressive disease (2).
P53 is commonly found mutated in other tumor types (3-6), while high levels of wild-
type p53 are expressed in testicular cancer (7-9). The p53 pathway is crucial for effective 
tumor suppression in humans and a major role for p53 in the response to chemotherapeutic 
drugs and the execution of apoptosis has been described (10-14). P53 plays a central role 
in the response to DNA-damage, induced by chemotherapeutic drugs such as cisplatin, and 
can activate both the extrinsic and intrinsic death signaling pathways (14-15). Together this 
suggests that p53 is an important factor in cisplatin hypersensitivity of TCs. Several in vivo 
and in vitro studies suggest an important role for p53 in TC cisplatin responses (16-21). In 
contrast, other studies have failed to support a role for p53 (22-23). To decipher the role and 
importance of p53 in testicular cancer this thesis focuses mainly on the functionality of wild-
type p53 and activation of the p53-dependent apoptotic pathway in TC. Understanding why 
these tumors are curable with cisplatin-based chemotherapy could lead to the development 
of more effective treatment for refractory TCs and other solid tumors.
In vitro, cisplatin treatment of TC cells resulted in enhanced levels of p53 and murine 
double minute 2 (MDM2), activation of the Fas apoptotic pathway, and induction of apop-
tosis, while the expression levels of the cyclin-dependent kinase (CDK) inhibitor p21 were 
almost not affected in cisplatin-sensitive cells (8,24). In contrast, gamma-irradiation induced 
p53 and MDM2 levels and massive levels of cytoplasmic p21 without inducing apoptosis or 
cell cycle arrest in TC cells (8). These results suggested an important role for cytoplasmic lo-
calized p21 in preventing DNA damage-induced apoptosis in TC cells. Therefore we explo-
red the role of cytoplasmic p21 in determining resistance to cisplatin of TC cells. In Chapter 
2, we provided evidence that one key determinant of cisplatin-resistance in the embryonal 
carcinoma component of testicular cancer is high cytoplasmic expression of p21. The EC 
component of the majority of refractory testicular cancer patients exhibited high cytoplasmic 
p21 expression, which protected TC cell lines against cisplatin-induced apoptosis via CDK2 
inhibition. Localization of p21 in the cytoplasm was critical for cisplatin-resistance since 
relocalization of p21 to the nucleus by Akt inhibition sensitized TC cell lines to cisplatin. 
We also demonstrated in TC cell lines and human tumor tissue that high cytoplasmic p21 
expression and cisplatin-resistance of the embryonal carcinoma component of testicular can-
cer were inversely associated with the expression of Oct4 and miR-106b seed family mem-
bers. Thus, targeting cytoplasmic p21, including by modulation of the Oct4/miR-106b/p21 
pathway, may offer new strategies for the treatment of chemo-resistant testicular and other 
types of cancer.
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In human TC, in contrast to murine TC, the role of p53 mutational status and functio-
nality at basal and after chemotherapeutic drugs response remains elusive. Therefore, we 
analyzed in Chapter 3 functionality of wild-type p53 in the unique cisplatin sensitivity of 
human TC using a short interfering (si)RNA approach. A panel of cisplatin sensitive TC cell 
lines (833KE and Tera), a subline with acquired cisplatin resistance (Tera-CP) and a panel 
of intrinsic resistant TC cell lines (Scha and 2102EP), all expressing wild-type p53 were 
used. Cisplatin sensitivity was related to apoptosis induction in the TC cell lines. P53 and 
p53-transcriptional targets MDM2 and p21 were expressed in all TC cell lines. Basal levels 
of MDM2 and p21 mRNA and protein were highest in Scha and 2102EP and depending on 
p53 transactivation. Following cisplatin exposure, expression levels of p53 increased within 
6 h and further enhanced at 24 h with a subsequent increase in MDM2 mRNA and protein 
levels and Fas cell membrane levels in all TC cell lines. Previously, we demonstrated that 
high induction of p21 protein levels protected TC cell lines against Fas-mediated apoptosis 
following irradiation. In contrast, cisplatin treatment resulted in only a small induction of 
p21 mRNA and protein in these TC cells. Down-regulation of p53 with siRNA lowered 
cisplatin-induced apoptosis in Tera and Tera-CP, which was associated with a diminished 
Fas membrane expression. In contrast, p53 suppression augmented cisplatin-induced apopto-
sis in Scha and 2102EP and concomitantly strongly suppressed MDM2 and p21 mRNA and 
protein expression. Our results indicate that p53 is involved in transactivation of pro- and 
anti-apoptotic genes in TC cells. The opposite role of p53 in cisplatin-induced apoptosis de-
monstrates the importance of the cellular context on the p53 transactivation pathway among 
TC cell lines.
MDM2, as transcriptional target of p53, is the main negative feedback regulator of p53. 
By binding to the transactivation domain of p53, MDM2 is able to regulate p53 activity and 
stability via several mechanisms such as promoting p53 degradation through ubiquitination, 
stimulating p53 nuclear export, and inhibiting acetylation of p53 (25-27). Thus, p53 function 
might be impeded by the interaction with MDM2 and the subsequent sequestration of p53 
in the cytoplasm in cisplatin-resistant TC cells. Therefore we sought a possible role for the 
negative feedback regulation of MDM2 on p53 in determining the response to cisplatin. In 
Chapter 4, we demonstrate that in intrinsic and acquired-cisplatin resistant TC cells p53 
resides in a complex with (MDM2) after cisplatin treatment. Hyper-activation of the p53 
pathway using the MDM2 antagonist Nutlin-3 in TC cells leads to nuclear localization of p53 
and effective apoptosis induction as single agent. Targeting MDM2 with Nutlin-3 or short 
interfering RNA extremely sensitize resistant TC cells to cisplatin. The observed effects are 
dependent on the presence of wild-type p53, since mutant p53 expressing TC cells or wild-
type p53 suppressed TC cells are resistant to Nutlin-3. These results indicate that targeting 
the p53/MDM2 axis, in combination with standard treatment, can be a powerful strategy to 
pursue in cisplatin-resistant or -refractory testicular cancers. Specifically, we show that the 
Fas death receptor pathway plays an important role in MDM2 antagonist-induced apoptosis 
in TC cells. Importantly, we have identified a similar mechanism in wt p53 expressing Hodg-
kin lymphoma and acute myeloid leukaemia cells, suggesting a common profile for Nutlin-
3-induced apoptosis, which involves the Fas death receptor pathway.
In Chapter 5 we discuss why testicular cancer is considered as paradigm of curable solid 
tumor and why it is an ideal model to investigate and understand the molecular determinants 
of chemotherapy sensitivity (and resistance) of solid tumors. This review summarizes the 
current knowledge on the biological basis of cisplatin-induced apoptosis and response to 
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chemotherapy in testicular cancer. Moreover, the fact that testicular cancer sustains high 
basal levels of wild-type p53 is discussed. In turn, presence of wild-type p53 is causative 
for the exquisite sensitivity to cisplatin of testicular cancers. Resistance to cisplatin occurs 
via changes in levels and balance of key-players, such as p21, Fas and MDM2, acting upon 
cisplatin-induced activation of the p53-pathway. Recent studies suggest that high levels of 
cytoplasmic localized p21 and tight regulation of p53 by MDM2 protect EC cells against 
cisplatin-induced apoptosis. Drugs targeting either the p53/MDM2 axis or cytoplasmic lo-
calized p21 showed, at least pre-clinically, a sensitizing effect to cisplatin treatment. These 
drugs may be further developed for the treatment of platinum resistant disease.
Apart from cisplatin, another important drug used as standard for testicular cancer treat-
ment is bleomycin. In combination with cisplatin, bleomycin adds significantly to the impro-
ved outcome. Bleomycin hydrolase (BLMH) is an enzyme capable of metabolic inactivating 
of bleomycin. Recently a SNP in the BLMH gene was associated with outcome of testicular 
cancer. In Chapter 6, we used a TC cell line panel consisting of Tera, the acquired cisplatin-
resistant subline Tera-CP, and the intrinsic cisplatin-resistant Scha cell line, all homozy-
gous wild-type A/A for the SNP A1450G. Therefore, differences in enzymatic properties of 
BLMH due to different SNP genotypes of the cell lines used in the present study could be 
excluded. Highest BLMH levels were detected in the 10-fold bleomycin-resistant Scha cells. 
Tera and Tera-CP had similar BLMH levels indicating that acquired cisplatin-resistance is 
not related to bleomycin-resistance. High levels of BLMH coincided with a decreased sensi-
tivity to bleomycin and a decrease in bleomcyin-induced apoptosis. Moreover, suppression 
of the high BLMH level using siRNA sensitized Scha cells to bleomycin-induced apoptosis 
but not to cisplatin. In conclusion the level of BLMH, especially when elevated, is an impor-
tant determinant of sensitivity to bleomycin in TC cells.
General discussion and future perspectives
Activation of pro-survival pathways, such as the PI3K/Akt pathway, as well as inhibition of 
the apoptotic pathway, by TP53 mutations for instance, can lead to chemotherapeutic drug 
resistance in tumors (28-29). Testicular cancers, however, express high levels of wild-type 
p53 and are most often extremely sensitive to cisplatin. In this thesis the importance of p53 
and its downstream targets p21, Fas and MDM2 in determining the response to cisplatin 
in testicular cancer models is described. In the next section the p53 pathways and other 
pathways that might influence levels of p21, Fas and MDM2 are highlighted as subjects 
for further research to uncover new therapeutic targets to improve the response to (cisplatin 
based) chemotherapy.
Role of p21 as putative target in TC. High cytoplasmic expression of p21 is one key 
determinant of cisplatin-resistance in the embryonal carcinoma component of testicular can-
cer, and cytoplasmic localization of p21 is strongly dependent on PI3K/Akt activity (Chapter 
2). High p-Akt levels might be the result of the lack of expression of PTEN (30-31) with 
or without the combined with activation of receptor tyrosine kinases (RTKs) in TCs. It is 
of therapeutic interest to identify which RTK(s) are important for Akt activity in TC, since 
inhibition of p-Akt retained p21 in the nucleus resulting in sensitization of high p21 expres-
sing EC cells to cisplatin-induced apoptosis (Chapter 2). Specific targeting of these RTK(s) 
with antibodies or RTK inhibitors may be a therapeutic option, therefore mass spectrometry 
on enzymatically cleaved membrane peptides or FACS analysis should be performed to find 
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possible RTKs. Moreover, the efficacy of the various subclasses of PI3K- or Akt-inhibitors 
to inhibit Akt resulting in relocalization of p21 and subsequently enhance cisplatin sensitivity 
in refractory TC patients needs to be further elucidated.
Mature teratomas are extensively differentiated parts of testicular cancer that often reside 
after chemotherapy and that are non-dividing and relatively chemoresistant. In these mature 
teratomas, p-p21 is present, but still p21 is mainly nuclear localized (Chapter 2). Therefore, 
other factors involved in regulating cytoplasmic versus nuclear localization of p21 might as 
well play a role. Two interesting candidate proteins have been described. First, Brap2 that 
can function as a cytoplasmic retention protein for p21 (32). Second, BCCIP that is reported 
to cause nuclear localization of p21 independent of p21-NLS phosporylation (33). Moreover, 
BCCIP regulates p21 expression (34-35) and modulates CDK2 kinase activity via p21 (36). 
It would be of interest to study expression of BCCIP and Brap2 in TC and to compare levels 
in relation to p21 localization between the various histological subtypes such as teratoma 
and EC.
Levels of cytoplasmic p21 are regulated by expression of the miR-106b seed family, 
while the levels of the miR-106b seed family in turn are regulated by Oct4 (Chapter 2). All 
these factors are implied in maintenance and control of differentiation of embryonal stem 
cells (37-40). Loss of these factors is of consequence for drug sensitivity and susceptibility 
for apoptosis induction of EC (Chapter 2). Further research is needed to obtain more insight 
into the mechanism of differentiation of EC cells, using for instance an inducible promoter 
system to over-express p21 or pursue strategies to repress Oct4 and or miR-106b seed family 
members in Tera cells. While we observed less expression of Oct4 and members of the miR-
106b seed family (Chapter 2), a recent study showed even a complete lack of Oct4 expression 
in cisplatin-resistant ECs (41). Thus, p21, Oct4 and miR-106b seed family might be bio-
markers of bad prognosis. Of interest, miRNAs are stably detected in plasma en serum (42-
43) and their expression patterns appear to be tissue-specific in human cancer (44). Further 
research is needed to determine if levels of the miR-106b seed family members in clinical 
samples can be used as a prognostic marker for testicular cancer and a predictive marker for 
outcome of TCs after standard treatment.
Role of the p53-MDM2 axis in TC. p53 has been shown to be important for apoptosis 
induction in testicular cancer cells upon DNA damage (Chapters 3-5 & refs 17-21,24,45,46-
47), although the exact mechanism behind p53 mediated trans-activation of pro-apoptotic 
and anti-apoptotic genes determining apoptotic outcome in testicular cancer cells is still un-
clear. This is most evident in Chapter 3, were we observed a cell context dependent effect of 
p53 suppression on apoptosis induction. This effect might be due to differences in balance 
of Fas and p21 levels (Chapters 2-4). After cisplatin treatment, elevated Fas membrane ex-
pression levels and low p21 levels were detected in cisplatin-sensitive cells while higher p21 
levels and only minor elevated Fas levels were found in cisplatin-resistant cells (Chapters 2-4 
& ref 24). In contrast to cisplatin treatment, despite an almost a similar p53 increase, gamma-
irradiation strongly induced p21 accumulation in the cytoplasm in both cisplatin-resistant 
Scha and cisplatin-sensitive Tera cells (Chapter 2 & ref 8). The observed induction of p21 
was p53 dependent, since inactivation of p53 completely abolished irradiation-induced p21 
upregulation in Tera cells (22). The differences between p21 and Fas levels might be ex-
plained by different regulation or expression of co-factors and negative feed-back regulators 
upon cisplatin versus gamma-irradiation, such as NF-Y, MDM2 and MDMX, regulating p53 
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transcriptional activity of pro- or anti-apoptotic genes.
NF-Y is a regulator of p53-mediated FAS transcription, while it represses CDKN1A pro-
moter activity (48-49) leading to reduced p21 expression. NF-Y mediated transactivation is 
in a dose-dependent manner suppressed by MDM2 (50). In turn, by binding to the transacti-
vation domain of p53, MDM2 is able to regulate p53 activity and stability via several mecha-
nisms, such as promoting p53 degradation through ubiquitination, stimulating p53 nuclear 
export, and inhibiting acetylation of p53 (25-27). MDM2 and the related protein MDMX are 
p53 regulating proteins, suggested to be of great importance in tailoring p53 response (51-
55). MDMX knockdown in TC cells resulted in higher p21 expression (56). Interestingly, 
either MDM2 suppression or interference with the p53-MDM2 interaction using Nutlin-3 led 
to a robust upregulation of Fas membrane expression (Chapter 4), while after both Nutlin-3 
and cisplatin treatment p21 mRNA and protein levels were very low in testicular cancer 
cells (8,24,56-57). Further research is needed to gain more insight in how the diverse co-
factors/regulators affect p53-mediated pro- and anti-apoptotic response in TC upon different 
DNA damage inducing treatments. The application of p53 CHIP analysis and mass-spec 
on immuno-precipitated p53 complexes might be pursued to find differential p53 co-factor 
complexes.
We show that in cisplatin-resistant TC cells p53 function is impeded by the interaction 
with MDM2 and the subsequent sequestration of p53 in the cytoplasm (Chapter 4). More 
attention should be given to the role of two additional factors affecting the p53-MDM2 axis, 
in particular MDM2 phosphorylation, in TC, which are the ATM/ATR family protein kina-
ses and the PI3K/Akt pathway. In general, DNA damage activates the ATM/ATR family 
protein-kinases and ATM/ATR fine-tunes the response of p53 by regulating additional post-
translational modifications leading to stabilization of the normally labile p53 protein (58) and 
by affecting the p53 regulators MDM2 and MDMX. ATM directly and indirectly induces 
MDM2 and MDMX phosphorylation, resulting in decreased activity and stability (59-60) 
and consequently loss of negative feedback on p53. In contrast, phosporylation of MDM2 
by p-Akt leads to the nuclear localization of MDM2 and consequently enhances MDM2-
mediated ubiquitination, sequestration and degradation of p53 (61-62). The balance between 
Akt versus ATM/ATR induced phosporylation of MDM2 might thus play an important role 
in determining the response to cisplatin, but this was not assessed in TC cells.
Induction of FasL and upregulation of the Fas receptor in a p53-dependent manner has 
been observed in several tumor cell lines after treatment with chemotherapeutic drugs, such 
as cisplatin, and is related to apoptosis induction (8,24,46-47,63-65). The Fas/FasL system 
is active and functional in cisplatin-sensitive but almost inactive in cisplatin-resistant TC 
cells (24). Interestingly, the massive apoptosis induction in both cisplatin-sensitive and -re-
sistant TC cells after Nutlin-3 treatment or Nutlin-3 in combination with cisplatin is to a large 
extent dependent on activation of the Fas death receptor pathway. This can be contributed 
to the strongly enhanced Fas membrane expression levels in TC cells (Chapter 4). Levels 
of FasL were also determined, by western blotting but no FasL upregulation could be de-
tected, while suppression and blocking of FasL significant reduced the apoptotic response. 
This is however not conclusive to define the importance of FasL levels or distribution of 
FasL for efficient apoptosis induction, as this technique cannot distinguish between cellular, 
soluble or membrane-bound FasL. Therefore, further research using for instance different 
constructs of FasL resulting in either membrane-bound or soluble FasL should be performed 
to gain insight in the importance of FasL redistribution to the membrane or to the extracel-
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lular compartment, i.e. membrane-bound vs. soluble FasL, in inducing apoptosis. Moreover, 
involvement of other genes in this pathway may be of interest. The Fas adaptor LRDD and a 
gene implicated in positive Fas regulation, PHLDA3 were found to be regulated by p53 upon 
cisplatin treatment in Tera (20), but the effect of Nutlin-3 treatment on their expression and 
activation remains unknown up to now. Therefore, microarray analysis could be performed 
to gain more insight in Nutlin-3 induced gene expression in cisplatin-resistant vs. -sensitive 
TC cells in the presence and absence of cisplatin or Nutlin-3.
Resistance to bleomycin in TC. In chapter 6, we concluded that the level of BLMH 
is an important determinant of sensitivity to bleomycin in TC cells. Recently, the somatic 
homozygous variant G/G for the single-nucleotide polymorphism (SNP) A1450G in BLMH 
was reported to be associated with reduced survival and a higher prevalence of early relapses 
in TC patients treated with bleomycin-containing chemotherapy (66). It is plausible that this 
specific polymorphism in the BLMH gene might affect bleomycin metabolism and thus in-
fluence bleomycin toxicity and/or anti-tumor efficacy. For that reason, future research has to 
determine if this SNP in the BLMH gene, by more stable expression or increased activity of 
BLMH, may influence enzymatic activity and thereby the response to bleomycin.
Conclusions
Testicular cancer is considered a paradigm of curable solid tumor and is therefore a very 
helpful “model” to investigate and understand the molecular determinants of chemotherapy 
sensitivity (and resistance) of solid tumors. Knowledge about mechanisms involved in the 
sensitivity and resistance of testicular cancer to DNA-damaging agents might contribute to 
the design of new treatment strategies to overcome cisplatin resistance of refractory testicular 
cancers and of other types of human cancers. Based on literature and the studies presented in 
this thesis, we show data suggesting that presence of wild-type p53 is causative for the cispla-
tin sensitivity in testicular cancer (chapter 3, 4 and 5), while resistance to cisplatin occurs via 
changes in levels of cytoplasmic p21 (chapter 2) and tight regulation of p53 by MDM2 (chap-
ter 4) in cisplatin-resistant cells. Additionally, expression levels of BLMH might determine 
the response to bleomycin (chapter 6), an important and essential component of the cisplatin-
based chemotherapy regimens used in treatment of testicular cancers. In pre-clinical studies 
enhanced cisplatin efficacy after modulation of p21, p53 and MDM2 is shown. Translation 
of these results to the clinic can lead to new treatments of (refractory) testicular cancers by 
the combination of conventional chemotherapy with the application of MDM2 antagonist or 
PI3K- or Akt-inhibitors, in order to induce pro-apoptotic proteins or to impair the localization 
of anti-apoptotic proteins.
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Introductie
Zaadbalkanker (testiskanker of kiemceltumor van de testis) is de meest voorkomende vorm 
van kanker bij mannen tussen de 20 en 35 jaar. De frequentie waarmee zaadbalkanker zich 
voordoet neemt wereldwijd toe (1). Op basis van histologie kunnen deze tumoren worden 
onderverdeeld in seminomateuze en non-seminomateuze zaadbalkanker. Non-seminomen 
hebben de neiging om op grote schaal te metastaseren (uitzaaien) en zijn daarnaast minder 
gevoelig voor radiotherapie dan seminomateuze zaadbalkanker. Dit heeft consequenties voor 
de prognose en voor de behandelingsstrategieën. Non-seminomen laten verschillende stadia 
van differentiatie zien, variërend van het ongedifferentieerde embryonale carcinoom (EC) tot 
de meer gedifferentieerde componenten zoals extra-embryonale dooierzak carcinoom (Yolk 
Sac YS) en choriocarcinoom (Chc) tot zeer gedifferentieerde teratoom (T) (2).
Op platina gebaseerde chemotherapie is de hoeksteen van de behandeling van vele ver-
schillende maligniteiten en wordt gebruikt als eerstelijns therapie voor zaadbal-, blaas-, long- 
en eierstok-kanker. In het geval van blaas-, long- en eierstokkanker is de eerste reactie op 
platina gebaseerde chemotherapie zeer goed, echter bij  de meerderheid van deze patiënten 
is de respons van beperkte duur. De meeste patiënten zullen uiteindelijk recidiveren met een 
platina resistente, refractaire tumor. Zaadbalkanker wordt beschouwd als een paradigma van 
een platina gevoelige solide tumor. Sinds de invoering van cisplatine in het midden van de 
jaren 1970 is er een enorme verbetering opgetreden in de effectiviteit van de behandeling en 
overlevingskansen voor patiënten met zaadbalkanker, zelfs als er sprake is van uitgebreid ge-
metastaseerde ziekte (3). Bouwend op het aanvankelijke succes, is de behandeling in de loop 
van jaren steeds verder verbeterd (4-5). Dit heeft geleid tot de huidige standaard behandeling 
voor zaadbalkanker, de combinatie chemotherapie BEP waarin bleomycine naast cisplatine 
en etoposide is opgenomen als een essentieel onderdeel. (6)
Patiënten met gemetastaseerde zaadbalkanker kunnen worden ingedeeld volgens de In-
ternational Germ Cell Consensus Classification (internationale kiemcel consensus classifi-
catie), deze onderscheid zaadbalkanker patiënten op de hoeveelheid aanwezige tumor. Drie 
groepen worden onderscheiden, namelijk patiënten met een goede -, een intermediaire - of 
een slechte prognose. De behandeling met op cisplatine gebaseerde chemotherapie combi-
natie zorgt voor een 5-jaars overleving van respectievelijk 91%, 79% en 48% in de hiervoor 
beschreven groepen (7). Ondanks het feit dat de totale behandeling meestal succesvol is zal 
ongeveer 20 ~ 50% van de zaadbalkanker patiënten met uitgebreid metastasering, behorende 
tot de intermediaire of slechte risico groep, geen langdurige remissie tonen na de eerste be-
handeling en uiteindelijk sterven als gevolg van hun ziekte (5).
Cisplatine moet worden geactiveerd door intracellulair hydratatie van een of beide van 
de twee chloride liganden voordat het covalent kan binden aan DNA (8). Terwijl bleomycine 
DNA klievende activiteit heeft wanneer het in complex is met een zuurstofhoudend ijzer 
molecuul (9). Na de behandeling met cisplatine worden letale DNA adducten gevormd (8-9). 
Wat zorgt voor een arrest in de DNA replicatie vork en verstoringen in het DNA die worden 
herkend door complexen van DNA-schade herkennende cellulaire eiwitten (8,10). Deze acti-
veren op hun beurt verschillende signaaltransductie routes, betrokken bij het herkennen van 
DNA schade, met als gevolg celcyclus arrest (remming van de celdeling) en reparatie van 
DNA schade óf apoptose (geprogrammeerde celdood) (8,10-11). Resistentie tegen cisplatine 
of bleomycine kan het gevolg zijn van verminderde opname -, toegenomen export -, intracel-
lulaire detoxificatie (afbraak) van de chemotherapeutica, een verhoogde efficiëntie van DNA 
reparerende systemen (8,10-13) en defecten in de apoptose route (14).
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Figure 1. Apoptose of geprogrammeerde celdood is een actief proces in de cel en wordt gekenmerkt door biochemi-
sche en morfologische veranderingen. Het p53 tumor suppressor eiwit speelt hierin een centrale rol. De reactie op 
de door cisplatine chemotherapie veroorzaakte DNA schade kan zowel de extrinsieke apoptose route (met inbegrip 
van Fas / FasL) als de intrinsieke (mitochondriale) apoptose route, bijvoorbeeld Bax en Bak activeren. Dit leidt tot 
verhoogde expressie van pro-apototische genen (groene lijnen) en anti-apoptotische genen (rode lijnen). Deze acti-
veren verschillende signaaltransductie routes die betrokken zijn bij DNA schade herkenning waarop cel cyclus arrest 
en reparatie (via p21) of apoptose volgen. Bij ernstige schade aan het DNA zal door pro-apoptotische eiwitten een 
proteolytisch systeem van caspases, een familie van proteasen geactiveerd worden. Deze leiden uiteindelijk tot het 
knippen van substraat eiwitten, resulterend in de totale demontage van de cel. Verdere uitleg is te vinden in de tekst. 
De fi guur is een bewerking van eerdere fi guren uit Di Pietro et al, 2005 en Spierings et al, 2003; referenties (22-23).
Apoptose, of geprogrammeerde celdood, is een actief proces in de cel dat wordt geken-
merkt door biochemische en morfologische (vorm) veranderingen (Figuur 1). Apoptose is 
betrokken bij de ontwikkeling en homeostase van normale weefsels (15), waaronder ook 
normaal testis weefsel. Tijdens de spermatogenese treedt apoptose op in de testis, als een 
belangrijk fysiologisch mechanisme voor kwaliteitsbewaking en aanpassing van de hoeveel-
heid kiemcellen aan de hoeveelheid ondersteunende Sertoli cellen (16-17). Een centraal on-
derdeel van het apoptose proces is de proteolyse uitgevoerd door een familie van proteasen, 
de caspasen. Het knippen van een set van substraateiwitten (proteolyse), door de caspasen, 
leidt uiteindelijk tot de totale demontage van de cel (Figuur 1). Dit proces kan worden aange-
stuurd door twee belangrijke apoptose signaalroutes namelijk de “extrinsieke”, death (dood) 
receptor, apoptose route en de “intrinsieke”, mitochondriële, apoptose route (15) (Figuur 1). 
Zowel de extrinsieke als intrinsieke signaalroute kan geactiveerd worden door het p53 tumor 
suppressor eiwit, dat een centrale rol speelt in de reactie op DNA schade, veroorzaakt door 
chemotherapeutische middelen (14) (Figuur 1).
P53 is een tumorsuppressor eiwit met een dubbele rol in de reactie op stress (zoals na 
chemotherapie). Het kan enerzijds genen transactiveren die apoptose induceren (zoals de Fas 
death receptor) en anderzijds genen transactiveren die aanzetten tot celcyclus arrest, zoals 
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leerd door MDM2, deze remt de transactivatie activiteit van p53 en reguleert de afbraak van 
p53 (18) (Figuur 1). P53 is het meest frequent gemuteerde gen in menselijke maligniteiten 
(19-20), maar is verrassend genoeg zelden tot nooit gemuteerd in zaadbalkanker (21). Bij de 
patiënten leiden mutaties in p53 tot cisplatine resistentie door de beïnvloeding van de apop-
totische route (21). De aanwezigheid van wild-type p53 zou daarom een verklaring kunnen 
zijn voor de gevoeligheid voor cisplatine (22-23), vooral omdat er ook véél p53 tot expres-
sie komt bij de meeste kiemceltumoren (24-27). Er zijn echter ook onderzoeken beschreven 
waarin geen rol voor wild-type p53 in de gevoeligheid voor chemotherapie werd gevonden 
(28-30). In recent onderzoek is aangetoond dat de blootstelling van zaadbalkankercellijnen 
aan cisplatine resulteerde in verhoogde niveaus van p53 en MDM2, activatie van de Fas 
apoptotische route, en inductie van apoptose, zonder verandering van de expressie niveaus 
van p21 (25,31). Deze resultaten tonen de betrokkenheid aan van de Fas apoptotische route 
bij cisplatine geïnduceerde apoptose in zaadbalkanker cellen (25,31). Het is echter niet be-
kend waarom cisplatine geïnduceerde activatie van p53 niet resulteerde in de verhoogde 
expressie van p21. Dit suggereert dat veranderingen in de balans van bepaalde sleuteleiwitten 
in de cisplatine geïnduceerde, p53-gemedieerde, apoptose route het lot bepalen van zaadbal-
kankercellen na behandeling met cisplatine. Het ontcijferen van de complexe regulatie van 
deze moleculaire determinanten van cisplatine gevoeligheid en resistentie in de behandeling 
van zaadbalkanker, kan leiden tot betere behandelingsmogelijkheden voor patiënten met een 
resistent vorm van zaadbalkanker en andere solide tumoren.
Doelstelling van dit proefschrift
Hoewel p53 één van de meest bestudeerde eiwitten is in kankercellen, is de precieze rol van 
wild-type p53 in de response op DNA schade in zaadbalkanker niet duidelijk. Om deze re-
den richt dit proefschrift zich voornamelijk op de functie van wild-type p53 en de door p53 
geïnduceerde eiwitten Fas, MDM2 en p21 en hun rol in cisplatine geïnduceerde apoptose in 
zaadbalkanker.
Samenvatting van de resultaten
Behandeling van zaadbalkanker cellijnen met cisplatine resulteerde in verhoogde expressie 
van p53 en MDM2, activering van de Fas apoptotische route én inductie van apoptose, terwijl 
in cisplatine gevoelige zaadbalkanker cellen de expressie van de cycline afhankelijke kinase 
(CDK) remmer p21 bijna niet steeg (25,31). Behandeling van zaadbalkanker cellijnen met 
gamma-straling daarentegen leidde tot verhoogde expressie van p53, MDM2 én cytoplasma-
tisch p21, zonder inductie van  apoptose of celcyclus arrest (25). Deze resultaten suggereren 
een belangrijke rol voor cytoplasmatisch gelokaliseerd p21 in het voorkómen van apoptose 
na DNA schade in zaadbalkanker cellen. Daarom onderzochten wij de rol van cytoplasma-
tisch p21 in cisplatine resistentie van zaadbalkanker cellen. In Hoofdstuk 2 laten we zien dat 
een hoge concentratie van cytoplasmatisch gelokaliseerd p21 een doorslaggevende factor is 
voor de cisplatine resistentie in de embryonale carcinoom (EC) component van zaadbalkan-
ker. De EC-component van de meerderheid van de patiënten met refractaire zaadbalkanker 
bracht cytoplasmatische p21 hoog tot expressie. Daarnaast vonden wij dat in cisplatine re-
sistente cellijnen p21 bescherming bood tegen cisplatine geïnduceerde apoptose via CDK2 
remming. Lokalisatie van p21 in het cytoplasma was van cruciaal belang voor de resistentie 
tegen cisplatine, omdat realloceren van p21 naar de kern, door Akt remming, zaadbalkanker 
cellijnen gevoeliger maakte voor cisplatine. Ook hebben we in zaadbalkanker cellijnen en 
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in tumorweefsel van patiënten aangetoond, dat hoge expressie van cytoplasmatische p21 
en resistentie tegen cisplatine in de embryonale carcinoom component van zaadbalkanker, 
omgekeerd evenredig is met de expressie van Oct4 en mir-106b familieleden. De modulatie 
van de Oct4/miR-106b/p21 route zou, via de verlaging van cytoplasmatisch p21, een aankno-
pingspunt kunnen zijn voor het ontwikkelen van nieuwe strategieën voor de behandeling van 
cisplatine resistente zaadbalkanker en andere vormen van kanker.
In humaan zaadbalkanker, is de rol van p53 mutatie status en het effect hiervan op de 
basale p53 functionaliteit en de functionaliteit na chemotherapie nog niet uitgekristalliseerd. 
Opmerkelijk hierbij is dat er een duidelijk verschil lijkt te zijn met muismodellen. Daarom 
hebben we in Hoofdstuk 3 de functionaliteit van wild-type p53 geanalyseerd met betrekking 
tot de unieke cisplatine gevoeligheid van de humane zaadbalkanker cellijnen met behulp 
van “short interfering” (si)RNA, specifieke korte stukjes RNA die de aanmaak van één eiwit 
remmen. Voor dit onderzoek werden cisplatine gevoelige zaadbalkanker cellijnen (833KE 
en Tera), een cellijn met verworven cisplatine ongevoeligheid (Tera-CP) en intrinsiek cispla-
tine resistente zaadbalkanker cellijnen (Scha en 2102EP), alle met wild-type p53 expressie, 
gebruikt. De gevoeligheid voor cisplatine was gerelateerd aan de inductie van apoptose in 
alle cellijnen. P53 en de p53-transcriptionele geïnduceerde eiwitten, MDM2 en p21, kwa-
men in alle zaadbalkanker cellijnen tot expressie. Basale niveaus van MDM2 en p21, zowel 
van mRNA als eiwit, waren het hoogst in Scha en 2102EP en afhankelijk van transactivatie 
door p53. Blootstelling aan cisplatine induceerde al binnen 6 uur p53 en de expressie nam 
verder toe na 24 uur, gevolgd door inductie van MDM2, zowel op mRNA als eiwit niveau, 
en sterk verhoogde expressie van Fas op de celmembraan in alle zaadbalkanker cellijnen. 
Eerder hebben we aangetoond dat, na bestraling, een sterke inductie van p21 zaadbalkanker 
cellijnen beschermt tegen Fas-gemediëerde apoptose. In tegenstelling daarmee resulteerde 
behandeling met cisplatine in slechts een lichte inductie van p21 mRNA en p21 eiwit in 
dezelfde cellijnen. Remming van p53 expressie met siRNA verlaagde de cisplatine geïn-
duceerde apoptose in Tera en Tera-CP en was geassocieerd met een verminderde expressie 
van Fas op de celmembraan. Remming van p53 in Scha en 2102EP leidde tot een verhoogde 
cisplatine geïnduceerde apoptose, waarbij de expressie van MDM2 en p21, mRNA en eiwit 
sterk onderdrukt werd. Onze resultaten geven aan dat p53 betrokken is bij transactivatie van 
zowel pro- als anti-apoptotische genen in zaadbalkanker cellijnen. Het tegenovergestelde 
effect van remming van p53 op cisplatine geïnduceerde apoptose in verschillende zaadbal-
kanker cellijnen demonstreert het belang van de cellulaire context voor de rol van de p53 
transactivatie route.
MDM2, een door p53 transcriptioneel geïnduceerd eiwit, is de belangrijkste regulator 
van de negatieve feedback op p53. Door binding aan het transactivatie domein van p53 is 
MDM2 in staat om, via verschillende mechanismen, de stabiliteit en de activiteit van p53 te 
reguleren. MDM2 bevordert ubiquitinatie van p53, en kan de nucleaire export en acetylatie 
van p53 stimuleren (32-34). In cisplatine resistente zaadbalkanker cellen zou het zo kunnen 
zijn dat de p53 functie wordt belemmerd door de interactie met MDM2 met verschuiving van 
p53 naar het cytoplasma als gevolg. Daarom hebben we de mogelijke rol voor de negatieve 
feedback regulatie van MDM2 op p53 in de reactie op cisplatine onderzocht in Hoofdstuk 4. 
Na blootstelling van zaadbalkanker cellijnen met intrinsieke en verworven cisplatine resis-
tentie aan cisplatine is p53 ondanks de sterke toename in expressie nog steeds in complex is 
met MDM2. Hyper-activatie van de p53 route met behulp van de MDM2-antagonist Nutlin-3 
brengt p53 terug naar de kern van de cel met effectieve inductie van apoptose als gevolg. Het 
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remmen van MDM2 activiteit met Nutlin-3 of remmen van MDM2 expressie met siRNA 
maakte de cisplatine resistente zaadbalkanker cellijnen gevoeliger voor cisplatine. De waar-
genomen effecten zijn afhankelijk van de toename van wild-type p53 activiteit, want zaad-
balkanker cellen met mutant p53 of zaadbalkanker cellen waarin de expressie van wild-type 
p53 onderdrukt is, zijn ongevoelig voor Nutlin-3. Daarbij blijkt de Fas death receptor route 
een belangrijk mechanisme in het voltrekken van apoptose na blootstelling aan deze MDM2 
antagonist, nutlin-3. Deze resultaten suggereren dat gerichte remming van de p53/MDM2 in-
teractie, in combinatie met de standaard chemotherapie behandeling, een krachtige strategie 
is, die in de behandeling van cisplatine resistente zaadbalkankers zeker verder onderzocht en 
overwogen moet worden. Dat dit mechanisme zich niet beperkt tot zaadbalkanker cellijnen 
blijkt uit het feit dat ook in een Hodgkin cellijnen en acute myeloïde leukemie cellijnen met 
wild type p53, een sterke inductie van apoptose via de Fas death receptoren werd gevonden 
na behandeling met Nutlin-3.
In Hoofdstuk 5 bespreken we waarom zaadbalkanker wordt beschouwd als paradigma 
van een te genezen vorm van kanker en tevens waarom het een ideaal “model” is om meer 
inzicht te krijgen in de moleculaire determinanten die bepalend zijn voor de chemotherapie 
gevoeligheid (en resistentie) van solide tumoren. In dit literatuur overzicht wordt actuele 
kennis van de biologische basis van cisplatine geïnduceerde apoptose en de respons op che-
motherapie van zaadbalkanker belicht. In dit kader werd nader gekeken naar het feit dat 
zaadbalkankers basaal een hoge expressie hebben van wild-type p53 en hoe de aanwezigheid 
van wild-type p53 bepalend is voor de uitzonderlijke gevoeligheid voor cisplatine. Ongevoe-
ligheid voor cisplatine kan verklaard worden door veranderingen in expressie en balans van 
door p53 transcriptioneel geïnduceerde sleuteleiwitten in de apoptose route zoals p21, Fas 
en MDM2. Recente studies laten zien dat hoge expressie van cytoplasmatisch gelokaliseerd 
p21 en of stringente regulering van p53, door MDM2, EC cellen beschermt tegen cisplatine 
geïnduceerde apoptose. Medicatie die zich richt op de p53/MDM2 as of op cytoplasmatisch 
gelokaliseerd p21 heeft, ten minste preklinisch, een sensibiliserend effect op de behandeling 
met cisplatine. Deze medicijnen kunnen verder ontwikkeld worden voor de behandeling van 
cisplatine resistente (zaadbal)kanker.
Naast cisplatine is bleomycine een belangrijk component van het chemotherapiesche-
ma dat standaard gebruikt wordt voor de behandeling van zaadbalkanker. In combinatie 
met cisplatine, draagt bleomycine in belangrijke mate bij aan het goede klinische resultaat. 
Bleomycine hydrolase (BLMH) is een enzym dat in staat is om bleomycine metabool te 
inactiveren. Onlangs werd een SNP in het BLMH gen geassocieerd met behandeluitkom-
sten van zaadbalkanker. In Hoofdstuk 6, gebruikten we een panel van zaadbalkankercel-
lijnen bestaande uit; Tera, Tera-CP, een Tera-sublijn met verworven cisplatine resistentie, 
en Scha, een intrinsieke cisplatine resistente cellijn. Alle drie de cellijnen zijn homozygoot 
wild-type A/A, voor de SNP A1450G van het BLMH. Daarom kunnen verschillen in enzy-
matische eigenschappen van BLMH, als gevolg van de verschillende SNP genotypen van de 
in deze studie gebruikte cellijnen worden uitgesloten. BLMH komt het hoogst tot expressie 
in de 10-voudige bleomycine resistente cellijn Scha. Tera en Tera-CP hadden vergelijkbare 
BLMH expressie niveaus, waaruit blijkt dat verworven cisplatine resistentie niet verbonden 
is met bleomycine resistentie. De hoge BLMH expressie viel samen met een verminderde 
gevoeligheid voor bleomycine en een afname in bleomcyin geïnduceerde apoptose. Rem-
ming van de BLMH expressie, met behulp van siRNA, maakte Scha cellen gevoeliger voor 
bleomycine geïnduceerde apoptose, maar niet voor cisplatine geïnduceerde apoptose. Hoge 
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expressie van BLMH is een belangrijke determinant van óngevoeligheid voor bleomycine in 
zaadbalkanker cellen.
Conclusies
Zaadbalkanker wordt beschouwd als een paradigma voor een te genezen vorm van solide 
tumoren. Dit maakt het een zeer behulpzaam “model” voor onderzoek naar moleculaire de-
terminanten die bepalend zijn voor de chemotherapie gevoeligheid (en resistentie) van so-
lide tumoren. Kennis over de mechanismen die betrokken zijn bij de gevoeligheid en de 
resistentie van zaadbalkanker voor DNA schade inducerende medicijnen, kan bijdragen aan 
de ontwikkeling van nieuwe behandelstrategieën om cisplatine resistentie te overwinnen in 
refractaire zaadbalkanker en andere vormen van humane kanker. Gebaseerd op de in dit 
proefschrift beschreven literatuur en studies, tonen we aan dat de aanwezigheid van wild-
type p53 in zaadbalkanker bepalend is voor de gevoeligheid voor cisplatine (Hoofdstuk 3, 
4 en 5), terwijl veranderingen in de niveaus van cytoplasmatisch p21 (Hoofdstuk 2) en een 
stringente regulering van p53 door MDM2 (Hoofdstuk 4) de resistentie tegen cisplatine kun-
nen verklaren. Daarnaast kan het expressie niveau van BLMH bepalend zijn voor de response 
op bleomycine (Hoofdstuk 6), een belangrijk en essentieel onderdeel van de op cisplatine 
gebaseerde chemotherapie welke wordt gebruikt in de behandeling van testiskanker. In pre-
klinische studies werd na modulatie van p53/MDM2 of p21 een verbeterde effectiviteit van 
cisplatine aangetoond. Het vertalen van deze resultaten naar de kliniek kan leiden tot nieuwe 
behandelingen voor (refractaire) zaadbalkanker, door de combinatie van conventionele che-
motherapie en toepassing van MDM2 antagonisten of PI3K/Akt remmers, om zo pro-apop-
totische eiwitten te induceren of anti-apoptotische eiwitten te realloceren waardoor apoptose 
niet meer geremd wordt.
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